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SUMMARY 
Background: 
Atherosclerosis is a gradual narrowing of the lumen of the arteries and chronic inflammation 
has long being regarded as crucial to the pathogenesis of the disease. Serum amyloid A1 
(SAA1) and serum amyloid A2 (SAA2) (A-SAA) are acute-phase proteins (APPs); the 
concentration of A-SAA can increase by 500-1000 fold during an acute systemic 
inflammation (Malle et al. 1993). The predominant form of A-SAA in plasma is reported to 
be SAA1 (Yamada et al. 1999). A-SAA has increasingly been associated with atherosclerosis 
(Johnson et al. 2004; Ogasawara et al. 2004; Ridker et al. 2000), this stem from its immune 
regulatory role as well as the inflammatory nature of atherosclerosis. However, its specific 
role in atherosclerosis, in particular, whether it is atherogenic or atheroprotective remains 
unknown. In addition, no prior genetic epidemiology study has been conducted on SAA1. 
 
Methods and results: 
Genetic variant screening was performed using cord blood DNA samples from 96 
anonymous, unrelated Singaporean Chinese neonates delivered in the National University 
Hospital, Singapore. Genetic association study was performed using DNA samples extracted 
from blood samples belonging to coronary artery disease (CAD) patients. In total, there were 
1243 healthy controls and 800 CAD patients. Healthy controls were recruited from subjects 
attending a routine health screening. Functional characterization of the genetic variant, 
p.Gly90Asp, was performed in vitro using human THP-1 derived macrophages.  
In total, 6 genetic variants were identified in the exons and promoter of SAA1, of which 2 
are novel - c.-913G>A and c.92-5T>G. The non-conservative genetic variant, p.Gly90Asp 
(c.269G>A), is not associated with CAD, the odds ratio is 1.61 (95% confidence interval 
     xii
(CI) 0.68-3.80; P-value =0.28) after adjustment for age, gender and BMI. In addition, the 
variant, p.Gly90Asp also induced a significantly lower level of inflammatory cytokines in 
THP-1 derived macrophages, the decrease in IL-8, MCP-1 and TNF-α secreted were 57%, 
50% and 39% respectively. Variant SAA1 also has a lower impact on the genetic expression 
level of a potentially atheroprotective gene, plasminogen activator inhibitor-2 precurosor 
(SERPINB2), the expression ratio of wild-type SAA1 to variant SAA1 is 1.8 (95% 
confidence interval (CI) 1.3-2.4; P-value < 0.0001). Microarray study also suggests an 
atherogenic role of SAA1 with the induction of genes that are involved in inflammation, 
angiogenesis, phagocytosis and tissue remodeling; these processes are crucial to the 
development of atherosclerotic lesion. 
 
Conclusions: 
The identification of a genetic mutant of SAA1, p.Gly90Asp that is associated with CAD 
supports the hypothesis that SAA1 has a direct role to play in the pathogenesis of CAD. 
p.Gly90Asp has altered functional effects and induces a lower extent of cytokine secretion in 
macrophages and potentially atheroprotective SERPINB2, the latter could account for the 
increased susceptibility of p.Gly90Asp to CAD. The alter effects of the mutant is probably 
due to the lower affinity of the genetic variant to cell surface receptors of SAA1 such as 
TLR2 and CLA-1. Lastly, SAA1 regulates expression of genes with functional roles in key 
processes of atherosclerosis; it thus plays a direct role in CAD and does not act as a mere 
marker of chronic inflammatory diseases. 
     xiii 
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1 INTRODUCTION 
1.1 Brief background 
APPs are produced by the liver in time of stress and they function to counteract infection 
and promote healing of damaged tissues; they are thus essential for the survival of living 
organisms. A-SAA is a major component of APPs and constitute 2.5% of the hepatic 
protein produced during an acute phase response (APR) (Shah et al. 2006). The level of A-
SAA is upregulated in patients with chronic inflammatory diseases such as coronary artery 
disease, cancer, rheumatoid arthritis (RA) and metabolic syndrome (Cho et al. 2010; Kotani 
et al. 2009; Kumon et al. 1997; Kumon et al. 1999; Ramankulov et al. 2008). A number of 
studies have suggested that A-SAA might play a direct role in atherosclerosis, however, the 
understanding of such role is complicated by reports documenting both the atherogenic and 
athero-protective effects of A-SAA (Zimlichman et al. 1990). Furthermore, as most existing 
studies involve the usage of a recombinant SAA with primary sequence that is a hybrid of 
both SAA1 and SAA2, it is difficult to ascertain the actual significance of such studies. 
  
1.2 Thesis objectives 
The study aims to investigate and clarify the role of SAA1 in CAD. As SAA1 was reported 
to be the predominant form of SAA in the plasma, the study will focus only on SAA1. Since 
no prior genetic epidemiological studies had been performed on SAA1, one of the main 
focuses of the studies is to identify and study the association of genetic variants of SAA1 
with CAD. The results of this study will support the hypothesis that SAA1 has a direct role 
to play in the pathogenesis of CAD. The objectives of the study include: 
(1): To screen the promoter and exons of human SAA1 for novel genetic variants. 
(2): To carry out association study of SAA1 with CAD. 
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(3): To carry out functional study of a genetic variant of SAA1, p.Gly90Asp that has a 
significant association with CAD. 
(4): To elucidate the surface receptors of SAA1 and the study the genetic expression 
induce by SAA1 in the macrophages. 
 
1.3 Thesis Organisation 
The thesis is organized into 7 other chapters. The thesis begins with a literature review that 
covers important aspects of the area of study. Materials and methods that were used in the 
study are documented in Chapter 3. The SNPs survey of SAA1, the association and 
functional study of the genetic variants are covered in Chapter 4, 5 and 6 respectively. In 
chapter 7, the effects of SAA1 on the global gene expression in THP-1 derived macrophages 
are reported. Chapter 8 sums up the thesis together with proposal for future works. 
Results that comprise part of Chapter 4,5 and 6 have been used for the preparation of 
manuscript to be submitted to a peer review journal, Atherosclerosis, the title of the 
manuscript is ‘Variant screening of the SAA1 gene and the association and functional study 
of the p.Gly90Asp mutant’. The results from Chapter 7 are included in the manuscript titled 
‘Effect of serum amyloid A1 (SAA1) treatment on global gene expression in THP-1-derived 
macrophages’ which will be published in Inflammation Research. 
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2 LITERATURE REVIEW  
2.1 Atherosclerosis and coronary artery disease (CAD) 
2.1.1 Atherosclerosis – a chronic inflammatory disease  
Atherosclerosis is a chronic inflammatory disease and the principal cause of death in most 
part of the world (Braunwald 1997; Breslow 1997). Until the 1970s, the excessive levels of 
lipids in the body and its accumulation in the walls of the artery were believed to be the main 
cause of atherosclerosis. However, over the past decade, it is widely recognized that the 
development of an atherosclerotic lesion is driven by a chronic inflammation of the tunica 
intima. Chronic inflammation is also responsible for the pathogenesis of other chronic 
diseases such as RA (Harris 1990; Sewell and Trentham 1993), pulmonary fibrosis (Brody et 
al. 1981; Kuhn et al. 1989; Lukacs and Ward 1996) and chronic pancreatitis (Sarles et al. 
1989). This shift in thought has a big impact on the scope of research; more importantly, 
with a deeper understanding of the processes leading to atherosclerosis, more efficacious 
drugs can be designed to for the treatment of atherosclerosis. 
 
2.1.2 Pathogenesis of atherosclerosis and acute coronary syndrome 
Atherogenesis begins when the endothelium of the artery is damaged by various substances 
including elevated level of modified low-density lipoprotein (LDL), free radicals caused by 
cigarette smoking and elevated plasma homocysteine concentration (Ross 1999). The 
development of an atherosclerotic lesion does not occur spontaneously throughout the 
length of the artery. The regions of the artery that are exposed to laminar shear stress flow 
are protected from atherosclerosis due to the upregulation of protective genes such as 
superoxide dismutase and nitric oxide (De Caterina et al. 1995; Topper and Gimbrone 1999). 
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Exposure to prolonged shear stress was also reported to suppress the production of 
adhesion molecules in endothelial cells (Chiu et al. 2004; Sheikh et al. 2003). 
Increased expression of cell adhesion molecules facilitates the adhesion of monoctye and its 
subsequent entry into the tunica intima. In the tunica intima, the monocytes differentiate 
into macrophages and express scavenger receptors such as scavenger receptor A (SRA) and 
CD36. Scavenger receptors facilitate the uptake of modified lipoproteins into the 
macrophages forming foam cells which are omnipresent in the atherosclerotic lesion. The 
macrophages contribute further to the growth of the lesion by secreting substances such as 
proinflammatory cytokines, chemokines and matrix metalloproteinases (MMPs).  
In addition to mononuclear phagocytes, other immune cells, in particular T-lymphocytes and 
mast cells also have a role to play in atherogenesis. In the intima, T-lymphocytes crosstalk 
with macrophages through CD154-CD40 interaction and induce the macrophages to secrete 
tissue factors, MMPs and pro-inflammatory cytokines. In addition, helper T-cells can 
polarize into TH1 cells which secrete pro-inflammatory cytokines. Mast cells undergo 
degranulation in the intima to produce serine proteinases which facilitate matrix degradation.   
In the later stage of the development of the atherosclerotic lesion, microvessel is formed in 
the atheroma. The formation of new vessels provides a new source of nutrients for the 
atherosclerotic plaque, facilitating its growth and hence angiogenesis is pro-atherogenic.  
The final stage in the development of an atheroma involves the rupturing of a plaque. Plaque 
rupturing involves the erosion of the endothelial cells and the fracture of the fibrous cap 
which exposes the blood to the content in the plaque. Rupturing of the plaque occurs as a 
result of the proteolysis of collagen in the extracellular matrix which forms the main support 
of the fibrous cap (Lee and Libby 1997).   
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2.1.3 Risk factors for CAD 
Atherosclerosis and CAD are multi-factorial disease and are greatly affected by a 
combination of both genetic and environment factors. Genetics is a big determinant on the 
development of CAD and in most studies the heritability of atherosclerosis exceeds 50% 
(Lusis 2000). In a standardized case-control study of acute myocardial infarction conducted 
in 52 countries (INTERHEART), nine risks factors were identified to be associated with the 
disease (Table 2-1) (Yusuf et al. 2004). Both genetic and environmental factors are crucial in 
the prevention of CAD. Among the 9 risk factors, ApoB:ApoAI ratio, diabetes, 
hypertension and to a certain extent abdominal obesity are influenced by the genetic makeup 
of an individual. Smoking, psychosocial stressors, alcohol consumption, regular physical 
exercise and consumption of vegetables are environmental risk factors.   
Table 2-1. Deleterious and protective risk factors for acute myocardial infarction. The 
data is based on a case-control study (INTERHEART) conducted in 52 countries. 
Deleterious/Protective Risk factor Odds ratio (99% CI) 
ApoB:ApoAI ratio (highest vs lowest decile) 4.73 (3.93-5.69) 
Smoking 2.87 (2.58-3.19) 
Psychosocial stressors 2.67 (2.21-3.22) 
Diabetes 2.37 (2.07-2.71) 
Hypertension 1.91 (1.74-2.10) 
Abdominal obesity (highest vs lowest tertiles) 1.62 (1.45-1.80) 
Protective  
Alcohol consumption, > 3 times a week 0.91 (0.82-1.02) 
Regular physical exercise 0.86 (0.76-0.97) 
Daily fruit and vegetable consumption 0.70 (0.62-0.79) 
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Among the deleterious risk factors, smoking is closely associated with acute coronary 
syndromes. It has the highest odds ratio among the non-genetic risk factors. Based on 
various studies, smoking exerts various effects on the vascular system which include (1): 
inducing oxidative stress in peripheral blood mononuclear cells (PBMCs) (Garbin et al. 
2009)  (2): elevating the level of thrombopoietin which contributes to enhanced platelet 
activation (Lupia et al. 2010) and (3): increasing systemic inflammation through an increased 
level of homocysteine, C-reactive protein (CRP) and fibrinogen (Yanbaeva et al. 2007).    
 
2.1.4 Existing drugs treatment for CAD 
Various drugs are currently prescribed to treat CAD and its clinical manifestations, these 
include calcium channel blockers, angiotension-converting enzyme inhibitors and 
angiotensin II type 1 receptor blockers to lower blood pressure, anti-platelet agent such as 
aspirin and clopidogrel to reduce blood clotting and HMG-COA (3-hydroxy-3-
methylglutaryl coenzyme A) reductase inhibitors (statins) to regulate lipids levels. Among 
them, statins have a more direct impact on CAD as they regulate LDL level which has a 
primary role to play in atherosclerosis.  
 
2.1.4.1 Statins 
Statins was approved for use in the treatment of hypercholesterolemia in 1987. Statins 
regulate LDL level through the inhibition of the rate limiting enzyme in cholesterol 
synthesis, HMG-COA reductase. Ever since its discovery, statins have been used rather 
routinely to reduce future cardiovascular events in patients; its benefical effect was supported 
by findings from various clinical trials (LaRosa et al. 2005; Nissen et al. 2004). In a meta-
analysis of 14 randomised trials of statins consisting of 90,056 participants, statins were 
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shown to reduce the 5 year incidence of cardiovascular events by 20% for every mmol/L of 
LDL cholesterol reduction (Baigent et al. 2005).   
Statins have also been used as a primary prevention in patients with clinical parameters that 
put them at risk of developing CAD. In a prospective, open-blinded end point study, 
Management of Elevated Cholesterol in the Primary Prevention Groups of Adult Japanese 
(MEGA), conducted among 5356 female Japanese patients, treatment with pravastatin 
results in a reduction of 26% to 37% in the occurrence of cardiovascular events. In another 
study conducted among women of age > 60 years, there was a greater reduction in 
cardiovascular events (45% for CAD, and 50% for CAD plus cerebral infarction) (Mizuno et 
al. 2008) for those treated with statin. To further validate those studies, another prospective 
study, Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating 
Rosuvastatin (JUPITER), was conducted among 6801 women with age > 60 years and 
11001 men with age > 50 years. The result again support the use of statins as a primary 
prevention against cardiovascular events in asymptomatic individuals. The absolute 
cardiovascular disease rate (per 100 person-years) in women is 0.57 for rosuvastatin against 
1.04 for placebo. In men, the absolute cardiovascular disease rate is 0.88 for rosuvastatin 
against 1.54 for placebo. The relative risk reduction is significant in both men (hazard ratio: 
0.58; 95% CI, 0.45 – 0.73; P< 0.001) and women (hazard ratio: 0.54; 95% CI, 0.37-0.80; 
P=0.002) (Mora et al. 2010). Since atherosclerosis is a progressive disease and that 
individuals can be asymptomatic for years while the artery continues to narrow, it might be a 
good clinical practice to put those at risk on statin treatment before an acute event occurs.  
Although statins have been used successfully in decreasing cardiovascular mortality and 
morbidity, an increasing number of studies have attributed the efficacy of statins to its 
pleiotropic effects. Simvastatin was reported to induce the regression of cardiac hypertrophy 
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in a rabbit model of human hypertrophic cardiomyopathy (Patel et al. 2001). In a case-
control study conducted in 2004 (Nishikawa et al. 2004), patients treated with either 
pravastatin or simvastatin (n =66) for an average of 31 months had a significant decrease in 
the left ventricular mass index. Hence, the therapeutic effects of statins might be derived 
from a combination of its influence on LDL level as well as its pleiotropic effects. The 
various pleiotropic effects observed with statins treatment are summarized in Table 2-2. 
Pleiotropic effects are known to be associated for a few statins. Some of the positive effects 
observed are independent of lipid levels as cells were treated for only a coupe of hours.   
Table 2-2. Pleiotropic effects observed with statin treatment. The effects observed were 
based on both in vitro and in vivo studies.  
Drug Pleiotropic effects 
Fluvastatin Prevent plaque rupturing in apoE knockout mice through decreased 
MMP-9 expression, gelatinolytic activity  and endothelial adhesion 
molecules expression (Nakamura et al. 2009) 
Simvastatin Reduce cell adhesion molecules in endothelial cells (Eccles et al. 2008) 
 Suppresses endotoxin induced upregulation of toll-like receptors 2 and 4 in 
human (Niessner et al. 2006) 
 Upregulation of endothelial nitric oxide synthase (eNOS) (Laufs et al. 
1998) 
Rosuvastatin Reduce MMP-7 production in human monocyte-derived macrophages 
(Furman et al. 2004) 
Lovastatin Upregulation of eNOS (Laufs et al. 1998) 
Cerivastatin/ 
Atorvastatin 
Induce direct vasodilation of isolated bovine coronary arteries through its 
effect on endothelial cells (Lorkowska and Chlopicki 2005) 
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2.1.5 Potential treatment strategies for CAD 
Statin has contributed greatly to the reduction of morbidity and mortality associated with 
CAD. However, existing drugs are still incapable of complete eradication of cardiovascular 
events from the high risk group. For the past two decades, most CAD drugs have been 
designed to alter plasma lipids levels. However, with more knowledge on the pathogenesis of 
atherosclerosis, new drugs such as antioxidant, secretory phospholipase A2 inhibitor 
(sPLA2), 5-lipoxygenase (5-LO) inhibitor and cholesteryl ester transfer protein (CETP) 
inhibitor are appearing on the pipeline of major drug companies.  
Table 2-3 shows the list of CAD drugs that are undergoing clinical trials. Torcetrapib, is one 
of the first CETP inhibitor to undergo phase 3 clinical trial. Although, torcetrapib was able 
to raise HDL-cholesterol level in patients substantially (Barter et al. 2007; McKenney et al. 
2006), the drug did not halt the progression of atherosclerosis and adverse effects such as 
higher systolic blood pressure in patients were reported (Vergeer et al. 2008). Further 
research on the adverse effects of torcetrapib indicates that the adverse effects are likely to 
be independent of CETP inhibition (Forrest et al. 2008; Hu et al. 2009) .Two other CETP 
inhibitors, dalcetrapib and anacetrapib (Cannon et al. 2009), are entering phase 3 clinical 
trials.  Anacetrapib had promising results in earlier trials: HDL-cholesterol level was doubled 
and LDL-cholesterol level was lowered by 70%. Importantly, anacetrapib does not appear to 
have adverse effects on blood pressure which doomed the first drug of its class, torcetrapib 
(Bloomfield et al. 2009). The results of the phase 3 clinical trials will validate whether CETP 
inhibitors can complement statins as an additional drug to combat atherosclerosis.  
Drugs with some anti-inflammatory effects are also being developed. Succinobucol is an 
anti-oxidant and a novel vascular protectant. Succinobucol has good preclinical results: (1) it 
inhibits lipopolysaccharide induction of atherogeneic tissue factor in both monocytic and 
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endothelial cells without altering the nuclear translocation of NF-kappaB (Luyendyk et al. 
2007) (2) it reduces aortic atherosclerosis in both LDLr-/- and ApoE-/- mice and (3) it raises 
HDL-cholesterol levels and lowers LDL-cholesterol level in hypercholesterolemic 
cynomolgus monkeys (Sundell et al. 2003). However, the beneficial effects of succinobucol 
are not observed in clinical studies, instead a dose-dependent decrease in HDL-cholesterol 
was observed upon drug treatment (Tardif et al. 2003).   
Two other classes of anti-inflammatory drugs with potent anti-atherosclerotic effects are 
drugs inhibiting sPLA2 and 5-LO. As with both succinobucol and torcetrapib, these are 
first-in-class drugs and that their potential clinical benefits remain to be seen. With anti-
inflammatory drugs on the pipeline as well as ongoing research on important inflammatory 
mediators, we will soon able to find out whether anti-inflammatory drug can be a standard 
medication for atherosclerosis.  
Table 2-3. Potential anti-atherosclerosis drugs in various stages of clinical trials. 
Drug Pharmacology Phase Findings 
Succinobucol Antioxidant 3 In a randomized, double-blind, placebo-
controlled trial, succinobucol had no effect on 
the secondary prevention of cardiovascular 
events (Tardif et al. 2008).  
A-002 sPLA2 
inhibitor 
2 Patients treated with A-002 have a reduction 
in sPLA2 concentration of 86.7% as 
compared to 4.8% in placebo (P <0.0001). 
There is also a significant reduction in 
inflammatory mediators and markers 
(Meuwese et al. 2009). 
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Drug Pharmacology Phase Findings 
Darapladib sPLA2 
inhibitor 
2 In phase 2 clinical trials, daraplaedib treatment 
retards the growth of the necrotic core 
(Mohler et al. 2008) accompanied by a 
decrease in the plasma level of inflammatory 




2 In a 12 week trial, patients on statin treatment 
and further treated with eprotirome have 
decreased levels of atherogeneic lipoproteins 
(Ladenson et al. 2010). 
VIA-2291 5-LO inhibitor 2 Patients on the drug for 12 weeks have 
significant reduction in both leukotrienes 
levels and noncalcified plaque volume (Tardif 





2 Patients treated with RVX-208 have increased 




T Patients treated with torcetrapib have a 
significant reduction in LDL cholesterol level 
and a substantial increase in HDL cholesterol 
level. However, the drug does not halt the 
progression of atherosclerosis (Kastelein et al. 
2007). 
T - Torcetrapib clinical trial was terminated due to its associated side effects in patients. 
     12
2.2 Serum Amyloid A (SAA) 
2.2.1 SAA gene and protein family 
SAA gene family is clustered in chromosome 11 in human. There are 4 members of the 
family, SAA1, SAA2, SAA3 and SAA4. SAA1 and SAA2 are located 18kb apart in 
chromosome 11 while SAA4 is positioned 11kb downstream from SAA2 (Kluve-
Beckerman and Song 1995). SAA3 is a pseudogene as no TATA-box is found in the 
upstream region of the gene (Malle et al. 1993). In mouse, the SAA gene family also consists 
of 4 members, SAA1, SAA2, SAA4 and SAA5. SAA1 and SAA2 encode for A-SAA while 
SAA5 encodes for constitutive SAA. SAA4 is a pseudo-gene. The gene family of SAA is 
thus well-conserved between human and mouse.  
SAAs are apolipoproteins of HDL. Both SAA1 and SAA2 consist of 122 amino acids in the 
fully-translated protein which includes a signal peptide consisting of 18 amino acids. SAA1 
and SAA2 differ only at seven positions with sequence identity of 95%.   
SAA4 is the constitutive SAA of the SAA protein family. The main organ of production of 
SAA4 is the liver and its production is not upregulated during APR. During homeostasis, 
SAA4 constitutes about 90% of the body SAAs (de Beer et al. 1995). Its exact role is, 
however, not known, a study however showed that SAA4 is associated with only a specific 
subpopulation of HDL particles which does not play a role in the cholesterol transfer 
between cells (de Beer et al. 1995).  
 
2.2.2 The acute phase response (APR) 
APR is a systemic response to injury and the presence of infectious agents. The APR 
constitutes part of innate immunity in human and serves to contain and counteracts     
infection or injury and eventually restores homeostasis in a timely manner.  
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Essential components of the APR include the macrophages and other immune cells, the liver 
and the hypothalamus. In the occurrence of an injury or infection, the macrophages which 
encounter the stimulating agent response by producing chemokines and cytokines. The 
secretion of cytokines stimulates the migration of monocytes to the inflamed site and 
facilitates local inflammation. Cytokines such as IL-1 and IL-6 also act on the liver and 
stimulate the hepatic production of plasma proteins, the APPs. In addition, the cytokines 
also act on the hypothalamus and induce a fever response.  
APPs that are produced by the liver include A-SAA, pentraxins, CRP, fibrinogen, 
haptoglobin and α1-acid glycoprotein (Jensen and Whitehead 1998; Malle et al. 1993).  The 
plasma concentration of A-SAA starts to decline after 72 hours and return to baseline after 
5-7 days (Gabay and Kushner 1999). The kinetic of A-SAA during an APR appears to reflect 
on their role as an important modulator of the innate immune system.  
 
2.2.3 Protein structure and functional domains of SAA1 
SAA1 transcript encodes for a protein of 122 amino acids. Upon translation, the signal 
peptide is cleaved to form the mature SAA1 which consists of 104 amino acids. Thus far, 
there has been no published data on the tertiary structure of SAA1. There have, however, 
been some predicted models of the secondary structure of SAA1 (Stevens 2004; Turnell et 
al. 1986).   
The important functional domains of SAA1 are elucidated through mutagenesis studies. The 
N-terminal region was reported to have several functional functions including its 
amyloidogenic potential and as a binding region for both lipid and prostacyclin. In 
amyloidosis, insoluble amyloid fibrils are deposited in tissues and organ. These deposits can 
damage the extracellular matrix of these tissues and impede their functions. The amyloid 
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fibrils are formed from the proteolytic cleavage of the N-terminal of SAA1 (Nakamura 
2008). The lipid binding region is elucidated through various independent studies and resides 
at the N-terminal region (residue 1-30). The region between amino acid 29 to 42 was 
reported to be important for the binding of SAA1 to components of the extracellular matrix 
(Uhlar and Whitehead 1999). The only reported role of the C-terminal domain is its 
facilitation of the binding of SAA1 to neutrophils; a peptide corresponding to residues 77-
104 of SAA1 was found to inhibit the binding of SAA1 to neutrophils (Preciado-Patt et al. 
1996b).  
Structural analysis of SAA1 by more advanced methods such as nuclear magnetic resonance 
and protein crystallography has not been possible due to the unstable nature of SAA1. A 
proposed secondary structure of SAA1 is composed of two α-helix region (residues 11-27 
and residues 72-86) and two beta-sheet regions (residues 36-45 and residues 59-68). The 
presence of alpha-helices in the structure of SAA1 is validated by circular dichorism analysis 
which indicates an alpha-helix content of between 33%-44% (Meeker and Sack 1998) and 
50% (Wang et al. 2002).               
 
2.2.4 Production of A-SAA and the role of perivascular adipocytes in CAD  
In human, A-SAA is produced in the liver during the APR. Under homeostatic condition, 
the adipose tissue is the major source of A-SAA. In a northern blot study, the expression of 
A-SAA was found to be at least 15 fold more in the adipose tissue than in the liver. In the 
same study, A-SAA was not expressed in most organs of the human including smooth 
muscle cells, kidney, liver, lung and brain. The dominant site of A-SAA production is most 
likely to be species specific; in the mouse, the expression of A-SAA appears to be solely in 
the liver (Yang et al. 2006). The secretion of A-SAA by the adipocytes is also verified by 
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various studies. Poitou et al found that A-SAA is expressed in the adipose tissue of obese 
subjects and the level of SAA protein is dependent on adipocyte size and macrophage 
infilitration (Poitou et al. 2009). In addition, in a study of two extremely obese subjects, the 
expression of A-SAA protein was found to increase by 3.5 fold as compared to lean subjects 
(Poitou et al. 2005). Although, there are currently no in-vivo study on the association of the 
development of the adipose tissue with A-SAA level, the earlier mentioned studies indicate 
the importance of adipose tissue as a dominant source of A-SAA under non acute-phase 
conditions and its relevance to the pathogenesis of CAD given that the level of A-SAA 
secreted by adipose tissue increases with macrophage infiltration. 
Since A-SAA is predominantly produced by adipocytes under homeostatic condition, the 
local production of A-SAA by perivascular adipocytes might play an important role in CAD. 
Perivascular adipose tissue is found in the vicinity of the aorta and it is not separated from 
the blood vessel wall by an anatomic barrier. The perivascular adipocytes thus provide a local 
source of A-SAA production to the developing lesion. Transport of A-SAA into the inner 
vasculature is facilitated by the vaso vasorum which was reported to proliferate during 
vascular inflammation (Gossl et al. 2009; Kwon et al. 1998) . This local source of A-SAA in 
the coronary artery might play a significant role in CAD as compared to the transient 
increase of A-SAA during acute phase response.  
 
2.2.5 Regulation of the expression of A-SAA 
Production of A-SAA is regulated at both the transcriptional level and post-translational 
level. The proximal 450 bases of the promoter region of SAA1 and SAA2 have a sequence 
identity of 87%. Transcription factor binding sites that are present in both SAA1 and SAA2 
includes NFkappaB (-85 to -93 for SAA1; -84 to -92 for SAA2), NF-IL6 (-171 to -187 for 
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SAA1; -170 to -186 for SAA2) and AP-2 (-253 to -264 and -382 to -387 for SAA1; -391 to -
396 for SAA2) (Thorn and Whitehead 2002). The potential of the NFkappaB and NF-IL6 
transcription factor binding sites to influence the transcriptional efficiency of SAA2 were 
verified using the chloramphenicol acetyl transferase  as a reporter gene and transfected into 
Hela cells (Edbrooke et al. 1991) and HepG2 cells respectively (Betts et al. 1993). In 
addition, the promoter regions of both SAA1 and SAA2 were also to found have similar 
induction profiles on A-SAA expression when induced with IL-1, IL-6 or both (Thorn and 
Whitehead 2002). Both NFkappaB and NF-IL6 are positive regulators of A-SAA 
transcription while AP2 is a repressor of A-SAA transcription.  
Production of A-SAA is stimulated by the presence of cytokines TNF-α, IL-1 and IL-6. The 
NF-IL6 binding site is important for IL6 stimulated A-SAA production. IL-6 binds to its 
receptor on the cell surface and stimulates the phosphorylation of the NF-IL6 transcription 
factor which translocates into the nucleus. In the nucleus, NF-IL6 binds to the DNA and 
upregulates A-SAA production. IL-6 synergises with IL-1 to bring about a greater increase in 
A-SAA expression. The mechanism of the synergy between IL-1 and IL-6 is not elucidated 
but it is postulated that it could be brought about by interaction between the bound factors 
at the NFkappaB binding site and NF-IL6 binding site. The binding of IL-1 to its receptor 
results in the phosphorylation of the NFkappaB-IkappaB complex and causes the 
subsequent dissociation of IkappaB from the complex. The liberated NFkappaB is able to 
translocate into the nucleus and promotes the transcription of A-SAA.  
Expression of A-SAA is also regulated by the glucocorticoids. The influence of 
glucocorticoids can be both direct and indirect. Glucocorticoid stimulates the expression of 
SAA1 through the glucocorticoid response element (GRE) present in the promoter of 
SAA1. However, the promoter of SAA2 does not process any GRE (Thorn and Whitehead 
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2002). The indirect effects of glucocorticoid on A-SAA expression occur through its 
interaction with NFkappaB (Koj 1996) and its negative regulation on the production of 
cytokines which stimulate A-SAA expression (Edwards et al. 2007).  
In addition to an increase in A-SAA mRNA expression, the increase in A-SAA is also 
facilitated by post-translation modification of A-SAA transcript which increases their half-
life. This is supported by a study in mouse in which there was a 10 fold difference between 
transcription rate and A-SAA mRNA level (Lowell et al. 1986). The stability of mRNA is 
probably regulated by polyadenylation which increases the half-life of A-SAA mRNA 
(Couttet et al. 1997). 
 
2.2.6 Surface receptors of A-SAA 
Kinkley et al reported that SAA1 and SAA2 have differential passage through peritoneal 
macrophages. At 37oC, SAA2 is able to move across the plasma membrane and into the 
nucleus, however, SAA1 is not readily taken up by the cells (Kinkley et al. 2006). Various in 
vitro studies have revealed that there might be a number of surface receptors for A-SAA 
which includes toll-like receptor 2 (TLR2), toll-like receptor 4 (TLR4), formyl peptide 
receptor like 1 (FPRL-1), CD36 and LIMPII analogous-1 (CLA-1) and receptor for 
advanced glycation end products (RAGE). The reported functions of these receptors are 
listed in Table 2-4. It is possible that the surface receptors are important for SAA1 signaling 
while SAA2 might alter cellular function through a combination of surface receptor signaling 
and its direct influence on nuclear receptors.  
Toll-like receptors, TLR2 and TLR4, are two of the surface receptors of A-SAA. In a study 
using TLR2 knockout mice, TLR2 was found to be responsible for A-SAA stimulated 
induction of granulocyte colony-stimulating factor in cultured macrophages (He et al. 2009). 
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In another study using TLR2 knockout mice, TLR2 was reported to be associated with the 
secretion of proinflammatory cytokines, IL-12p40 and TNF-α from mouse macrophages 
(Cheng et al. 2008). The role of TLR4 as a receptor of A-SAA was elucidated using TLR4-/- 
mice; SAA stimulated induction of nitric oxide is almost completely abrogated in 
macrophages isolated from the knockout mice (Sandri et al. 2008).   
RAGE is another receptor for A-SAA. SAA induced secretion of tissue factor in PBMCs 
was reduced by 40-50% in the presence of a peptide antagonist of RAGE (Cai et al. 2007). 
CLA-1, the human orthologue of scavenger receptor class B type I (SR-BI), is another 
reported receptor of SAA, in Hela cells, over-expression of CLA-1 results in increased IL-8 
secretion (Baranova et al. 2005).   
The last known receptor of A-SAA is FPRL-1. In human umbilical vein endothelial cells, 
siRNA of FPRL-1 was enough to completely block the A-SAA induced production of 
chemokine (C-C motif) ligand 2 (CCL2) (Lee et al. 2009b).  SAA stimulated proliferation of 
human fibroblast-like synoviocytes was also inhibited when short interfering RNA of FPRL-
1 was introduced (Lee et al. 2006).   
Most of the studies on the surface receptors of SAA were conducted using a recombinant 
form of SAA with sequence that is a hybrid of SAA1 and SAA2. Further study will need to 
be performed in order to verify whether these receptors are gene-specific. The numerous 
receptors of A-SAA might indicate that SAA can activate numerous pathways and modulate 
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Table 2-4. Reported surface receptors of A-SAA. There are limited studies on most of the 
reported receptors of A-SAA. 
Receptor Pathway activation 
CLA-1 Regulates the selective uptake and efflux of cholesterol from cells that 
expresses CLA-1 receptor (Ji et al. 1997). 
 Mediates SAA induced activation of ERK1/2 and p38 (Baranova et al. 
2005). 
FPRL-1 Facilitates invasion and migration of cancerous cells (Cheng et al. 2010; 
Coffelt et al. 2009). 
 Induces chemotaxis of human neutrophils and phagocytes through 
activation of p38 MAP kinase-mediated signaling pathway (Selvatici et al. 
2006; Shim et al. 2009). 
 Promotes secretion of inflammatory cytokines and chemokines (Lee et al. 
2009a; Lee et al. 2009b). 
RAGE Binds numerous ligands, high mobility group box 1 (HMBG1), calcium 
binding S-100 family of proteins, immunoglobulin light chains and prions 
that are produced in response to cellular or physiological stresses and results 
in the activation of various pathways including MAPK, PI3k-Akt, Jak-STAT 
and NF-kappaB (Sims et al. 2010).  One consequence of RAGE interaction 
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Receptor Pathway activation 
TLR2 Induction of apoptosis through MyD88 activation of caspase 8 (Aliprantis et 
al. 2000). 
 Promotes secretion of proinflammatory cytokines, TNF-α, IL-8, and IL-12, 
through phosphatidylinositol 3-kinase (PI3K)-NF-kappaB pathway (Lee et 
al. 2010; Meng et al. 2008). 
TLR4 Stimulates pro-inflammatory response through TRAF6-NF-kappaB pathway 
(Verstak et al. 2009). 
 
2.2.7 A-SAA as a clinical biomarker 
Various studies have been conducted to study whether the level of A-SAA can be used as a 
clinical biomarker for chronic inflammatory diseases. The level of A-SAA has been indicated 
as a useful clinical marker for acute coronary syndrome, stable CAD, cancer and metabolic 
syndrome (Cho et al. 2010; Kotani et al. 2009; Ramankulov et al. 2008).  
In study of subjects with non-ST-segment elevation acute coronary syndromes (NSTE-
ACS), elevated level of A-SAA was found to be a good predictor of adverse clinical events 
within 30 days of the occurrence of NSTE-ACS (Kosuge et al. 2007). It is also a reliable 
marker to predict 14-day mortality in patients with unstable angina or myocardial infarction 
(Morrow et al. 2000). A-SAA level is also useful as a biomarker for future cardiovascular 
events and is highly predictive for 3 year cardiovascular events in patients with myocardial 
ischemia (Johnson et al. 2004). However, the level of A-SAA is not useful as a biomarker for 
cardiovascular mortality within 5 years in patients with acute coronary syndromes (Zairis et 
al. 2007). Lastly, the complex, SAA-LDL, was reported to be a good prognosis indicator in 
patients with stable coronary disease (Ogasawara et al. 2004).  
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Although, A-SAA appears to be an important clinical marker for cardiovascular diseases, the 
aim of this study is to further clarify the pathogenic role of SAA1 in atherosclerosis rather 
than its use as a prognostic factor. This research interest is supported by various studies 
which suggest a direct role of A-SAA in atherosclerosis as written in section 2.2.8 and 2.2.10. 
 
2.2.8 Atherogenic effects of A-SAA 
In vitro and in vivo studies appear to indicate that A-SAA might have a more direct effect on 
atherosclerosis. In a study by Meek et al, mRNA of A-SAA was found in important 
components of the atherosclerotic lesion including endothelial cells lining the lumen of 
coronary artery, the vaso vasorum as well as in newly formed vessels. In addition, the 
expression was especially high in macrophage foam cells and in adventitial adipocytes (Meek 
et al. 1994). A-SAA also has other atherogenic effects such as facilitating the remodeling of 
the extracellular matrix, debilitating the anti-oxidant effects of HDL through remodeling of 
the HDL and stimulating the secretion of inflammatory cytokines from endothelial cells and 
monocytes.   
A-SAA was reported to stimulate the hydrolytic activity of sPLA2. sPLA2 hydrolyses 
lipoproteins and converts the phospholipids into atherogenic oxygenated and non-
oxygenated fatty acids. In addition, acute-phase HDL, which is predominantly enriched with 
A-SAA, was found to be more susceptible to the hydrolytic activity of sPLA2 (Pruzanski et 
al. 1995).  
Another known atherogenic effect of A-SAA is its induction of the secretion of 
inflammatory cytokines and chemokines from endothelial cells and monocytes (Yang et al. 
2006). In addition, A-SAA also stimulates the synthesis of inflammatory compounds such as 
eicosanoids and thromboxane A2 (Malle et al. 1997). As a result of the secretion of 
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chemokines as well as other unidentified molecules, A-SAA was reported to induce the 
migration and adhesion of monocytes and T-lymphocytes (Badolato et al. 1994; Preciado-
Patt et al. 1996a; Xu et al. 1995). Hence, A-SAA can function as a stimulant of 
chemoattractant and facilitates the migration of immune cells that form an important 
component of atherosclerotic lesion.  
A-SAA also facilitates the remodeling of the HDL molecules. A-SAA substitutes and 
replaces apo-AI in the HDL molecule; HDL enriched with A-SAA has lost 87% of its apo 
AI content and 91% of its paraoxonase activity (Van Lenten et al. 1995). Both apo-AI and 
paraoxonase have anti-oxidant properties and increased paraoxonase activity in transgenic 
mice was shown to have a negative impact on the formation of atherosclerotic lesion (Tward 
et al. 2002). In addition to losing its anti-oxidant components, acute-phase HDL has 
increased level of pro-oxidant ceruloplasmin (Navab et al. 1998). As a result of the 
remodeling, acute-phase HDL was observed to amplify the increase in monocyte 
transmigration as a result of LDL oxidation (Van Lenten et al. 1995).   
Lastly, A-SAA level was found to correlate with lesion size and the extent of atherosclerosis 
in both mice and rabbits fed on a high fat diet. The extent of atherosclerosis was, however, 
found to be independent of circulating lipid and lipoprotein concentrations for both studies 
(Lewis et al. 2004; Van Lenten et al. 2007). In another study, when both atherosclerosis 
susceptible mice (C57BL/6) and atherosclerosis resistant mice (C3H/HeJ) were fed on a 
high fat diet, the former had a five fold increase in A-SAA level. A-SAA, apo A-I and 
proteoglycans were also found to colocalise in atherosclerotic lesion and thus A-SAA 
appears to play an important role in the development of the lesion (Liao et al. 1994). It 
mediates its role possibly through a combination of its ability to induce the migration of 
immune cells and its pro-oxidant capability which facilitates the remodeling of HDL.  
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2.2.9 Atheroprotective effects of A-SAA 
There are fewer reports on the atheroportective effects of A-SAA. A-SAA was reported to 
inhibit the oxidative burst response in neutrophils (Linke et al. 1991). A-SAA also inhibits 
the activation of platelet and prevent its aggregation which might be beneficial in curbing 
atherogenesis at site of injury (Zimlichman et al. 1990). Acute-phase HDL has better affinity 
for macrophages as compared to normal HDL and this improved affinity aids in its reverse 
cholesterol transport from the macrophages (Kisilevsky and Subrahmanyan 1992). 
Furthermore, acute-phase HDL that was remodeled by heparan sulfate was found to have a 
3-fold increase in cholesterol efflux activity. Since SAA has a binding site for heparan sulfate, 
the result is supportive of the hypothesis that SAA aids in the removal of cholesterol 
sequestered by macrophages from site of injury (Tam et al. 2008) .   
  
2.2.10 Role of A-SAA in other chronic inflammatory diseases 
Expression of A-SAA is also elevated in other chronic diseases such as RA and systemic 
lupus erythematosus (SLE) where immune reaction plays a significant role in the 
pathogenesis. Patients with RA were reported to have high serum levels of SAA (De Beer et 
al. 1982). In addition, A-SAA induces the secretion of chemokines from synovial cells and in 
a RA synovial/SCID mouse chimera model A-SAA was shown to promote synovial cell 
proliferation and angiogenesis (Connolly et al. 2010). In another study, the binding of SAA 
to FPRL-1 aids in the proliferation of human fibroblast-like synoviocytes by preventing its 
apoptosis (Lee et al. 2006). The increased susceptibility of patients with rheumatoid arthritis 
or SLE to cardiovascular diseases (Manzi et al. 1997; Trager and Ward 2001) highlights the 
inflammatory nature of these diseases and that increased susceptibility could be due to a 
dysfunctional immune regulation on a systemic level. As there are similarities in the disease 
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pathogenesis of these three diseases, it is possible that A-SAA might play a role in these 
diseases and could be an important risk factor. 
Elevation of A-SAA was observed in various cancers including lung cancer and endometrial 
endometroid carcinoma (Cremona et al. 2010). In one study, there was a 77% elevation of 
A-SAA in patients with poor prognosis (Cho et al. 2010). In patients with endometrial 
endometrioid carcinoma, there was on average a 4 fold increase in serum A-SAA. A-SAA 
was also observed to be secreted by endometrioid carcinoma cell line in vitro (Cocco et al. 
2010). The exact mechanism through which A-SAA might influence the development of 
cancer is currently unknown, it is, however, postulated that A-SAA might modulate cancer 
development through its effect on the extracellular matrix. A-SAA has binding domains for 
laminin and heparan sulfate which are components of the extracellular matrix. As a result of 
its interaction with the extracellular matrix, increased secretion of A-SAA might decrease the 
adhesion of metastatic cells to the extracellular matrix and facilitates metastasis (Malle et al. 
2009).   
. 
2.3 Genetic Analysis of Complex Diseases 
2.3.1 Complex Diseases 
Complex diseases are polygenic and multifactorial diseases in which multiple genes can alter 
susceptibility to the disease. The phenotypic expression of the disease usually involves the 
interaction of several disease-causing genotypes, each conferring additional risk to disease 
susceptibility. In additional, the environment also plays a role in disease susceptibility such as 
diet in the case of CAD.  Due to the polygenic nature, it is difficult to determine genes that 
are important in that pathogenesis of complex diseases in the past. With the availability of 
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modern high-throughput tools which facilitate the undertaking of genome-wide association 
study, the genetic study of complex diseases should gather pace.   
 
2.3.2 Genetic variation and SNPs 
Genetic variation refers to the change of nucleotide in a DNA sequence. When a variation 
occurs in the exon region of a gene, it can alter the primary sequence of the protein and 
possibly its structure. Variation in the regulatory region, such as in the promoter can affect 
the regulation of the protein expression. Variation can occur through various means such as 
a nucleotide substitution, an insertion or deletion of either a single or multiple nucleotides as 
well as duplication of segment of nucleotides. When the nucleotides are not inserted or 
deleted in multiple of threes, as in frameshift mutation, all the encoded amino acids 
following the mutation will be altered. Although frameshift mutation is more likely to have a 
significant effect on the protein structure, it is rare as such mutation is more likely to be 
deleterious and possibly lethal to the individual.    
SNP is a single nucleotide change in the DNA sequence that exhibits variation in a 
population. A single nucleotide variation is labeled a SNP if the frequency in the population 
is 1% or more (Twyman and Primrose 2003). SNPs constitute more than 90% of the 
variation in the human genome (Collins et al. 1998). There is on average a SNP every 1,000 
nucleotides, 20% of the SNPs occur in the exon region and half of the SNPs in the exon 
region encodes for synonymous amino acids (Li and Sadler 1991). Due to the frequency of 
SNPs, they are useful as genetic markers for genome wide association study. As genetic 
markers, SNPs have advantage over microsatellites as they are generally more stable. In 
addition, non-synonymous SNPs can contribute to the pathogenesis of complex diseases 
although its effect is modest in most cases (Casas et al. 2006).   
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2.3.3 Methods for genetic analysis of human diseases 
There are various methods for studying human diseases that are heritable to a certain extent. 
Three of the methods, parametric linkage analysis, non-parametric linkage analysis and 
association study are discussed below. The choice of method is usually dependent on the 
nature of the disease. As parametric linkage analysis requires a precise genetic model in order 
to determine the linkage of the disease mutation to the marker, it is useful for investigating 
linkage in a monogenic disease as the allele frequencies, penetrance and mode of inheritance 
is easier to determine in a monogenic disease. For multi-factorial diseases such as CAD, 
diabetes and cancer, the polygenic nature of the diseases make it difficult for a genetic model 
to be employed. Despite its limitations, parametric linkage analysis has been used in the past 
for the genetic analysis of multi-factorial diseases such as breast cancer and schizophrenia 
with sporadic success. Parametric linkage studies for these diseases involve the studies of 
rare families where the diseases were inherited in a Mendelian pattern. The study leads to the 
identification of the BRCA1 and BRCA2 genes. However, the application of this method for 
the study of schizophrenia was not successful (Strachan and Reed 1999). As it is difficult to 
identify families in which complex genetic diseases are inherited in a Mendelian pattern, 
these diseases have often been analysed using non-parametric linkage and association study 
in which a genetic model need not be specified. Parametric linkage analysis, non-parametric 
linkage analysis and genetic association study are described in details below. 
 
2.3.3.1 Parametric linkage analysis 
Parametric linkage analysis is based on the concept that two genes residing on the same 
chromosome are most likely to segregate together during meiosis if they are in close 
proximity. Hence, if a disease mutation is located in between two genetic markers, the whole 
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segment will be inherited together by the offspring. This linkage of the disease mutation to 
genetic marker can be statistically accessed by the ‘logarithim of the odds’ (LOD) score. The 
LOD scores from independent study of pedigrees can be combined together as long as the 
two analysis are performed using the same genetic model. Through determining the linkage, 
parametric linkage analysis can narrow down the location of the disease mutation.  
Parametric linkage analysis is only useful for simple Mendelian diseases such as cystic fibrosis 
or sickle-cell anaemia where a single mutation in a gene is responsible for the disease. In 
multi-factorial disease, the combined effects of multiple genes limit the usefulness of 
parametric linkage analysis. Other limitations of parametic linkage analysis include the need 
to recruit large pedigree as well as the requirement to make assumption regarding the mode 
of inheritance of the disease gene (Tang et al. 2008).    
 
2.3.3.2  Non-parametric linkage analysis 
An alterative to linkage analysis is the non-parametric linkage analysis. Non-parametric 
linkage analysis is also called the allele-sharing method. One major difference for the allele 
sharing method as compared to parametric linkage analysis is that the mode of genetic 
inheritance is not considered in the analysis. The basis of allele-sharing methods is illustrated 
in the genetic analysis of siblings affected with a certain disease which is named the affected 
sibpair analysis. In sibpair analysis, the marker alleles are analysed in affected siblings. If the 
affected siblings share similar maker alleles and this sharing deviates from the ratio of that of 
random Mendelian segregration, the marker alleles and the disease allele are genetically 
linked (Zhu et al. 2010).  
The advantage of allele-sharing methods is that a large pedigree need not be recruited. Its 
application in the genetic analysis of complex disease is, however, limited by the polygenic 
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nature of such disease. The polygenic nature of complex disease implies that each allele 
might have subtle effects on disease susceptibility and thus disease allele with subtle 
influence might be missed.  
 
2.3.3.3  Genetic association study 
Association study is pertinent to the genetic analysis of complex disease. Unlike the other 
two approaches, association study is able to identify alleles either with a subtle or significant 
effect on susceptibility to complex diseases (Risch and Merikangas 1996). One form of 
association studies is the case-controlled study. In the case-controlled study, two groups of 
subjects, healthy and disease are recruited and genotyped for the allele of interest. The allele 
frequencies of both groups are compared and level of significance is determined by χ2. The 
strength of association of the allele with the disease is determined by the odds ratio.   
Unlike, linkage study, association study is conducted at the population level, sample subjects 
need not be related and hence recruitment of subjects is less challenging. Since association 
study is performed at population level, care must be taken to ensure that the population is 
homogenous and that cases and controls are well-matched. An inability to ensure population 
homogeneity can lead to inaccurate result. 
   
2.3.4 Mutation screening 
A number of methods exist for mutation screening. Some methods that are suitable for 
mutation screening of a candidate gene are discussed below. Denaturating gradient gel 
electrophoresis (DGGE), denaturing high performance liquid chromatography (DHPLC) 
and high resolution melting (HRM) identify mutation through altered melting property of 
the double-stranded DNA as a result of the nucleotide(s) change. Single-strand 
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conformation polymorphism (SCCP) differentiates alleles through different secondary 
structure conformation that results from the base change. 
 
2.3.4.1 Denaturating gradient gel electrophoresis (DGGE) 
Polymerase chain reaction (PCR) product is melted and allowed to reanneal to facilitate the 
formation of heteroduplex. In the presence of a variant allele, a heterogenous mix containing 
wild-type and mutant homoduplexes and heteroduplexes DNA will be formed. This mixture 
is separated using a denaturing gradient gel. As the homoduplex and heteroduplex denature 
at different rates in the gel, they are efficiently separated and thus the variation can be 
identified. Although DGGE is an inexpensive method, the preparation of the denaturing 
gradient gel is a relatively tedious process. In addition, variation in the procedure of gel 
preparation often lead to variable results; reproducibility is often an issue with DGGE 
(Balogh et al. 2004)      
 
2.3.4.2  Denaturing high performance liquid chromatography (DHPLC) 
Similar to DGGE, DHPLC identifies mutation through the differentiation of homoduplexes 
and heteroduplexes. The separation cartridge has higher affinity for the homoduplexes and 
as such heteroduplexes will be eluted first. Eluted DNA is captured by a UV detector and 
the result is displayed in the form of electropherogram. The presence of a heterozygote is 
evident from the multiple peaks in the electropherogram. DHPLC have numerous 
advantages including its reproducibility and high sensitivity. DHPLC also have comparable 
sensitivity and is able to detect mutations in amplicons of up to 700 bases (O'Donovan et al. 
1998). One key disadvantage of DHPLC is that the machine requires regular maintenance.    
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2.3.4.3  High resolution melting (HRM) 
In HRM, a saturating double strand DNA (dsDNA) binding dye is used. PCR amplification 
is carried out in the presence of the dsDNA binding dye. The PCR product is melted and 
the change in fluorescence levels during melting is captured at high resolution. 
Heteroduplexes are less stable and hence its melting profile will be different from the 
homoduplexes. The advantages of HRM are that it is inexpensive as the procedure only 
requires standard PCR reagent plus a dsDNA binding dye and that the procedure is much 
faster as compared to other listed methods as no separation step is required (Vossen et al. 
2009). HRM also has high sensitivity, however, its sensitivity is dependent on the amplicon 
having a single melting domain, the amplicon size is thus minimized in most cases for 
optimal result.   
 
2.3.4.4  Single-strand conformation polymorphism (SCCP) 
SSCP is performed using single stranded DNA. A single nucleotide change can alter the 
secondary structure of single stranded DNA. The altered secondary structure will have 
differential mobility in non-denaturing polyacrylamide gel which is distinguishable from the 
wild-type. SSCP has being used in the past for mutation screening and it is inexpensive and 
does not require dedicated equipment. However, its principle disadvantage is its 
inconsistency; its sensitivity can range from 50% to 97% (Liu et al. 1996; Mogensen et al. 
2003). Various factors can affect the sensitivity of SSCP including the size of amplicon, 
choice of gel matrix, CG content and DNA concentration (Hayashi and Yandell 1993; 
Humphries et al. 1997). SSCP is now replaced by more sensitive methods that are also 
relatively economical.   
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2.3.4.5  Choice of method for mutation screening 
Both high sensitivity and reproducibility are important criteria for accurate mutation 
screening. HRM and DHPLC both meet these criteria and both have other advantages. The 
usage of either method will depend on availability of equipment. Although, HRM is relatively 
new, the procedure is fast and as much as 384 samples can be processed by the equipment 
simultaneously; this is a big advantage compared to DHPLC which take a few minutes to 
analyse each sample. However, HRM works best when the amplicon has only a single 
melting domain; an amplicon with multiple melting domains will disrupt the melting profile 
and the resultant curve is not suitable for analysis. Under such circumstance, DHPLC would 
be a better alternative.   
Table 2-5. Comparision of the various methods for genetic variant screening. 
Method Ease of 
optimisation 
Ease of setup Fast High 
sensitivity 
Reproducibility 
HRM      
DHPLC      
SSCP      
DGGE      
 
2.3.5 Methods of SNP genotyping 
SNP genotyping methods should preferably be efficient, inexpensive and have a very high 
degree of specificity. The gold standard for genotyping a SNP is through direct sequencing 
of the amplicon containing the SNP. Sequencing is, however, a tedious and time-consuming 
process and not sufficiently high throughput. Other SNP genotyping approaches include 
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restriction fragment length polymorphism (RFLP), allele-specific PCR, primer extension, 
molecular probes such as molecular beacons, oligonucleotide ligase assay and HRM.  
 
2.3.5.1  Allele-specific PCR 
There are two main procedures in which allele-specific PCR can be carried out. In the more 
commonly used procedure, the amplification refractory mutation system, two separate PCR 
reactions are used to genotype an unknown sample. In each PCR reaction, there is one 
common primer and one allele specific primer which has its 3’ end complementary to the 
allele it recognizes. When the sample is a homozygote, successful amplification will only 
occur in one of the tube. The products of both PCR reactions are separated by gel 
electrophoresis and the genotype can be ascertained. The two major advantages of 
amplification refractory mutation system are that unlike RFLP it can theoretically be 
employed to genotype most SNPs and that it is inexpensive as it does not require the use of 
dedicated equipment or expensive probes. One disadvantage of allele-specific PCR is that 
two reactions are needed to genotype one sample while other alternatives that require the use 
of differentially labeled probes only require one reaction.   
 
2.3.5.2  Restriction fragment length polymorphism (RFLP) 
The specificity of restriction enzyme (RE) to recognize and cleave a particular DNA 
sequence is used to differentiate between wild-type and mutant. A RE that recognizes one of 
the alleles is chosen. As a result of selective cleavage, different genotypes will have different 
cleavage patterns that are evident upon running gel electrophoresis. RFLP is a traditional 
method used for genotyping before the advent of more modern genotyping tools. There are 
numerous advantages including its simplicity, specificity and the lack of need for the usage of 
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dedicated equipment (Xu et al. 2003). However, RFLP cannot be used for all genotyping 
procedures as there might not be any RE with the matching recognition sequence. RFLP is 
also relatively more tedious compared to modern methods such as HRM which does not 
require gel electrophoresis to differentiate the product.  
 
2.3.5.3  HRM 
The mechanism is similar to that as described for the application of HRM in genetic variant 
scanning. In one method of HRM genotyping, primers are designed to flank the SNP; as the 
the wild-type and variant amplicons have different melting temperatures, they can be 
distinguished from the resultant melting curves. Genotyping using HRM is efficient for class 
1 and 2 SNPs where there is a difference in CG content between the amplicons containing 
the two different alleles. For class 3 and 4 SNPs whereby there is no overall change in the 
CG content of the amplicon, Liew et al reported that such SNPs can still be genotyped using 
small amplicon melting if the sample is spiked with a sample of known genotype prior to the 
genotyping procedure (Liew et al. 2004). The inability to genotype class 3 and 4 SNP 
efficiently is a significant disadvantage of HRM genotyping. However, other methods of 
HRM genotyping such as using unlabeled probes to differentiate the different genotypes has 
being reported (Zhou et al. 2004). Overall, genotyping using HRM is still in its nascent stage 
and the fine tuning of this technique will probably make it an attractive alternative to other 
more expensive methods.   
 
2.3.5.4  Primer Extension 
In primer extension, primer is designed to hydridise to the base adjacent to the SNP of 
interest. The primer is extended through the incorporation of dideoxynucleotides (ddNTPs), 
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which is tagged with a fluorescence signal. Incorporation of the ddNTP ceases further 
extension and the genotype can be identified through the capturing and analysis of the 
fluorescence signal. Primer extension is suitable for high throughput, multiplexing SNP 
genotyping and has been used in several fine-mapping genotyping platforms such as 
MassArray (Sequenom, San Diego, CA) and SNPstream (Beckman Coulter, Brea, CA).   
 
2.3.5.5  Hybridisation probes 
Both molecular beacons and Taqman probes are based on the principle of fluorescence 
resonance energy transfer (FRET). FRET involves the process of energy transfer from a 
donor fluorophore to an acceptor fluorophore (quencher) when they are in close proximity. 
As a result, the fluorescence that is emited by the donor is quenched in the presence of the 
acceptor. A Taqman probe consists of a donor fluorophore and an acceptor fluorophore at 
opposite ends. Two allele-specific taqman probes are used for each set of genotyping assay 
with each probe tagged with a unique donor fluorophore. If the probe binds to its target 
DNA, it will be cleaved by the activity of the Taq polymerase during PCR amplification 
resulting in the emission of fluorescence as the donor is no longer quenched by the acceptor. 
The analysis of the fluorescence signal will indicate the genotype of the DNA. Hybridisation 
probes are sensitive when the probes are well-designed. The chemistry of hybridisation 
probe has been incorporated into commercially available high throughput genotyping 
platform, TaqMan open array (Life Technologies, Carlsbad, CA), that allows for multiplexing 
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2.3.5.6  Selection of method for SNP genotyping 
Most of the above methods are good alternatives to DNA sequencing which is relatively less 
efficient. The purpose for SNP genotyping is usually the most important criteria in deciding 
on the choice of method used. A high throughput platform such as Taqman open array is 
useful for SNP genotyping in genome wide association studies where a large number of 
SNPs need to be genotyped. In a candidate gene approach where there are fewer SNPs to be 
genotyped, it is not cost-efficient to use multiplexing high throughput platform. For such 
study, methods such as RFLP or allele-specific PCR would be more relevant. Primer 
extension which uses enzyme-linked immunosorbent assay (ELISA) as a detection tool does 
not offer a good alternative to either RFLP or allele-specific PCR as it also involves 
additional post-PCR steps. HRM is a useful genotyping tool for SNP analysis; it is, however, 
still a relatively new method and that thorough optimization should be performed for each 
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Table 2-6. Comparison of the various methods for SNP genotyping. 













     
RFLP a     
Primer 
Extension 
   b  
HRM      
Hybridisation 
probes 
     
a: The cost of RFLP is dependent on the cost of the specific RE used.  
b: Primer Extension is also used for high throughput system that requires dedicated 
equipment. 
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MATERIALS AND METHODS 
3.1 SAA1 SNPs survey 
3.1.1 Study subjects 
Cord blood DNA samples from 96 anonymous, unrelated Singaporean Chinese neonates 
delivered in the National University Hospital, Singapore, were used in the study. Ethical 
approval from the university IRB was obtained for the usage of the DNA for the purpose of 
the study.  
 
3.1.2 DNA extraction 
DNA was extracted from blood samples using the phenol-chloroform method. The blood 
sample was first centrifuged at 3500 rpm for 7 min to obtain the cellular components of the 
blood. TE buffer was then added to lyse the red blood cells. The lysate was centrifuged and 
the white blood cell pellet was collected. The pellet was incubated overnight at 37oC with TE 
buffer supplement with 0.5% SDS and 300 µg Proteinase K. Lysed pellet was mixed and 
centrifuged at 3500 rpm for 10 min first with phenol and then with chloroform. The purified 
DNA obtained was transferred into a clean tube for DNA precipitation. DNA was 
precipitated by adding a solution mixture containing 0.1 M sodium acetate and 100% ethanol 
to the purified DNA.   
 
3.1.3 Primer design and PCR amplification 
Primers used for the amplification of the 3 exons of SAA1 were designed using the 
published sequence on NCBI (Ref Seq: NM_199161.2). The sequence for the promoter 
region used was based on a released human genomic sequence annotated in 2006 by the 
International Human Genome Sequencing Consortium. The PrimerQuest (Integrated DNA 
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Technologies, Coralville, Iowa, United States) software was used for designing primers. 
Primers were designed to yield an amplicon size of not more than 300 bases for optimal 
screening using HRM. Due to the high sequence similarity between SAA1 and SAA2, the 
primer sequences were aligned with the genomic sequence of SAA2 to ensure that either the 
forward or reverse primer was SAA1 specific. The specificity of the primers was tested using 
an online application (http://genome.ucsc.edu/cgi-bin/hgPcr?command=start).  For both 
exon 1 and 2, non SAA1-specific amplicons were designed due to the near identical 
sequences of both genes at both regions. 
PCR amplification was carried out in a thermocycler (Biometra, Göttingen, Germany). The 
reaction mixture consists of 20ng genomic DNA,  5X reaction buffer, 2.0mM Mg2+, 0.2 mM 
dNTPs, 1 µM forward and reverse primers, 1X LC Green dye (Idaho Technology, Salt Lake 
City, Utah, United States) and 1 unit Taq Polymerase (Promega, Madison, Wisconsin, United 
States). The primer sequences and their annealing temperature are as shown in Table 3-1. 
Amplification conditions consist of an initial denaturation at 95oC for 3 min and 35 cycles of 
30s of denaturation at 95oC, 30s of annealing at the indicated Tm as shown in Table 4.1, and 
30s of extension at 72oC. A final extension step of 72oC for 5 min was included and 
thereafter the amplicons were loaded onto a 96 well plate for melting analysis to be carried 
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Table 3-1. Primer sequences for amplification of selected regions of SAA1.   









5’  CTTGACCTCCTGGGTCTC  3’ 
5’  CCTCTGAAATGAAGTCCCTC  3’ 
277 61 - 
Promoter 2 
(c.-1088  to 
c.-809) 
5’  GACCTAGTCTGTCAGCTTTG  3’ 
5’  CAACCTGAGGGAACAAGATG  3’ 




5’  TGGTCTCCTGCCCTGACA  3’ 
5’  GCGGTGGCTGCTATTTATACTGAG  3’ 
221 64 - 
Exon 1 
 
5’  CAGGCTCTCGTCGGAATA  3’ 
5’  AGTTTATCAGGTCCAGGGTG  3’ 
238 64 - 
Exon 2 
 
5’  TGTTCTCCTGATGTCCCTTC  3’ 
5’  CAGCCTCTAACTTCTCCACA  3’ 
280 62 + 
Exon 3 
 
5’  TAATCTCCTTCTTGCCTGCC  3’ 
5’  CCCATTGTGTACCCTCTCC  3’ 
254 64 + 
 
3.1.4 High resolution amplicon melting and automatic calling 
HRM was carried out in the LightCycler 480. The samples were first heated at 95oC for 1 
min to denature the double-stranded DNA. Upon denaturation, the samples were incubated 
at 40oC for 1 min to facilitate the formation of heteroduplex, and then progressively heated 
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from 65oC to 95oC at a ramp rate of 1oC/s with the fluorescent signal levels simultaneously 
acquired 25 times for every degree change.  
The fluorescent melting curves generated were analysed using LC480 Gene Scanning 
software v1.5 (Roche Diagnostics, Indianapolis, Indiana, United States). All curves were 
normalized and temperature shifted before they were automatically assigned into different 
subgroup by the calling tool module of the software.  
The automatic calling tool provided by the Gene Scanning software was used to differentiate 
the wild type from the genetic variants based on the melting curves. The sensitivity of the 
calling tool is the only parameter to be set and it ranges from 0 to 1. A lower sensitivity will 
produce a smaller number of subgroups while a higher sensitivity will yield a greater number 
of groups albeit with more false positives. A sensitivity setting of 0.15 was deemed to be 
optimal for our study. The identity of the variants in the various subgroups as assigned by 
the Gene Scanning software was determined by DNA sequencing.   
 
3.1.5 DNA sequencing 
Amplicons were treated with 5 units of exonuclease I (Fermentas, Burlington, Ontario, 
Canada) and 1 unit of shrimp alkaline phosphatase (Fermentas) at 37oC for 15 min to 
degrade any of the remaining primers. Subsequently, 2.0 µl of the PCR product was mixed 
with 0.16 µM of either the forward or reverse primer, and 1.0 µl of the BigDye terminators 
(Life Technologies, Carlsbad, California, United States) in a 5 µl reaction mix. The 
sequencing mix was incubated in the thermocycler with 35 cycles of 10s of denaturation at 
96oC, 5s of primer annealing at 50oC and 4 min of primer extension at 60oC.   
DNA incorporated with BigDye was precipitated using the ethanol/sodium acetate method. 
The precipitation mix consisting of 5.0 µl of BigDye incorporated DNA, 0.1M sodium 
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acetate and 62.5% ethanol was incubated at -20oC for 20 min. Upon incubation, the mixture 
was centrifuged at 13,000 rpm for 15 min to obtain the DNA pellet. The DNA pellet was 
washed with cold 70% ethanol and centrifuged at 13,000 rpm for 5 min. The supernatant 
was then aspirated and the pellet was left to dry in the dark. 12 µl Hi-Di formamide was 
added to the dried pellet and the mixture was loaded onto the sequencing plate. Sequencing 
was carried out in the 16-capillary ABI 3100 (Life Technologies) and analysed using 
sequencing analysis software v3.7 (Applied Biosystems).   
 
3.1.6 In silico SNP discovery and in silico prediction of biological significance of 
polymorphisms 
In silico SNP discovery using sequences deposited in public databases was performed to 
supplement our experimental approach. The SNPFINDER program (Buetow et al., 1999; 
http://lpgws.nci.nih.gov/perl/snpbr) which predicts SNPs based on deposited expressed 
sequence tags (EST). SNPs were discovered using Unigene SAA1 cluster, Hs. 632144 and 
the analysis was carried out with an expect value of 0.01 to minimize false positive.  
For non-synonymous SNP that is found in the coding region, the change is analysed for its 
likely impact on the protein function using ClusterW and BLOSUM62. ClusterW was used 
to determine whether the amino acid at the indicated position is well-conserved among 
various species. The amino acid sequence of human SAA1 (CAG47037.1) was aligned with 
that of rabbit (Oryctolagus cuniculus; AAB20616.1), Syrian hamster (Mesocricetus auratus; 
AAB27187.1), Mouse (Mus musculus; NP_0.331431.1), Rhesus monkey (Macaca mulatto; 
XP_001086137.1), Cheetah (Acinonyx jubatus; BAG06986.1).  The impact of amino acid 
change on the primary structure of the protein was analysed by using the substitution matrix, 
BLOSUM62 (Henikoff and Henikoff, 1992). Positive values on the BLOSUM62 are 
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indicative of frequent and conservative substitution while negative values indicate rare and 
non-conservative substitution. The naming of the genetic variant is based on NM199161.2 
for the exons and NG_021330.1 for the promoter.   
 
3.2      Genetic association study 
3.2.1 Study subjects 
Samples from CAD patients who underwent coronary bypass graft surgery were used. All 
cases have at least 50% stenosis in at least one of the major coronary arteries as revealed by 
angiography. In addition, cases that have valve diseases, hypertension and diabetes were 
excluded from the study.  
The controls were healthy subjects attending a routine health screening or rhinologic 
examination in the Ear, Nose and Throat clinic of the National University Hospital. Control 
subjects were screened for potential confounders through a combination of questionnaire, 
physical examinations and laboratory tests. The confounders that were screened include both 
personal medical history of CAD and diabetes. Tests that were conducted include glucose 
level quantification and electrocardiogram. Control subjects with these potential 
confounders were excluded from the study. Ethical approval from the university IRB was 
obtained for the usage of the DNA for the purpose of the study.   
 
3.2.2 Genotyping by allele-specifc PCR 
The SNP, c.-913G>A, was genotyped using allele-specific PCR. Two PCR reactions were set 
up for each sample; in one of the reactions the reverse primer has a 3’ end that is 
complementary to the wild type while in the other reaction a primer with 3’ end 
complementary to the variant was added. The universal forward primer used was 5’ 
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GCAGATGCACACTACCA 3’ while the reverse primers used were 5’ 
GCGGAGTTGAGAGTTGGAGCACC 3’ (wild type complementary) and 5’ 
GCGGAGTTGAGAGTTGGAGCACT 3’ (variant type complementary).    
The reaction mix consists of 1 µl genomic DNA,  5X reaction buffer, 2.0mM Mg2+, 0.2 mM 
dNTPs, 1 µM forward and reverse primers and 1 unit Taq Polymerase (Promega). 
Amplification conditions consist of an initial denaturation at 95oC for 2 min and 35 cycles of 
30s of denaturation at 95oC, 30s of annealing at 61oC, and 30s of extension at 72oC. A final 
extension step at 72oC for 5 min was included and the samples were then loaded onto 2% 
agarose gel.    
 
3.2.3 Genotyping by RFLP  
208C>T, 224 C>T, and 269G>A were genotyped using RFLP. PCR was carried out in a 20 
µl reaction mix containing 1 µl genomic DNA, 0.2 mM dNTPs (Fermentas), 0.5 µM forward 
and reverse primers and 0.4 units DNA polymerase (Finnzymes, Espoo, Finland). The 
primers used were 5’ GCCAATTACATCGGCTCAG 3’ (forward) and 5’ 
TGGCCAAAGAATCTCTGGAT 3’ (reverse) for 208C>T and 224C>T. 5’ GCT CAC 
TCG CCT GAT TAT TA 3’ (forward) and 5’ ATACCCATTGTGTACCCTCT 3’ (reverse) 
were used for the genotyping of 269 G>A. Amplification conditions consist of an initial 
denaturation at 95oC for 3 min and 30 cycles of 15s of denaturation at 96oC, 30s of annealing 
at 58oC, and 25s of extension at 72oC. A final extension step at 72oC for 2 min was included.   
208C>T, 224C>T and 269G>A were genotyped using BanI, BclI, and NcoI restriction 
enzyme respectively. The digested products were resolved using 2.5% agarose gels. Gel was 
visualized under ultraviolet illumination and images were captured using ChemiDoc XRS 
(Bio-Rad Laboratories, Hercules, California, United States).   
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3.2.4  Data analysis 
Allele frequencies were determined by the gene-counting method. Significant departure of 
genotype frequencies from Hardy–Weinberg expectation and the test of allele frequencies 
difference between cases and controls were determined by the chi-square test. The effects 
from confounding variables such as age, gender and BMI were adjusted using a binary 
logistic regression model. The odds ratios for the various SNPs were determined using co-
dominant, dominant and recessive genetic models when possible. Odds ratios are presented 
with 95% confidence intervals (CI). Statistical significance is set at p < 0.05.   
  
3.3 Functional study of p.Gly90Asp 
3.3.1 Preparation of recombinant human SAA1 
3.3.1.1 Plasmid construction 
Both wild-type and variant SAA1 cDNAs were synthesized using custom gene synthesis 
service (Genscript, Piscataway, New Jersey, United States). The synthesized sequence 
contains the sequence 5’ CATGGATCCGATGATGATGATAAG  3’  at the 5’ end which 
incorporates the BamHI restriction enzyme recognition site. The 3’ end contains the 
sequence 5’ CTGAGAAATACTGAGCTTCCTCGAATTCTGTCGACG 3’ with the 
EcoRI recognition site. The cDNAs were subcloned into pET21-a (+) vector (Novagen, 
Madison, Wisconsin, United States). Subcloning service was provided by Genscript.   
The pET21-a vector was transformed into E. coli strain BL21(DE3)pLysS competent cells 
(Novagen). 1 µl of plasmid vector was added to 20 µl of competent cells and the mixture was 
incubated on ice for 5 min, followed by incubation at 42oC for 30s. The tube was then 
placed on ice and 80 µl of SOC medium was added. Transformants were plated on agar plate 
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containing 300 µg/ml carbenicillin (Novagen) and 34 µg/ml chloramphenicol (Sigma 
Aldrich, St. Louis, Missouri, United States). Successful transformants were verified by 
sequencing the plasmid DNA extracted from the colony using a pair of primers, 5’ 
TAATACGACTCACTATAGGG 3’ (F) and 5’ GCTAGTTATTGCTCAGCGG 3’ (R). 
   
3.3.1.2 Production of wild-type and variant human SAA1 protein 
Successful clones of wild-type and variant SAA1 were grown overnight by innoculating a 
single colony in 10 ml LB medium supplemented with 500 µg/ml carbenicillin and 34 µg/ml 
chloramphenicol at 37oC. Overnight culture was then transferred into a flask containing 300 
ml of LB medium supplemented with the same concentration of carbenicillin and 
chloramphenicol. The culture was incubated at 37oC until the OD600 of the medium reached 
0.6 upon which expression of the recombinant protein was induced by the addition of 1mM 
iso-propylthio-ß-D-galactoside (IPTG). After 30 min, 200 µg/ml rifampicin (Novagen) was 
added to inhibit E.coli RNA polymerase. The culture was incubated for 3 hr before the cells 
were collected by centrifugation at 1000 rpm. Cell pellet obtained was lysed using a lysis 
buffer containing 4.29 mM Na2HPO4, 1.47 mM KH2PO4, 2.7mM KCl, 0.137M NaCl, 0.1% 
Tween-20, 0.002% sodium azide supplemented with protease inhibitor cocktail (Roche). The 
lysate was homogenated and 150U of benzonase nuclease (Novagen) was added and the 
resulting mixture was incubated for 30 min at 4oC.   
 
3.3.1.3 Purification of recombinant SAA 
Recombinant SAA was purified from the cell lysate using immunoaffinity purification. T7-
tag antibody agarose resin (Novagen) was loaded onto a centrifuge column (Thermo 
Scientific, Rockford, Illinois, United States). Resin was equilibrated by washing with 4 ml of 
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lysis buffer; the process was repeated 4 times. Cell lysate was then loaded and the lysate was 
washed 5 times with 4 ml of lysis buffer. Binded protein was eluted using 0.1M citric acid 
and the eluent was immediately neutralized with 2M Tris base. The purity of the eluted 
protein was ascertained by SDS-PAGE followed by Coomasie Blue staining. In addition, the 
functionality of the protein was verified by determining its ability to induce cytokine release 
from THP-1 dervied macrophages as outlined in 3.3.3.   
 
3.3.1.4 Endotoxin removal and detection 
Endotoxin was removed from the recombinant SAA protein using an endotoxin removal kit 
(Norgen Biotek, Thorold, Ontario, Canada). Purified protein was loaded onto a spin column 
prior to the addition of a proprietary Endotoxin Removal solution. The mixture was 
incubated for 5 min and centrifuged to remove the endotoxin. Endotoxin-free protein was 
eluted using the elution buffer supplied and the eluted protein was neutralized immediately 
upon elution. Endotoxin level in the protein was detected using a single test gel clot limulus 
amebocyte lysate kit (Lonza, Allendale, New Jersey, United States); both wild-type and 
variant protein were verified to have an endotoxin level of less than 0.0625EU/µg of 
protein.   
 
3.3.1.5 Concentration and quantification of protein 
The protein was dialysed and concentrated using a concentrator unit (Millipore, Billerica, 
Massachusetts, United States) with a molecular weight cutoff of 10kDa. Concentrated 
protein was quantified using Nanodrop (Thermo Scientific) and diluted to 1mg/ml using 
endotoxin-free water (Lonza). The recombinant protein was stored at -80oC until use.   
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3.3.2 Cell culture of macrophages and neutrophils 
Human monocytic leukaemia cell line, THP-1, was obtained from the American Type 
Culture Collection (ATCC, Manassas, Virginia, United States). Cells were grown in RPMI 
medium supplemented with 10% FBS (Life Technologies), 0.05 mM 2-mercaptoethanol, 100 
units/ml penicillin and 100 µg/ml streptomycin in a 5% CO2 humidified atmosphere. Cells 
were seeded at 2.5 X 106 cells/ml in a 6-well plate in the presence of 0.1 µg/ml phorbol 
myristate acetate (PMA) for 7 days to induce differentiation into macrophages. 
Differentiation of monocytes into macrophages was confirmed through an observable 
morphological change.  
Human promyleocytic leukaemia cell line, HL-60, was purchased from ATCC. Cells were 
grown in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 20% FBS, 100 
units/ml penicillin and 100 µg/ml streptomycin in a 5% CO2 humidified atmosphere. Cells 
were seeded at 1.0 X106 cells/ml and incubated with 1.3% DMSO for 5 days to induce 
differentiation into neutrophils. Cellular viability was performed on the fifth day using 
Trypan blue and differentiation of HL-60 cells into neutrophils was confirmed by Wright-
Giemsa staining. Differentiated cells have multi-lobular nucleus which are stained purple.   
 
3.3.3 Measurement of cytokines release from macrophages and neutrophils  
THP-1 induced macrophages were incubated for 1 hr at 37oC in 1ml serum-free RPMI 
medium supplemented with 0.05 mM 2-mercaptoethanol, 100 units/ml penicillin and 100 
µg/ml streptomycin. Wild-type and variant SAA were added into separate wells at a 
concentration of either 3 µg or 15 µg per ml of medium. Cells were incubated for 24 hours 
in a 5% CO2 incubator. The supernatants were assayed for IL-8, TNF-α and MCP-1 using 
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enzyme-linked immunosorbent assay (ELISA) kit (RayBiotech, Norcross, Georgia, United 
States). All assays were carried out in triplicates and according the instruction of the vendor. 
The colour intensity was measured at 450 nm using an ELISA plate reader (BioRad, 
Hercules, California, United States).   
HL-60 induced neutrophils were incubated for 1 hr at 37oC in 1 ml serum-free IMDM 
medium supplemented with 0.05 mM 2-mercaptoethanol, 100 units/ml penicillin and 100 
µg/ml streptomycin. Wild-type and variant SAA were added into separate wells at a 
concentration of either 4 µg or 20 µg per ml of medium. Cells were incubated for 24 hours 
in a 5% CO2 incubator. The supernatants were assayed for IL-8 and MCP-1 using ELISA  
kits (RayBiotech).  
 
3.3.4 Neutral cholesteryl ester hydrolase (nCEH) activity assay 
Cholesteryl oleate (Sigma Aldrich) was dissolved in a solution containing 1.7%(v/v) 
polyoxyethylene 9 lauryl ether (Sigma Aldrich) and 0.8% (w/v) NaCl. Sodium taurocholate, 
sodium cholate hydrate, 4-aminoantipyrine, cholesterol oxidase, horseradish peroxidase Type 
II and porcine nCEH were obtained from Sigma Aldrich. A 1 ml reaction mix containing 
700 µl potassium phosphate buffer (400 mM, pH 7.0), 16.7 µl sodium taurocholate (15% 
w/v), 16.7 µl sodium cholate hydrate (15% w/v), 33.3 µl horse radish peroxidase type II (50 
units/ml), 166.7 µl cholesteryl oleate (8.6 mM), 16.7 µl phenol (5% w/v) and 20 µg of 
recombinant SAA1 were added into a curvette. The solution was mixed and allowed to 
equilibrate to 37oC.  16.7 µl each of 4-aminoantipyrine (1.76% w/v), cholesterol oxidase (30 
units/ml) and porcine nCEH (0.40 units/ml) were added to the curvette. The mixture was 
mixed and incubated at 37oC for either 15 or 45 mins and the colour intensity was measured 
at 500nm.   
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3.3.5 Data analysis 
Measurements were expressed as mean of 3 independent experiments. The difference 
between wild-type SAA1 treatment and variant SAA1 was compared using Student’s t-test 
and was deemed significant for P-value <0.05.  
 
3.4 Microarray study 
3.4.1 Cell culture 
THP-1 was grown in RPMI medium supplemented with FBS in a 6-well plate and induced 
to differentiate into macrophages as described in section 3.3.2. After 7 days, the medium was 
replaced with serum-free RPMI medium and 1 µg/ml of recombinant wild-type or variant 
SAA1 was added into the appropriate well. The cells were incubated for either 8 h or 24 h. 
Upon incubation, the cells were removed by scraping and the cell pellet was collected upon 
centrifugation.   
 
3.4.2  RNA isolation and cRNA synthesis 
RNA was extracted from cell pellet using a RNA extraction kit (Qiagen). Prior to RNA 
amplification, the integrity of RNA was verified using formaldehyde gel electrophoresis.  
RNA amplification was carried out with Illumina TotalPrep RNA amplification  
kit (Life Technologies). The amplification procedure consists of first strand and second 
strand cDNA synthesis, following which the double-stranded cDNA was purified and used 
for cRNA synthesis using biotinylated nucleotides. The concentration  and integrity of the 
cRNA was determined using Nanodrop (Thermo Scientific) and Bioanalyser (Agilent, Santa 
Clara, California, United States) respectively. cRNA was stored at -20oC prior to 
hybridization onto microarray chip.     
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3.4.3  Array hybridization and scanning 
The hybridation mixture consists of 750 µg of cRNA and hybridization buffer that is 
supplied with the kit. Hybridisation mixture was heated at 65oC for 5 min and loaded onto 
Illumina HT-12 microarray chip (San Diego, California, United States). Microarray chip was 
incubated for 16 hr in a hybridization oven. Upon hybridization, the chip was washed using 
the proprietary buffer supplied and stained with Streptavidin Cy3. The stained chip was dried 
by centrifugation and the chip was read using a BeadArray reader.    
 
 3.4.4 Quantitative real-time PCR validation of microarray results 
Real-time PCR was conducted to validate differential RNA concentration between wild-type 
SAA1, variant SAA1 and untreated control as identified through microarray analysis. The 
primers for real-time PCR were designed using Primer3  
(http://frodo.wi.mit.edu/primer3/). The cDNA sequences used for primer design are 
available from genome browser (http://genome.ucsc.edu/). The melting temperature for all 
primers was set as 60oC for easy optimization and running of the assay. The sequences of the 
primers are as shown in Table 3-2.    
cDNA was synthesised from total RNA using a first strand cDNA synthesis kit (Fermentas) 
and quantified using Nanodrop. Real-time PCR was carried out using Roche light cycler 480. 
The reaction mixture consists of reaction master mix, 0.2 µM of forward and reverse primer 
and 30ng of cDNA in a 10 µl reaction mix. Amplification conditions consist of an initial 
denaturation at 95oC for 10 min, 45 cycles of 10s of denaturation at 95oC, 30s of annealing at 
60 oC and 8s of extension at 72oC. The threshold cycle (CT) value was determined using the 
accompanied software. The relative changes in gene expression between wild type SAA1, 
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variant SAA1 and untreated were determined using a software for gene expression analysis, 
REST 2009 (Qiagen).    
Table 3-2. Primer sequences for real-time PCR. 
Comparison in 
expression 
Gene Forward Primer /  
Reverse Primer 
Wild-type vs 
untreated (8 h) 
Baculoviral IAP repeat-
containing protein 3 
(BIRC3) 
5’ ATGCTTTTGCTGTGATGGTG 3’ 
5’ CGGATGAACTCCTGTCCTTT 3’ 
 Chemokine (C-C motif) 
ligand 3 (CCL3) 
5’ GGCTCTCTACAACCAGTTCT 3’ 
5’ CTGGCTGCTCGTCTCAAAG 3’ 
 Chemokine (C-C motif) 
ligand 4-like 1 (CCL4L1) 
5’ GCTGCCTTCTGCTCTCTAGC 3’ 
5’ ACCACAAAGTTGCGAGGAAG 3’ 
 Interleukin 23A (IL23A) 5’ ACAGAAGCTCTGCACACTGG 3’ 
5’ CCACACTGGATATGGGGAAC 3’ 
 Integrin, alpha 1 (ITGA1) 5’ GTCCAGTTGGGAGAGGTGAA 3’ 
5’ CTCCATTTGGGTTGGTGACT 3’ 
 Myristoylated alanine-rich 
C-kinase substrate 
(MARCKS) 
5’ ATGAGTGCCCAGTTCTCC 3’ 
5’ AGTGTCGCCGTTTACCTT 3’ 
Wild-type vs 
untreated (8 h) 
Oxidised low density 
lipoprotein receptor 1 
(OLR1) 
5’ AAGGACCAGCCTGATGAGAA 3’ 
5’ AGGCAAAGGACCCCTAGAGT 3’ 
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Comparison in 
expression 
Gene Forward Primer /  
Reverse Primer 
Wild-type vs 
untreated (8 h) 
Plasminogen activator 
inhibitor 2 precursor 
(SERPINB2) 
5’ CATTCATCCTTCCGCTCTCT 3’ 
5’ CTACTGCCTGGGGTTCTGAG 3’ 
Wild-type vs 
variant (8 h)  
Bone morphogenetic  
protein receptor type II 
(BMPR2) 
5’ TCATTGCTTTGGCATCAGTC 3’ 
5’ ATCAAGAGAGGGTTCGGATG 3’ 
 Prolyl 4-hydroxylase 
(P4HA1) 
5’ AAGACAGAAGAGGACAAGTTAGAA 3’ 
5’ GCATTTACTGGATGCCCAAC 3’ 
Wild-type vs 
variant (24 h) 
Acyl-coenzyme A 
thioesterase 8 (ACOT8) 
5’ TGTGAGACCCTCATTGACCA 3’ 
5’ GGATGGGTTTACTGGCTTGA 3’ 
 CD63 5’ TTGCTCTACGTCCTCCTGCT 3’ 
5’ GTAGCCCCCTGGATTATGGT 3’ 
 Carboxylesterase 1 
(CES1) 
5’ CACTCCTGCTGACTTGACCA 3’ 
5’ CAGATGCCCAGGCGATATT 3’ 
 Integrin beta-1 binding 
protein 1 (ITGB1BP1) 
5’ CAGATGCAAGCAATGAGGAA 3’ 
5’ CAGAGTCAAAAGCGGTGGAT 3’ 
Wild-type vs 
variant (24 h) 
Lysyl oxidase homolog 
3 (LOXL3) 
5’ AGCGAAAAGAGGGTCAACG 3’ 
5’ AGGGAACAGAGGGAGAGGTG 3’ 
 Myosin 1f (MYO1F) 5’ GTGCTTCTTCCCCAGATCAC 3’ 
5’ GTAGGGCATCTGCTTGAAGG 3’ 
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Comparison in 
expression 
Gene Forward Primer /  
Reverse Primer 
Wild-type vs 
variant (24 h) 
5’-AMP-activated protein 
kinase subunit gamma-1 
(PRKAG1) 
5’ CACTACCACCCCCGTCTATG 3’ 
5’ GGTCTTTTCTGCTGCCAGAT 3’ 
 Sterol regulatory element-
binding protein 1 
(SREBF1) 
5’ AGCTCAAGGATCTGGTGGTG 3’ 
5’ GTTTCTGGTTGCTGTGTTGC 3’ 
Internal Control  Beta-2 microglobulin 
(B2M) 
5’ GTGCTCACGCTACTCTCTCT 3’ 
5’ TCAATGTCGGATGGATGAAA 3’ 
 LIM and SH3 domain 
protein 1 (LASP1) 
5’ CCACGGAGAAGGTGAACTGT 3’ 
5’ GTGAAGGACTGCTTGGGGTA 3’ 
 FXYD domain-containing 
ion transport regulator 5 
(FXYD5) 
5’ CCTGTGTCTTCTCACCATCG  3’ 
5’ GGAACCTGAATGTCCATGAT 3’ 
 
3.4.5  Data analysis 
The quality of the microarray data was determined using Genome Studio (Illumina) while 
normalization and analysis were performed using Beadstudio and R/Bioconductor. For each 
treatment group, the average of the two readings was determined and fold change was 
determined between SAA1 and untreated at both 8 h and 24 h. For each treatment group, 
the average of the two readings was determined and fold change was determined at 8 h and 
24 h. Genes with a differential expression of >1.5 fold (wild-type vs variant) or > 2.0 fold 
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(wild-type vs untreated) were analysed using gene annotation software, GOEAST 
(http://omicslab.genetics.ac.cn/GOEAST/).  
To find enriched pathways at 8 h, the upregulated genes were mapped onto PathwayAPI 
(Soh et al. 2010) which comprises of information extracted from KEGG (Kanehisa 2009), 
WikiPathways (Kelder et al. 2009; Pico et al. 2008) and IPA(Jimenez-Marin et al. 2009). The 
online repository is available at http://pathwayapi.com/. There are 4268 nodes and 35307 
nodes, corresponding to 544 pathways. Statistical significance for pathway enriched was 
determined using hypergeometric method (P < 0.05).  
For real-time PCR, statistical difference between two different treatment groups was 
determined using randomization and bootstrapping technique that is incorporated into the 
REST 2009 software (Qiagen). Readings from 3 independent experiments were used for the 
statistical analysis.  Statistical difference between treatment and control in the quantification 
of the levels of chemokines was compared using Student’s t-test (P < 0.05). 
 
3.5  Elucidation of surface receptors of SAA1 
3.5.1  Cell culture 
RAW264 mouse macrophages (ATCC) were grown in DMEM medium supplemented with 
10% FBS, 100 units/ml penicillin and 100 µg/ml streptomycin. 1.0 X 105 cells were seeded 
in a 6-well plate one day prior to the assay and on the day of assay the medium was replaced 
with serum free DMEM medium. 1 µg of recombinant human SAA1 and either 10 µg of 
anti-mouse TLR2 (eBiosience, San Diego, California, United States) antibody or 5 µl of anti-
mouse SR-BI antibody (Novus Biologicals, Littleton, Colorado, United States) were added 
into the appropriate wells. The culture was incubated in a 5% CO2 incubator at 37
oC for 8 h 
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and the supernatant was collected. The cytokine levels in the supernatants were determined 
using ELISA as outlined in section 3.3.3.   
 
 3.5.2 Data Analysis 
Results were obtained from the mean of 3 independent experiments. The difference between 
antibody treatment and untreated was compared using Student’s t-test and was deemed 
significant for P-value <0.05. The P-value cut-off for significance when multiple 
comparisons were involved was adjusted by the Bonferroni correction.   
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4 SAA1 SNPs SURVEY  
4.1 Introduction 
Chronic inflammation plays an important role in the pathogenesis of atherosclerosis. Given 
its immune regulatory role in protecting the body from infection and the inflammatory 
nature of atherosclerosis, A-SAA has increasingly been associated with atherosclerosis. A-
SAA consists of SAA-1 and SAA2 of which SAA1 was reported to be the predominant form 
of A-SAA present in plasma and the precursor of fibrillar deposits in reactive amyloidosis 
(Yamada et al. 1999). The potential role A-SAA might play in atherosclerosis suggests that 
certain polymorphisms of SAA1 might be associated with coronary artery disease (CAD). 
However, to date, no genetic variant screening has been conducted on SAA1.  
Prior to the SNPs survey conducted in 2008, only 2 non-synonymous SNPs of SAA1, 
p.Ala70Val (rs1136743) and p.Ala75Val (rs1136747), were reported in publication. SNP 
survey was carried out in the exon and promoter region of SAA1 as polymorphisms in these 
regions should have a more direct impact on the function and plasma concentration of 
SAA1. Variant screening was performed using cord blod DNA from 96 annoymous, 
unrelated Singaporean Chinese neonates delivered in the National University Hospital, 
Singapore. The method of HRM was used for the variant screening. The result is 
supplemented with data obtained from dbSNP and a SNP discovery program SNPFinder. 
The SNPfinder program, (http://lpgws.nci.nih.gov/perl/snpbr), (Beutow et al, 1999) was 
used for SNP discovery using information deposited in UniGene. Unlike other programs, 
which mine SNP by alignment of deposited text-based sequences (Cox et al, 2001), 
SNPfinder analyses the DNA electrophoretogram of the accompanied sequence to ensure 
that allelic variant identified does not arise due to a sequencing error.  
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4.2 Results 
4.2.1 SNPfinder analysis of deposited Unigene Expressed Sequence Tags (ESTs) 
In silico discovery was performed in 2007 using SNPfinder. The program uses deposited 
genetic information from Unigene HS.632144 which consists of 11 mRNA sequences and 
332 non-redundant EST sequences. ESTs were obtained from various human tissues 
including kidney, mammary gland, prostate, lung, liver and adipose. The list of SNPs as 
predicted by SNPfinder after analyzing deposited DNA electrophoretograms, together with 
the corresponding Blosum62 score is as shown in Table 4-1. A positive Blosum62 score is 
indicative of conservative amino acid substitution. In total, 18 non-synonymous SNPs were 
predicted by SNPFinder. The multiple sequence alignment of SAA1 from various species is 
as shown in Figure 4-1. The alignment of the sequences from ESTs and the subsequent 
prediction of the SNPs, p.Met42Thr, are shown in Figure 4-2. Due to its algorithms and its 
source data, SNPFinder does not predict SNP present in the promoter region.  
Table 4-1. List of predicted SAA1 SNPs by SNPFINDER. 
SNP Ref CDS SNP Blosum 62 
Score 
Conserved in multiple 
organisms* 
Region  
rs11545475 p.Leu12Ser -2 Yes Exon 1 
- p.Leu14Pro -3 Yes Exon 1 
- p.Met42Thr -1 Yes Exon 2 
- p.Glu44Gly -2 Yes Exon 2 
- p.Tyr47His 2 No Exon 2 
- p.Tyr53His 2 Yes Exon 2 
- p.Tyr53Cys -2 Yes Exon 2 
rs1136743 p.Ala70Val 0 No Exon 2 
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SNP Ref CDS SNP Blosum 62 
Score 
Conserved in multiple 
organisms* 
Region  
rs11545468 p.Trp71Arg -3 Yes Exon 2 
rs1136747 p.Ala75Val 0 No Exon 2 
- p.Asp78Asn 1 Yes Exon 3 
- p.Ile83Thr -1 No Exon 3 
- p.Gln84Pro -1 Yes Exon 3 
rs1059559 p.Phe86Leu 0 No Exon 3 
- p.Asp93Gly -1 No Exon 3 
- p.Ala96Val 0 Yes Exon 3 
rs17850140 p.Asn101Asp 1 Yes Exon 3 
- p.Pro119Ser -1 Yes Exon 3 
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                                                   (1)                     (2) (3)                                                                          
(4) (5)    (6)            (7) 
Rabbit          MKLLSGLLLCSLVLGVSSQRWFSFIGEATQGAWDMWRAYSDMREANYINADKYFHARGNY 60 
Cheetah         MKLFTGLIFCSLVLGVSS-EWYSFLGEAAQGAWDMWRAYSDMREANYIGADKYFHARGNY 59 
Human           MKLLTGLVFCSLVLGVSSRSFFSFLGEAFDGARDMWRAYSDMREANYIGSDKYFHARGNY 60 
Monkey          MKLLTGLVFCSLVLGVNSRSWFSFLGEAYDGARDMWRAYSDMKEANYKNSDKYFHARGNY 60 
Hamster         --------------------WFSFIREAYQGAEDMWRAYSDMKEANWRDSDKYFHARGNY 40 
Mouse           MKLLTSLVFCSLLLGVCHGGFFSFVHEAFQGAGDMWRAYTDMKEANWKNSDKYFHARGNY 60 
                                    ::**: ** :** ******:**:***: .:********** 
 
                                       (8)(9)     (10)  (11)     (12, 13)(14)                 (15)(16)    (17)  (18)       
(19,20)          (21) 
Rabbit          DAAQRGPGGVWAAKVISDAREDLQRL--------MGHGAEDSMADQAANEWGRSGKDPNH 112 
Cheetah         DAAQRGPGGAWAAKVISDARENSQRVTDFFRHGSSGHGAEDSKADQAANEWGRSGKDPNH 119 
Human           DAAKRGPGGAWAAEVISDARENIQRF--------FGHGAEDSLADQAANEWGRSGKDPNH 112 
Monkey          DAAQRGPGGVWAAEVISDARENIQKL--------LGRGAEDTLADQAANEWGRSGKDPNH 112 
Hamster         DAAKRGPGGVWAAEVISDAREGIQSL--------MGRGHEDSMADQEANRWGRSGNDPNH 92 
Mouse           DAAQRGPGGVWAAEKISDGREAFQEF--------FGRGHEDTIADQEANRHGRSGKDPNY 112 
                ***:*****.***: ***.**  * .         *:* **: *** **. ****:***: 
 
                     (22) (23)   
Rabbit          FRPKGLPDKY 122 
Cheetah         FRPAGLPDKY 129 
Human           FRPAGLPEKY 122 
Monkey          FRPAGLPEKY 122 
Hamster         YRPAGLPDKY 102 
Mouse           YRPPGLPDKY 122 
                :*****:*** 
Figure 4-1. Multiple sequence alignment of SAA1 in Cheetah (BAG06986), Hamster 
(ABB27187), Human (CAG47037), Monkey (XP_001086137), Mouse (NP_033143) and 
Rabbit (AAB20616). The underlined sequence represents the signal peptide which will be 
cleaved to produce the mature protein. Highlighted in blue is the non-synonymous SNP 
identified by dbSNP which includes p.Leu3Pro (1), p.Phe87Ser(15), p.His89Arg (16), 
p.Glu102Lys (20), p.Lys108Arg (21)  and p.Lys121Arg (23). The position highlighted in 
green are SNPs identified by SNPfinder which includes p.Leu14Pro (3), p.Met42Thr (4), 
p.Glu44Gly (5), p.Tyr47Cys (6), p.Tyr53His, p.Tyr53Cys (7), p.Asp78Asn (11), p.Ile83Thr 
(12), p.Gln84Pro (13), p.Asp93Gly (17), p.Ala96Val (18) and p.Pro119Ser (22). SNPs that 
are predicted by SNPfinder and listed in dbSNP are in yellow: p.Leu12Ser (2), p.Ala70Val (8), 
p.Trp71Arg (9),  p.Ala75Val (10), p.Phe86Leu (14) and p.Asn101Asp (19).  
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Figure 4-2. Pictorial representation of a SNPfinder result. SNPfinder result showing the 
p.Met42Thr SNP using EST data deposited in Unigene. The highlighted blue line plus the 
adjacent bases encodes the codon for methionine (ATG) at the 42th position. A substitution 
of cytosine for thymine results in an amino acid change to threonine. The base substitution 
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4.2.2 SNPs survey using deposited data in dbSNP 
A manual search of dbSNP in 2007 for polymorphisms in SAA1 returns a total of 15 SNPs 
of which 12 are non-synonymous SNPs in the exon region and 3 are found in the promoter 
region (Table 4-2). SNPs in the intronic region and synonymous SNPs are not taken into 
consideration for the SNPs survey. Of the 3 SNPs in the promoter region, only 1 of them, 
c.-685C>G (rs1829575), is validated by frequency data as well as data published in journal 
(Moriguchi et al. 2005). Of the 12 non-synonymous SNPs identified, only 6 of the SNPs are 
validated by available frequency data, these include p.Ala70Val, p.Ala75Val, p.Phe86Leu, 
p.His89Arg, p.Glu102Lys, p.Lys108Arg.  
To obtain a more meaningful compilation of the results from the in silico studies, the non-
synonymous and non-conservative SNPs (with negative Blosum62 score) are consolidated 
together (Table 4-3). A total of 12 non-synonymous and non-conservative SNPs are 
obtained through the combined results of dbSNP and SNPFinder. None of the 12 is 
validated by frequency data in the dbSNP database, and hence a comparison with the actual 
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Table 4-2.  List of SAA1 SNPs obtained from a manual search of dbSNP. For the SNPs 
in the coding region, only p.Ala70Val, p.Ala75Val, p.Phe86Leu, p.His89Arg, p.Glu102Lys 
and p.Lys108Arg have accompanied population data. 








Region Found in 
SNPfinder 
rs7103956 c.-955C>T - - Promoter - 
rs1829575 c.-685C>G - - Promoter - 
rs7103441 c.-667G>C - - Promoter - 
rs11545470 p.Leu3Pro -3 Yes Exon 1 No 
rs11545475 p.Leu12Ser -2 Yes Exon 1 Yes 
rs1136743 p.Ala70Val 0 No Exon 2 Yes 
rs11545468 p.Trp71Arg -3 Yes Exon 2 Yes 
rs1136747 p.Ala75Val 0 No Exon 2 Yes 
rs1059559 p.Phe86Leu 0 No Exon 3 Yes 
rs1059560 p.Phe87Ser -2 No Exon 3 No 
rs2229338 p.His89Arg 0 No Exon 3 No 
rs17850140 p.Asn101Asp 1 Yes Exon 3 Yes 
rs1059567 p.Glu102Lys 1 No Exon 3 No 
rs1059571 p.Lys108Arg 2 Yes Exon 3 No 
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Table 4-3.  Non-synonymous and non-conservative amino acid changes predicted by 
SNPfinder and dbSNP. 
SNP Ref CDS SNP Blosum 62 Predictor/Database Region 
rs11545470 p.Leu3Pro -3 dbSNP Exon 1 
rs11545475 p.Leu12Ser -2 dbSNP/SNPFinder Exon 1 
- p.Leu14Pro -3 SNPFinder Exon 1 
- p.Met42Thr -1 SNPfinder Exon 2 
- p.Glu44Gly -2 SNPfinder Exon 2 
- p.Tyr53Cys -2 SNPfinder Exon 2 
rs11545468 p.Trp71Arg -3 SNPfinder/dbSNP Exon 2 
- p.Ile83Thr -1 SNPFinder Exon 3 
- p.Gln84Pro -1 SNPFinder Exon 3 
rs1059560 p.Phe87Ser -2 dbSNP Exon 3 
- p.Asp93Gly -1 SNPFinder Exon 3 
- p.Pro119Ser -1 SNPFinder Exon 3 
 
4.2.3 Variant screening of promoter and exons of SAA1 
The promoter region and the 3 exons of SAA1 were screened for novel variants using 
HRM. As the amplicon containing exon 2 has multiple melting domains, DNA sequencing 
was used to screen exon 2. A novel variant, c.92-5T>G, was found in the intron-exon 
boundary of exon 2. Two variants, p.Ala70Val and p.Ala75Val, were identified in exon 2 and 
a synonymous SNP, c.279C>T was identified in exon 3. c.-685C>G and c.-913G>A, were 
identified in the promoter region of SAA1 of which the latter is novel (Table 4-4).  
The temperature shifted curves and the difference plots for each of the 6 regions together 
with the corresponding DNA electrophoretograms are as shown in Figure 4-3 and Figure 4-
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4. Although, c.43G>A was initially identified as a genetic variant, it was found to be a false 
positive due to the heterogenous amplification of SAA1 and SAA2. Genetic variants were 
determined by the accompanied software which analyses changes in fluorescence levels from 
the melting curve. The various settings for the analysis of the melting curve are deemed to 
be appropriate if the temperature shifted melting curve and the difference plot correspond 
to each other.  
In summary, a novel SNP is discovered in the promoter region and there is no novel non-
synonymous SNP identified. 
Table 4-4. Polymorphisms identified in the exons and promoter of SAA1. *c.92-5T>G, 
c.209C>T and c.224C>T were identified from the sequencing of exon 2; the rest of the 
genetic variants were identified using HRM. 
SNP Position SNP Ref Novel variant 
c.-913G>A Promoter - Novel 
c.-685C>G Promoter rs1829575 - 
c.92-5T>G* Intron - Novel 
p.Ala70Val* 
(c.209C>T) 
Exon rs1136743 - 
p.Ala75Val* 
(c.224C>T) 
Exon rs1136747 - 
c.279C>T Exon rs15790 - 
 















Figure 4-3.  Normalised high resolution melting curves and the corresponding difference plots. The variants are differentiated from the 
wild-type by the relative difference in their normalized fluorescence. The wild-types are all coloured blue while variants are in various 
colours. (A-B) Melting curves and difference plots of Exon 1. (C-D) Melting curves and difference plots of Exon 3. (E-F) Melting curves 
and difference plots of promoter segment 1 (c.-857 to c.-637). (G-H) Melting curves and difference plots of promoter segment 2 (c.-1088 to 






















Figure 4-4.  Electrophoretograms of the various identified SNPs. The arrow indicates the 
orientation of the DNA sequence in the 5’ to 3’ direction (: coding strand; : reverse 
complementary strand). All SNPs are named according to the location of the nucleotide 
substitution in the coding strand. (A-B): Wild-type G allele and variant A allele of c.-
913G>A.. (C-D): Wild type C allele and variant G allele (present in heterozygote) of c.-
685C>G. (E-F): Wild-type T and variant G allele of c.92-5T>G. (G-H): Wild-type C allele 
and variant T allele of p.Ala70Val. GCC encodes for alanine while GTC encodes for 
valine in the coding strand. (I-J): Wild type T allele and variant C allele of p.Ala75Val. 
GTG encodes for valine while GCG encodes for alanine in the coding strand. (K-L): Wild 
type C allele and variant T allele (present in heterozygote) of D93D, both GAC and GAT 
encodes for aspartic acid. 
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4.3 Discussion 
4.3.1 SNPs survey using in silico SNPFINDER and dbSNP 
SNPFINDER and dbSNP offer a convenient way to retrieve and predict SNPs on the gene 
of interest. However, the information provided by these data-mining tools need to be 
carefully analysed as false-positives can arise as some of the underlying data are not validated. 
For the current study, there are differences between the results from SNPFINDER and 
dbSNP as compared to the variant screening performed using HRM. In total, there are 23 
non-synonymous SNPs in the coding region predicted by SNPFINDER and dbSNP, 
however, only 2 non-synonymous SNPs were found through the variant screening by HRM. 
In comparing the results from the various programs and the actual variant screening, only 
non-synonymous SNPs were taken into consideration. 
The results obtained from dbSNP were analysed and only 6 of the non-synonymous SNPs 
reported by dbSNP were found to be validated by population data. Genotyping was thus 
performed on one of the SNP, pHis89Arg, using 200 cord blood DNA samples to validate 
the data. Based on dbSNP, p.His89Arg (rs2229338) has a genotype frequency of 0.138 in a 
mixed population of sample size of 58. There is, however, no variant allele of rs2229338 
found in our cord blood DNA samples. Instead, a rare allele adjacent to rs2229338, 
p.Gly90Asp, was identified. There is a 90% sequence similarity between SAA1 and SAA2 
and out of the 6 validated variants identified by dbSNP, 4 of them, p.Phe86Leu, p.His89Arg, 
p.Glu102Lys and p.Lys108Arg, are the corresponding wild-type alleles for SAA2 (Figure 4-
5). As such, it is speculated that the variant alleles identified on dbSNP could be due to a 
heterogenous sequencing of both SAA1 and SAA2. To validate our speculation, 8 DNA 
samples were amplified to yield amplicons containing either SAA1 or SAA2. The amplicons 
were genotyped for p.Phe86Leu; the allele encoding for phenylalanine was found in the 
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amplicon containing SAA1 and the allele encoding for leucine was found in the amplicon 
containing SAA2. Thus, upon excluding the four non-synonymous SNPs, the number of 
validated non-synonymous SNPs is agreeable with that obtained from the variant screening. 
SAA2_AAA64800.1 MKLLTGLVFCSLVLSVSSRSFFSFLGEAFDGARDMWRAYSDMREANYIGSDKYFHARGNY 60 
SAA2_AAA64801.1 MKLLTGLVFCSLVLSVSSRSFFSFLGEAFDGARDMWRAYSDMREANYIGSDKYFHARGNY 60 
SAA1_CAG47037.1 MKLLTGLVFCSLVLGVSSRSFFSFLGEAFDGARDMWRAYSDMREANYIGSDKYFHARGNY 60 
SAA1_AAA64799.1 MKLLTGLVFCSLVLGVSSRSFFSFLGEAFDGARDMWRAYSDMREANYIGSDKYFHARGNY 60 
                **************.********************************************* 
 
SAA2_AAA64800.1 DAAKRGPGGAWAAEVISNARENIQRLTGHGAEDSLADQAANKWGRSGRDPNHFRPAGLPE 120 
SAA2_AAA64801.1 DAAKRGPGGAWAAEVISNARENIQRLTGRGAEDSLADQAANKWGRSGRDPNHFRPAGLPE 120 
SAA1_CAG47037.1 DAAKRGPGGAWAAEVISDARENIQRFFGHGAEDSLADQAANEWGRSGKDPNHFRPAGLPE 120 
SAA1_AAA64799.1 DAAKRGPGGVWAAEAISDARENIQRFFGHGAEDSLADQAANEWGRSGKDPNHFRPAGLPE 120 
                *********.****.**:*******: *:************:*****:************ 
 
SAA2_AAA64800.1 KY 122 
SAA2_AAA64801.1 KY 122 
SAA1_CAG47037.1 KY 122 
SAA1_AAA64799.1 KY 122 
                ** 
Figure 4-5. Multiple sequence alignment of the primary sequence of SAA1 and SAA2. 
Amino acids that differ between SAA1 and SAA2 are highlighted in green. 
 
Majority of the SNPs predicted by SNPFINDER are novel SNPs that have not been 
deposited in dbSNP. Over half of the non-synonymous SNPs are non-conservative SNPs 
with a negative Blosum62 score. In total, 8 non-synonymous SNPs were predicted to be 
found in exon 2, however, when sequencing were performed on 96 DNA samples, only 2 
non-synonymous SNPs were identified. Thus, the results derived from SNPFINDER either 
consists of a large number of false positives or that most of the polymorphisms predicted are 
rare mutants. As the results from SNPFINDER are based on EST data, there are inherent 
errors associated with it. ESTs obtained from tumour tissue can contribute to an increase in 
false discovery rate. The large number of non-synonymous SNPs predicted by 
SNPFINDER and the close proximity of some of the SNPs (p.Met42Thr, p.Glu44Gly, 
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p.Tyr47His, p.Ile83Thr, p.Gln84Pro, p.Phe86Leu) suggest the the likely occurence of false 
positives. Deficiency of EST mining program and its associated false discovery rate in 
predicting SNP were also reported in a few studies (Buetow et al. 1999; Cox et al. 2001). 
SNP data from large scale genome projects that were subsequently archieved in dbSNP are 
more reliable than SNP predicted from mining program. The high level of identity between 
SAA1 and SAA2 results in heterogenous sequencing of both genes of A-SAA; 
heterogenous sequencing could likely possibly account for the differential number of SNPs 
observed between dbSNP and the variant screening conducted. 
  
4.3.2 SNPs survey by the method of HRM 
HRM has been increasingly used for genetic variant screening (Dagar et al. 2009). For the 
screening of a single gene, the direct method of gene sequencing is too expensive and time 
consuming. In addition, much time is needed to analyse the electropherograms. One 
significant advantage of HRM over both DNA sequencing and DHPLC is its ease of setup. 
While in DHPLC, the sample is analysed one at a time, in HRM the entire plate of amplified 
products is analysed simultaneously within a short interval of time. However, certain 
modifications were made to the experimental protocol to ensure that the results are accurate 
and reproducible. As the Roche’s HRM master mix that is optimized for use with the Roche 
480 appears to interfere with DNA amplification, an alternative double stranded binding dye, 
LC green, was used. Amplification was also carried out in a separate thermocycler as 
amplification is inefficient in the Roche 480. Lastly, LCgreen was added prior to PCR as the 
results were inaccurate when the dye was added post-amplification. Variant screening by 
HRM was successful after the above modifications were made. 
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Although, HRM might not be able to differentiate between wild-type and variant 
homozygote for certain genetic variants, the method is able to consistently differentiate 
heterozygote from the homozygote. As the frequency of heterozygote variant is generally 
higher than homozygote variant, HRM can be used for variant screening without the use of 
additional probes. Pilot study was conducted on known variants and a sensitivity setting of 
0.15 for the analysis of the melting curves was found to be sufficient for the detection of 
genetic variants with minimal false positives. HRM was used for the variant screening of all 
the promoters and exons of SAA1 except for exon 2. As exon 2 has two melting domains, 
the melting curves are no longer smooth and as such it is not optimal for analysis by HRM 
(Figure 4-6). The presence of multiple melting domains might interfere with the analysis of 
the melting curves and result in inaccurate analysis. The inability to screen amplicons that 
contain multiple melting domains is the main drawback of HRM. However, its 
reproducibility and ability to differentiate genetic variants efficiently should render it a 
suitable method for high throughput genetic variant screening.  
 
Figure 4-6. Multiple melting domains disrupt an otherwise smooth melting curve. As a 
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4.3.3 Significance of variant screening of SAA1 
SAA1 is one of the major APPs produced during an APR and as such its functional roles are 
probably critical for survival. The variant screening of SAA1 reflects its evolutionary 
conserved status as few genetic variants were discovered. The variant, c.-913G>A, does not 
lie in known transcription factor binding sites and as such it might not exert significant 
effects on SAA1 production. p.Ala70Val and p.Ala75Val are the only two non-synonymous 
SNPs present in SAA1; however, alanine and valine are structurally similar and thus the 
Blosum62 score is 0. The high prevalence of both genetic variants and the nature of the 
substitution suggest that the functional effects exerted by both variants might be similar to 
the wild-type. However, it will be interesting to investigate the differential functional effects 
of a rare mutant, p.Gly90Asp, against wild-type SAA1. p.Gly90Asp is the only genetic 
variant identified in which the amino acid substitution is non-conservative. The genetic 
association study conducted on these variants as documented in the following section will 
help determine whether these variants have altered structure that can alter the susceptibility 
to CAD. 
 
4.3.4 Caveats of SNP survey 
Genetic variant screening was conducted using cord blood DNA from Chinese neonates. 
Other races were excluded from the study as limited DNA samples are available for the 
Malays and the Indians. The sample size for the variant screening is only 96 which allows for 
the detection of SNP with allele frequency of > 1%. The variant screening shows that there 
are only a small number of non-synonymous SNPs; as SAA1 plays a central role in the 
immune system, it is possible that non-synonymous SNPs might be deleterious and hence its 
frequency of occurrence is low. As it is difficult to set a limit on the sample size to detect 
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rare mutant, the design of the variant screening did not allow for the discovery of rare 
mutant. Nonetheless, through the validation of dbSNP, a rare mutant, p.Gly90Asp was 
discovered.  
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5 Association study of SAA1 SNPs in Singapore Chinese population 
5.1 Introduction 
As the study of the role SAA1 plays in the pathogenesis of atherosclerosis only gathers pace 
in the past few years, there has been no prior genetic association studies of genetic variants 
of SAA1 with CAD conducted. Genetic epidemiology study is also limited by the number of 
known genetic variants of SAA1. There are, however, two recent genetic association studies 
conducted on genetic variants of SAA1; a non-synonymous SNP of SAA1 (rs12218) was 
found to be associated with increased carotid intima-media thickness (cIMT) (Xie et al. 
2010). In another study, rs1520887, located thousands of bases upstream of SAA1 5’UTR, 
was reported to be associated with slightly lower HDL level. However, there was no 
association of the SNP with cIMT in an African-American population (Carty et al. 2009).  
A number of genetic association studies of SAA1 with other inflammatory diseases such as 
RA, Turkish familial Mediterranean fever (FMF) and Behcet’s disease were conducted 
previously (Table 5-1). Majority of the studies involve association studies of 2 haplotypes 
(p.[Val70Ala; Ala75Val]; p.[Ala70Val; Val75Ala]) of SAA1 with susceptibility to amyloidosis 
in patients with the abovenamed diseases. In the Turkish population, the p.[Val70Ala; 
Ala75Val] haplotype is associated with higher susceptibility to amyloidosis in patients with 
FMF and Behcet’s disease (Utku et al. 2007; Yilmaz et al. 2003). However, in the Japanese 
population, both p.Ala70Val and the haplotype p.[Ala70Val; Val75Ala] are associated with 
increased susceptibility to amyloidosis in patients with RA (Ajiro et al. 2006; Nakamura et al. 
2006) . Hence, the SNPs might be genetically linked with other polymorphisms that might 
account for the increased susceptibility to amyloidosis. However, there has not been any 
genetic association study conducted to study the association between these genetic variants 
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with susceptibility to CAD. As the pathogenesis of amyloidosis and CAD are wholly 
different, it is unkown whether these genetic variants will alter the susceptibility to CAD.  
Case-control genetic association study was conducted in two phases. In the first phase, about 
150-200 cases and controls were used for each SNP of interest to determine the approximate 
odds ratio as well the the frequency of the variant allele. The approximate sample size 
required for each SNP was then determined from the obtained result; when the odds ratio is 
around 1, the study for that SNP was not extended. 
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Table 5-1.  Association of genetic variants/haplotypes of SAA1 with susceptibility to certain medical conditions in patients with FMF, 
Hyper-IgD, Behcet’s disease, amyloidosis and RA. 








FMF Higher susceptibility to amyloidosis 
p.[Val70Ala; 
Ala75Val] 




Hyper-IgD No susceptibility towards IgD 
p.[Val70Ala; 
Ala75Val] 




FMF/ Amyloidosis Higher susceptibility to amyloidosis in 
patients with FMF. Haplotype also has a 
higher prevalence in patients with 
amyloidosis. 









     78




(Utku et al. 
2007) 
Turkish population, Behcet’s disease Higher susceptibility to amyloidosis 
p.Ala70Val 
 
(Ajiro et al. 
2006) 
Japanese population RA Higher susceptibility to amyloidosis 
c.-637C>T (Ajiro et al. 
2006) 




(Nakamura et al. 
2006) 
Japanese population RA Higher susceptibility to amyloidosis 
p.[Ala70Val; 
Ala75Val] 
(Yamada et al. 
2001) 
Japanese population RA Higher serum SAA1 levels 
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5.2 Results 
5.2.1 Population demographics 
The population demographics of both cases and controls are as shown in Table 5-2. CAD 
patients are significantly older with a mean of 59.7 as compared to 42.1 in controls. BMI is 
also significantly higher in cases. There is a higher portion of smokers in CAD patients 
making up 52.8% of the sample population as compared to 15.6% in healthy controls. HDL 
cholesterol is, however, significantly higher in healthy controls. 
Table 5-2.  Population demographics of Chinese cases and controls used in the study. 
Variables CAD- CAD+ P-value 
 n = 1261 n = 800  
Age (years) 42.1±13.2 59.7±8.8 <0.0001 
BMI (kg/m2) 22.9±3.6 24.2±3.6 0.0009 
Sex (Male) (%) 40.9 76.7 <0.0005 
TC (mM) 5.5±1.1 4.6±1.2 <0.0001 
HDL-C (mM) 1.5±0.4 1.0±0.3 <0.0001 
LDL-C (mM) 3.5±1.0 3.3±6.6 0.298 
TG (mM) 1.4±1.1 1.8±1.0 <0.0001 
Smokers* (%) 15.6 52.8 <0.0005 
* Both smokers and ex-smokers are classified as smokers in the table.  
 
5.2.2 Single locus case control association study of c.-913G>A, c.-637C>T, 
c.209C>T (p.Ala70Val) and c.224C>T (p.Ala75Val) 
Case control association study was initially conducted with a smaller sample size of cases and 
controls for 5 selected SNPs, c.-913G>A, c.-637C>T, c.209C>T, c.224C>T and c.269G>A 
(p.Gly90Asp). However, the study was not extended beyond the small sample size for 4 of 
the SNPs as the odds ratio between cases and controls were not sufficiently high. c.269G>A 
has an initial odds ratio of > 2.0 and as such the study was extended to include a bigger 
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sample population. The association study of c.269G>A (p.Gly90Asp) is reported in section 
5.2.2. 
  
5.2.2.1 Genotyping of c.-913G>A, c.-637C>T, c.209C>T and c.224C>T  
c.-913G>A was genotyped using allele-specific PCR while c.-637C>T, c.209C>T and 
c.224C>T were genotyped using RFLP (Figure 5-1). The enzymes used were BsrBI, BanI 
and BclI for c.-637c>T, c.209C>T and c.224C>T respectively. For genotyping by allele-
specific PCR, two separate amplification reactions are needed; one contains a primer that is 
complementary to the wild-type while the other contains a primer that is complementary to 
the variant. A heterozygote has two visible bands when the PCR products for both reactions 









Figure 5-1.  Genotyping results of (A) c.-913G>A (B) c.-637C>T (C) c.209C>T (D) 
c.224C>T. c.-913G>A was genotyped using allele-specific PCR while c.-637C>T, 




CT     CC     TT      TT      CC     CC     CC     CC 
 GA        GG             GG        GG       GG        GG                     
GG 
CT      CT       TT      CC       TT       CT     TT       CC 
 CT     TT      CT       CC       TT        CC     CC      CC 
     81
5.2.2.2 Genotype and allele frequency 
The genotype frequencies do not deviate significantly from Hardy-Weinberg expectation 
(HWE) except for the SNP c.-637C>T in CAD patients (Table 5-3). The P-values for HWE 
for CAD patients were shown for reference; the genotype frequencies might deviate from 
HWE as the cases are a selected group and thus its allele frequencies might not conform to 
HWE.   There are no significant differences in the allele frequencies of c.-913G>A, c.-
637C>T, c.209C>T and c.224C>T between cases and controls.  Odds ratio of the variant 
allele c.-637C>T, c.209C>T and c.224C>T are 1.21, 1.10 and 0.95 respectively, all of which 
do not deviate largely from 1 (Table 5-4). The P-values were not corrected for the two-stage 
design and multiple testing as they were not statistically significant before correction. 
Although, the odds ratio is relatively lower for c.-913G>A, a large sample size is needed to 
determine its association with CAD due to its low allele frequency. Given that the level of 
association of the 4 SNPs are likely to be weak, the sample size was not increased further. 
Table 5-3. Genotypes distribution and allele frequencies of healthy controls and CAD 
patients for c.-913G>A, c.-637C>T, c.209C>T and c.224C>T. 
 Healthy Controls CAD Patients 
Frequency HWE χ2 P-value Frequency HWE χ2 P-value 
c.-913G>A       
GG 178 0.051 0.821 186 0.021 0.885 
GA 6   4   
AA 0   0   
Allele       
A 0.984   0.990   
G 0.016   0.010   
 
     82
 Healthy Control CAD Patients 
 Frequency 
 





c.-637C>T       
CC 89 0.627 0.428 52 5.86 0.0155 
CT 110   98   
TT 27   21   
Allele       
C 0.637   0.591   
T 0.363   0.409   
       
c.209C>T       
CC 77 3.36 0.067 79 3.60 0.058 
CT 80   93   
TT 10   14   
Allele       
C 0.700   0.675   
T 0.300   0.325   
       
c.224C>T       
CC 114 0.102 0.749 132 0.124 0.724 
CT 128   122   
TT 33   31   
Allele       
C 0.647   0.675   
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Table 5-4.  Odd ratios of the variant allele of the various SNPs of SAA1 and their 
association with CAD. 
SNP Odds ratio 95% CI P-value 
c.-913G>A 0.64 0.18-2.29 0.492 
c.-637C>T 1.22 0.91-1.62 0.182 
c.209C>T 1.12 0.82-1.55 0.460 
c.224C>T 0.87 0.68-1.12 0.290 
 
5.2.2.3 Odds ratio of c.-637C>T, c.209C>T and c.224C>T as analysed using different 
genetic models 
For c.-637C>T, c.209C>T and c.224C>T, genetic association were further determined using 
codominant, dominant and recessive genetic models. This analysis was not carried out for   
c.-913G>A as the homozygous variant was not present in either the controls or cases. For 
c.-637C>T, under the dominant model the odds ratio is 1.49. However, the odds ratio under 
the recessive model is 1.03, thus the choice of genetic model used might have important 
significance for c.-637C>T. For c.209C>T and c.224C>T, the odds ratio were close to 1 
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Table 5-5. Odds ratio of c.-637C>T, c.209C>T and c.224C>T as determined using 
codominant, dominant and recessive genetic models. 
SNP Model Genotype Odds ratio 95% CI P-value 
c.-637C>T Codominant CC 1.00   
0.16   CT 1.52 0.98-2.36 
  TT 1.33 0.68-2.59 
 Dominant CC 1.00   
0.063   CT + TT 1.49 0.98-2.27 
 Recessive CC + CT 1.00   
0.92   TT 1.03 0.56-1.90 
      
c.209C>T Codominant CC 1.00   
0.72   CT 1.13 0.73-1.75 
  TT 1.36 0.57-3.26 
 Dominant CC 1.00   
0.49   CT + TT 1.16 0.76-1.77 
 Recessive CC + CT 1.00 0.55-2.96  
0.57   TT 1.28  
      
c.224C>T Codominant CC 1.00   
0.51   CT 0.82 0.58-1.17 
  TT 0.81 0.47-1.41 
 Dominant CC 1.00   
0.25   CT + TT 0.82 0.59-1.15 
 Recessive CC + CT 1.00   
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5.2.3 Single locus case control association study of c.269G>A 
c.269G>A was genotyped by RFLP using NcoI (Figure 5-2). DNA from 1243 healthy 
controls and 800 CAD patients were used in the study. The genotype frequencies do not 
deviate significantly from Hardy-Weinberg expectation (Table 5-6). There is no significant 
difference in the allele frequencies between cases and controls. The odds ratio for the variant 
allele is 0.86 (CI: 0.50 -1.47, P-value = 0.57). There is no correction needed for multiple 
comparison as c.269G>A is the only SNP that was determined for genetic association using 
a larger sample size. 
However, in an initial study of 590 healthy controls and 547 CAD patients, the odds ratio 
was 2.72 (CI: 1.05-7.03, P-value = 0.032) (Appendix 5-1 and 5-2). The A allele which 
encodes for aspartic acid instead of glycine for the C allele has a higher frequency in CAD 
patients. 
 
Figure 5-2. Genotyping results of c.269G>A. RFLP was used to genotype the samples; 






 GG    GG      GG     GG     GA      GG     GG     GG 
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Table 5-6.  Genotypes distribution and allele frequencies of healthy controls and CAD 
patients for c.269G>A. 
 Healthy Control CAD Patients 
 Frequency HWE χ2 P-value Frequency HWE χ2 P-value 
c.269G>A       
GG 1205 0.30 0.58 779 0.14 0.71 
GA 38   21   
AA 0   0   
Allele       
G 0.985   0.987   
A 0.015   0.013   
 
5.2.4 Genotyping results of the 5 SNPs after adjustment for age, gender and BMI 
For c.637C>T, c.209C>T and  c.224C>T, there are slight differences in the odds ratio for 
the variant allele after adjustment for age, gender and BMI. The odds ratios are still 
insignificant as before the adjustment. Upon adjustment, there is a bigger change in the odds 
ratio for both c.-913G>A and c.269G>A. The odds ratio for c.-913G>A was 0.91 before 
adjustment and 0.64 after adjustment. For c.269G>A, the odds ratio was 0.85 before 
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Table 5-7.  Odds ratio of c.-913G>A, c.-637C>T, c.209C>T, c.224C>T and c.269G>A 
after adjustment for age, gender and BMI.  
SNP Model Genotype Odds ratio 95% CI P-value 
c.-913G>A NA GG 1.00   
0.51   GA 0.91 0.09-9.25 
      
c.-637C>T Codominant CC 1.00   
0.29 
  CT 1.78 0.86-3.66  
  TT 1.47 0.47-4.66 
 Dominant CC 1.00   
0.13 
  CT + TT 1.72 0.86-3.46  
 Recessive CC + CT 1.00   
0.94 
  TT 1.04 0.36-3.01  
      
c.209C>T Codominant CC 1.00   
0.89 
  CT 0.91 0.45-1.84  
  TT 1.25 0.31-5.01 
 Dominant CC 1.00   
0.88 
  CT + TT 0.95 0.48-1.87  
 Recessive CC + CT 1.00   
0.7 
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SNP Model Genotype Odds ratio 95% CI P-value 
c.224C>T Codominant CC 1.00   
0.7 
  CT 1.15 0.63-2.12  
  TT 0.80 0.33-1.91  
 Dominant CC 1.00   
0.86 
  CT + TT 1.05 0.60-1.86  
 Recessive CC + CT 1.00   
0.48 
  TT 0.74 0.33-1.69  
      
c.269G>A NA GG 1.00   
0.28   GA 1.61 0.68-3.80 
      
 
 
5.2.5 Sample size determination for the various SNPs 
The sample size required for the various SNPs are as shown in Table 5-7. The sample size 
was determined based on the initial genotype frequencies obtained from the genotyping 
performed in the initial smaller sample size and that it will have a power of 80%. 
Table 5-8.  Sample size determination for all 5 SNPs  
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5.3 Discussion 
5.3.1 Choice of SNPs for genotyping and genotyping methods 
Genetic association study was carried out on five selected variants of SAA1. As there are 
limited number of known genetic variants of SAA1, the non-synonymous variants, 
c.209C>T and c.224C>T were selected. Although, the two variants, c.-913G>A and c.-
637C>T, do not lie in known transcription factor binding site, genetic association was also 
carried out to test its possible association with CAD. Lastly, genotyping was also carried out 
on the rare mutant, c.269G>A. c.269G>A was chosen as it is the only non-synonymous 
SNP that was discovered from the variant screening with a non-conservative amino acid 
substitution. 
HRM was not used to genotype any of the variants as no positive control was available for 
the optimization of -913G>A and c.269G>A. As such, RFLP and allele-specific PCR were 
used for the genotyping as both are inexpensive and the accuracy of the genotyping of each 
allele can be validated.  
 
5.3.2 Genotyping results of c.-913G>A, c.-637C>T, c.209C>T and c.224C>T 
A smaller sample size was used for the genetic association study of c.-913G>A, c.-637C>T, 
c.209C>T and c.224C>T. In this smaller sample size, the allele frequencies do not appear to 
differ between healthy controls and CAD patients before and after adjustment for age, 
gender and BMI. As the odds ratio for the variant allele of all the 4 SNPs does not differ 
greatly from 1, and a much larger sample was not needed to attain a power of 80% the 
sample size was not increased. One caveat of this study is that the sample size was not 
extended based on the odds ratio obtained from an initial sample size of 200 to 300. 
However, it was reported that a smaller sample size has a tendency to overestimate the odds 
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ratio (Nemes et al. 2009) and as such a larger sample size is unlikely to yield an odds ratio 
that deviates significantly from 1 since the odds ratio that was obtained from this smaller 
sample was close to 1. 
c.-913G>A is a novel SNP and no prior genetic association study has been performed on 
the SNP. The predicted transcription factor binding sites of SAA1 include SP1 (c.-668 to c.-
660), NF-kappaB (c.-720 to c.-712), NF-IL6/STAT (-814 to -798) and AP2 (c.-891 to c.-
880) (Thorn and Whitehead 2002). c.-913G>A is not located at any of the predicted 
transcription factor binding site of SAA1, as such the substitution might not have any effect 
on the expression of SAA1 and thus has little association with CAD. The case is similar for 
c.-637C>T which is not located near any transcription factor binding site. However, the T 
allele was found to be associated with higher susceptibility to amyloidosis in patients with 
RA (Akar et al. 2006). The association between serum SAA1 level and amyloidosis is, 
however, unknown. Given that polymorphism in the promoter will have a greater impact on 
expression level than on the function of the protein, the increased susceptibility to 
amyloidosis is probably not directly due to the base substitution. Instead, c.-637C>T could 
probably be genetically linked with other allele that could explain the susceptibility to 
amyloidosis. 
There have been a number of studies involving either C.209C>T or haplotypes of 
C.209C>T and C.224C>T. However, as mentioned to date no study has been performed on 
the genetic association of these SNPs with CAD. Our study shows that both the variant 
alleles in c.209C>T and c.224C>T are not genetically associated with CAD. As both alanine 
and valine have similar structural properties, the functional impact of these two substitutions 
on CAD susceptibility is probably very subtle. Further doubts on the non-synonymous 
substitution having a functional impact can be gathered from the studies of the TC and CT 
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haplotypes in Turkish and Japanese populations. In the Turkish population, the TC 
haplotype was associated with increased susceptibility to amyloidosis (Yilmaz et al. 2003), 
however, the contrasting haplotype, CT, was associated with increased susceptibility to 
amyloidosis in the Japanese population (Nakamura et al. 2006). Thus, there is a possibility 
that the non-synonymous substitutions do not account for the phenotypic change observed. 
The genetic association study carried out for these SNPs do not have sufficient power. To 
attain a power of 80%, the sample sizes required as shown in Table 5-7 are sufficiently large 
due to a relatively low odds ratio of most of the SNPs. Due to the likely benign effects of 
these SNPs and the large sample sizes required, the study was not extended. For -269G>A, 
as the amino change is non-conservative, a functional study was carried out to further 
characterized the SNPs as a larger population could not be recruited. 
 
5.3.3 Genotyping result of -269G>A and significance of results of genetic 
association study 
There is no genetic association of -269G>A with CAD in our study of 1243 healthy controls 
and 800 CAD patients. The odds ratio for the variant allele is 0.86 before adjustment and 
1.61 after adjustment for age, gender and BMI. The odds ratio before adjustment is in 
contrast with the initial study of 547 CAD patients and 590 healthy controls. In the initial 
study, -269G>A was associated with CAD and the odds ratio for the variant allele was 2.72 
(CI: 1.05-7.03, P-value = 0.032). This difference could be due to the low frequency of the 
variant allele and thus the result might be different with a bigger population size. Another 
area where discrepancy might arise is that SAA is also involved in a number of inflammatory 
diseases such as rheumatoid arthritis. These diseases were not identified as potential 
confounders when the sample subjects were first recruited. This could partly account for the 
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observation that the allele frequency of the variant in the cases is consistent between the 
initial sample group and the additional sample group that is subsequently included. In 
contrast, the allele frequency of the variant in the controls is not consistent between the 
original group and the additional group of samples that is subsequently added. Although, the 
genetic association of -269G>A could not be ascertained, this is the only SNP that was 
found to be significantly associated with CAD in the initial study, a more stringent study can 
be carried out in the future if a bigger population size can be recruited for the study.  
As SAA1 is a relatively small protein of only 104 amino acids for the mature protein, a non-
conservative substitution of amino acid might have a significant functional effect. In 
addition, a multiple sequence alignment of protein sequences from 6 organisms suggest that 
the 90th position is well conserved among the 6 organisms with no variant amino acid 
present. Due to the low allele frequency, there are in total only 6 and 15 heterozygotes 
present in the healthy controls and CAD patients group respectively. As the corresponding 
serum samples for the heterzygotes were depleted, it is not possible to study whether the 
allele alters the levels of inflammatory and atherogenic markers. Further characterization of -
269G>A (p.Gly90Asp) will have to be performed by functional assays as outlined in Chapter 
7. 
 
5.3.4 Caveats of genetic association study 
The genetic association study did not include the measurement of the levels of SAA1 and 
inflammatory mediators in both cases and controls. These levels were not determined as the 
plasma samples from our subjects were depleted.  SAA1 level was also not monitored as 
there is no commercial kit that is specific for SAA1 due to its sequence similarity to SAA2. 
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There are significant differences in the age and gender distribution between cases and 
controls. The healthy controls have a mean age of 42.1 yr while the cases have a mean age of 
59.7 yr. CAD cases also have a higher proportion of male comprising 76.7% of the sample 
size as compared to 40.9% for healthy controls. As the susceptibility to CAD increases with 
age, there is a concern that the healthy controls might contain subjects that might develop 
CAD at an older age. The odds ratio might be altered under such circumstances. Ideally, an 
alternative way to ameliorate the selection bias is to use younger cases compared with older 
controls, however, this is difficult to accomplish in this study due to two concerns. Firstly, 
the selection of cases was based on subjects with more than 50% stenosis in major arteries 
and subjects that meet these criteria are usually older. It is also harder to recruit significant 
number of healthy controls that are older than cases. Secondly, as CAD is a multi-factorial 
disease, genetic association study should be conducted with a large population size and there 
is substantial difficulty to recruit significant number of subjects that fit these criteria. We 
took the next best alternative by statistically adjusting for the confounding effect of age in 
our analysis.  Age is included in the logistic regression model when determining the strength 
of association. 
Although there are a number of other SNPs of SAA1 listed on dbSNP, those SNPs were 
not included in the study. The focus of the study is on SNPs that have a direct impact on 
either the structure of SAA1 or on its expression level as these SNPs are more likely to have 
an impact on disease susceptibility. Thus, only genetic association study of non-synonymous 
SNPs and SNPs in the promoter region of SAA1 were investigated. Furthermore, these 
SNPs can be functionally characterized and its specific role in disease susceptibility 
investigated. This could not be performed for SNPs that are located in the introns. 
Haplotypes analysis was also not carried out as no SNP was found to be independently 
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associated with CAD. Ideally, a large scale SNP chip assay will allow for a more 
comprehensive association study of SAA1; however a much larger sample size would be 
needed for the study to attain significant power. Furthermore, the number of SNPs 
deposited in the SNP database at the time of the study was not large enough for the need to 
undertake such a high throughput assay. Nonetheless, the study manages to achieve the basic 
objective of studying the genetic association of common known variants and a rare mutant 
with CAD. 
 
5.3.5 Future works 
In a well-conserved protein such as SAA1, the presence of a non-conservative substitution 
such as in p.Gly90Asp might have a significant effect. However, this mutant has a low allele 
frequency and thus a larger population size is needed for a genetic association study of 
sufficient power. The sample size should be increased if sufficient number of cases and 
controls can be recruited in the future. In addition, healthy controls should also be screened 
for whether they suffer from inflammatory diseases such as rheumatoid arthritis as SAA was 
reported to play a role in the pathogenesis of these diseases. The impact of p.Gly90Asp on 
the plasma levels of inflammatory cytokines such as IL-8, TNF-α and SAA1 should also be 
determined if a larger population sample can be recruited. 
As CAD is a mutli-factorial disease, the contribution of other SNPs will determine the 
susceptibility of an individual to the disease. A multiple SNPs analysis will allow for the 
combined effects of these SNPs on CAD susceptibility to be studied. Through this study, 
the synergy of certain subsets of genes might be discovered and this will allow for a better 
understanding of the pathogenesis of CAD at a gene level. The SNPs that might be used for 
this study include inflammatory genes such as IL-16 (Wu et al. 2011), CX3CR1 (Sirois-
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Gagnon et al. 2011), IL-6, IL1-B  (Rios et al. 2010), CD14 (Rizzello et al. 2010) and TNF 
(Ghazouani et al. 2009), all of which were found to be associated with CAD.  Similarly, the 
levels of inflammatory cytokines and lipids could be measured to determine whether the 
combined effects of multiple SNPs would have an impact on the levels of these proteins. 
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6  Functional study of p.Gly90Asp 
 6.1 Introduction 
The rarity of non-conservative SNP of SAA1 suggests that SAA1 might play a critical role in 
the regulation of important life processes in humans. p.Gly90Asp is the only non-
conservative SNP that was identified from our variant screening. In addition, p.Gly90Asp 
has a high odds ratio in the performed genetic association study which is rare for a 
multifactorial disease such as CAD. The characterization of p.Gly90Asp will help identify 
possible processes that are affected due to the amino acid substitution and explain the 
association of the SNP with CAD. 
As there is limited information on the functional domains of SAA1, the choice of functional 
assays to be conducted was based on the reported effects that SAA1 has on macrophages. 
This is the first time that functional characterization of genetic variants of SAA1 was 
conducted using in vitro assays involving cell culture. Previously, the only characterization of 
p.Gly90Asp involves the electrofocusing of both the wild-type and variant proteins. Variant 
SAA1 was reported to be more acidic with a pI value of 6.1 as compared to 6.5 in wild-type 
SAA1 (Kluve-Beckerman et al. 1991). A-SAA induces the secretion of pro-inflammatory 
cytokines (Song et al. 2009; Yang et al. 2006),  facilitates cholesterol efflux  in macrophages 
(Tam et al. 2008) and increases nCEH activity. Induction of pro-inflammatory cytokines is 
deemed to be atherogenic while the latter two are most probably atheroprotective. 
Differences in the induced level of cytokines or the rate of cholesterol efflux and nCEH 
activity between wild-type or variant SAA1 treatment will help account for the association of 
p.Gly90Asp with CAD. In addition, the induced changes in global gene expression levels in 
macrophages upon treatment with either wild-type or variant SAA1 treatment were also 
determined. The combination of both approaches will help characterize p.Gly90Asp given 
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the limited information that is known about the structure of SAA1 as well as its functional 
effects.  
Functional assays were carried out using THP-1 derived macrophages. Upon treatment with 
PMA, THP-1 monocytes differentiate into human macrophages. As THP-1 monocyte is one 
of the few cell lines that can be used to derive macrophages, it was used for the assay. The 
macrophages were used as they are crucial for both atherogenesis and the development of 
atherosclerotic lesion. Both recombinant wild-type and variant SAA1 were produced using 
E.coli. Glycosylation is not required to produce mature SAA1 hence E.coli is suitable for the 
production of the recombinant protein (Marsche et al. 2007). Recombinant SAA1 was used 
instead of transfecting SAA1 DNA into macrophages as endogenous production of SAA1 is 
limited in the macrophages. The major sources of SAA1 production are the liver and adipose 
tissues. Hence, the likely impact of variant SAA1 on macrophages could probably be due to 
its altered binding with cell surface receptors as SAA1 has limited ability to translocate across 
cell membrane (Kinkley et al. 2006). In addition to macrophages, neutrophils were used in 
the initial functional assays to determine the level of inflammatory cytokines secreted when 
incubated with SAA1. Neutrophils were used to determine whether the differential 
production of cytokines observed in THP-1-dervied macrophages could be observed in 
other immune cells. The importance of neutrophils to CAD has been highlighted in a 
number of studies that were reported after this work was completed; these studies will be 
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6.2 Results 
6.2.1 Production of IL-8, TNF-α and MCP-1 from THP-1 macrophages 
When macrophages were incubated with variant SAA1, the amount of IL-8, MCP-1 and 
TNF-α produced were significantly lower as compared to wild-type SAA1 treatment (Figure 
6-1 to Figure 6-3). At 3 µg/ml of SAA1, the decrease in IL-8, MCP-1 and TNF-α production 
were 57%, 50% and 39% respectively. Although, the amount of cytokines secreted were less 
for variant SAA1, there were still a great induction of secretion of IL-8 and TNF-α from 
macrophages; IL-8 and TNF-α levels increased by 5 and 60 fold respectively as compared to 
untreated control when macrophages were incubated with 3 µg/ml of variant SAA1. 
  
Figure 6-1. Differential effects of wild-type and variant SAA1 treatment on IL-8 secretion 
by THP-1 derived macrophages. Cells were incubated with SAA1 for 24 h and the 
supernatants were assayed for IL-8 using ELISA. Error bars represent standard deviations 
(n =3). *P <0.005 for variant SAA1 vs wild-type SAA1. 
* 
* 
P = 0.004  
P = 0.001  































Figure 6-2.  Differential effects of wild-type and variant SAA1 treatment on MCP-1 
secretion by THP-1 derived macrophages. Cells were incubated with SAA1 for 24 h and the 
supernatants were assayed for MCP-1 using ELISA. Error bars represent standard 



































Figure 6-3. Differential effects of wild-type and variant SAA1 treatment on TNF-• 
secretion by THP-1 derived macrophages. Cells were incubated with SAA1 for 24 h and 
the supernatants were assayed for TNF-• using ELISA. Error bars represent standard 




P = 0.0002  
P = 0.04  
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P = 0.003  
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6.2.2 Production of IL-8 and MCP-1 from neutrophils like differentiated HL-60 
cells 
Variant SAA1 has a lower cytokine induction capability as compared to wild-type SAA1 
(Figure 6-4 to Figure 6-5). The differences were significant for the production of MCP-1 at 
both concentrations of SAA1. At 3 µg/ml of SAA1, there was a decrease of 23.5% as 
compared to wild-type SAA1 (P = 0.003) and a decrease of 40% when the concentration of 
SAA1 was increased to 15 µg/ml (P =0.001). Although, there was a general decrease in IL-8 
production of 10% (3 µg/ml of SAA1) and 21.2% (15 µg/ml of SAA1) when variant SAA1 
was incubated with the neutrophils as compared to wild-type SAA1, the differences were not 
significant. Variant SAA1 retains its cytokine induction capability with a 7.8 fold increase of 
IL-8 and a 14 fold increase of MCP-1 as compared to the untreated control when 



































Figure 6-4. Differential effects of wild-type and variant SAA1 treatment on MCP-1 
secretion by HL-60 derived neutrophils. Cells were incubated with SAA1 for 24 h and the 
supernatants were assayed for MCP-1 using ELISA. Error bars represent standard 
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Figure 6-5.  Differential effects of wild-type and variant SAA1 treatment on IL-8 
production by HL-60 derived neutrophils. Cells were incubated with SAA1 for 24 h and the 
supernatants were assayed for IL-8 using ELISA. Error bars represent standard deviations (n 
=3).  
 
6.2.3 Effects of SAA on nCEH activity 
Both wild-type and variant SAA1 have no effect on cholesterol esterase activity (Figure 6-6). 
A-SAA from mouse was found to stimulate an increase in cholesterol esterase activity by 3-7 
fold (Lindhorst et al. 1997). In another study, mouse SAA2 was found to have an impact on 
cholesterol esterase activity whereas mouse SAA1 has negligible impact on cholesterol 
esterase activity (Tam et al. 2005). Since A-SAA consists of both SAA1 and SAA2, the 
observed effects might be from either one of SAA1 or SAA2. The experiment was repeated 
using apoSAA (Peprotech, Rocky Hill, New Jersey, United States) which has a 99% sequence 
similarity to SAA1 and similarly there was no apparent effect on cholesterol esterase activity 
(data not shown). Hence, it is safe to conclude that SAA1 has no effect on cholesterol 
esterase activity and that the association of the genetic variant with CAD is not due to an 
altered activity in cholesterol esterase. 






























Figure 6-6. Effects of SAA1 on nCEH activity. Both wild-type and variant SAA1 have 
negligible effects on nCEH activity. An in vitro mixture containing cholesteryl oleate, horse 
radish peroxidase, 4 amino-antipyrine, cholesterol oxidase and porcine cholesterol esterase 
was incubated in the presence of recombinant SAA1 at 37oC. The colour intensity was 
measured at 500nm . Data are expressed as the mean of 3 independent experiments. 
 
6.2.4 Microarray studies of wild-type SAA1 (Gly90) and variant SAA1 (Asp90) in 
THP-1 derived macrophages 
6.2.4.1 Differential gene expression between wild-type SAA1 and variant SAA1 at 8 h 
In total, there were 67 genes that were differentially downregulated between wild-type and 
variant SAA1 with a fold difference of more than 1.5. However, the functions of most of the 
genes in the list were relatively unkown; genes that were differentially upregulated and with 
function that might play a role in atherosclerosis are shown in Table 6-1. Proline 4-
hydroxylase (P4HA1) is required for the synthesis of collagen (Kivirikko et al. 1990) and 
inhibition of collagen synthesis was shown to increase the rate of degradation of extracellular 
matrix (Greenwel et al. 2000; Verrecchia et al. 2002). Mutations in the bone morphogenetic 
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protein receptor, type II (BMPR2) gene are associated with primary pulmonary hypertension 
(PPH) and account for 50% of familial cases of PPH (Deng et al. 2000). PPH results from 
the development of obstructive lesions in small pulmonary arteries leading to heart failure 
(Tobin and Celeste 2006).  
There are no genes that were differentially upregulated between wild-type and variant SAA1 
with a fold difference of less than 0.67. As the fold difference between wild-type and variant 
SAA1 is very small, the chance of picking up a false positive is relatively high. One possible 
way to reduce false positive is to observe the ratio of wild-type SAA1/untreated. A low ratio 
of less than 2 suggests that the gene is not activated upon SAA1 treatment and hence the 
possibility of differential expression between wild-type and variant SAA1 treatment is lower. 
Nonetheless, the results were validated using real-time PCR so that a conclusion on the 
genes that were differentially expressed between the two variants of SAA1 can be drawn. 
Table 6-1. Decreased relative genetic expression upon variant SAA1 treatment as compared 
to wild-type SAA1 treatment after 8 h of treatment. Fluorescence signals were normalized and 
the mean from two independent experiments were calculated. Fold difference was obtained 
by taking the ratio of fluorescence signal from wild-type treatment to that of variant SAA1 
treatment. 






APAF1 interacting protein (APIP) 1.62 1.44 
Fibrinogen-like 1 (FGL1) 1.61 1.35 
Granulocyte chemotactic protein 2 (CXCL6) 1.60 3.18 
Plasminogen activator inhibitor-2 (SERPINB2) 1.59 4.45 
Bone morphogenetic protein receptor, type II 
(BMPR2) 
1.54 1.20 
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Prostaglandin G/H synthase and cyclooxygenase 
(PTGS2) 
1.53 2.71 
Proline 4-hydroxylase (P4HA1) 1.50 1.16 
 
 
6.2.4.2 Differential gene expression between wild-type SAA1 and variant SAA1 at 24 h 
3 genes were differentially downregulated between wild-type and variant SAA1 with a fold 
difference of more than 1.5 (Table 6-2). However, these genes are not well characterized 
with unknown functional roles. There were 1110 genes that were differentially upregulated 
between wild-type and variant SAA1 with a fold difference of less than 0.67. As there were 
too many genes that were differentially downregulated only a selected few with either 
atherogenic or atheroprotective roles are shown in Table 6-3. These genes include lysyl 
oxidase-like 3 (LOXL3), which was reported to be associated with diet induced 
atherosclerosis in rabbit (Kagan et al. 1981) and carboxylesterase 1 (CES1), which regulates 
intracellular triacylglycerol accumulation and is associated with obesity (Ko et al. 2009; 
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Table 6-2. Decreased relative genetic expression upon variant SAA1 treatment as 
compared to wild-type SAA1 treatment after 24 h; data is obtained from the analysis of 
microarray result.  







Additional sex combs like 2 (ASXL2) 1.62 1.91 
Transmembrane protease, serine 7 (TMPRSS7) 1.58 1.03 
Zinc finger protein 749 (ZNF749) 1.51 1.36 
 
Table 6-3. Increased relative genetic expression upon variant SAA1 treatment as compared 
to wild-type SAA1 treatment after 24 h of treatment.  







CD63 0.43 0.58 
Myosin (MYO1F) 0.53 0.73 
Sterol regulatory element binding transcript 
factor 1 (SREBF1) 
0.55 0.90 
Acyl-CoA thioesterase 8 (ACOT8) 0.56 0.81 
Protein kinase, AMP-activated, gamma 1 non-
catalytic subunit (PRKAG1) 
0.57 0.88 
Carboxylesterase 1 (CES1) 0.58 0.76 
Lysyl oxidase-like 3 (LOXL3) 0.58 0.79 
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6.2.4.3 Real-time PCR validation of microarray result 
For the validation of the microarray result at 8 h, five genes were chosen for validation by 
real-time PCR. Genes were chosen based on their functional effects and its possible 
contribution to atherosclerosis. SERPINB2 and PTGS2 had decreased expression upon 
variant SAA1 treatment as compared to wild-type SAA1. There does not appear to be any 
differential expression in BMPR2, P4HA1 and CXCL6 between SAA1 and wild-type SAA1 
treatment. PTGS2 and SERPINB2 were upregulated upon SAA1 treatment (wild-type 
SAA1/untreated > 2) while BMPR2 and P4HA1 have wild-type SAA1/untreated ratio of < 
2. Thus, the differentially expressed genes between wild-type and variant SAA1 treatments 
are probably those genes with a wild-type SAA1/untreated ratio of > 2 and a high ratio for 
wild-type SAA1/variant SAA1. Using this criteria, it is safe to conclude that only 2 genes 
were differentially regulated between wild-type and variant SAA1 at 8 h (Table 6-4). 
For the 24 h incubation, all the genes listed in Table 6-3 were not differentially expressed 
between wild-type and variant SAA1 treatment (Table 6-5). This is within expectation, as 
genetic induction of expression by SAA1 appears to cease at 24 hours with wild-type 
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Table 6-4.  Real time PCR verification of microarray results at 8 h. Real-time PCR results 
was obtained from 3 independent assays and analysed using a software for real time PCR 
analysis, REST 2009. Differential expression was observed in SERPINB2 and PTGS2. 
Gene Expression Standard 
Error 
P-value 
CXCL6 1.29 0.77-2.22 0.325 
 SERPINB2 1.76 1.42-2.18 <0.0001 
 BMPR2 1.04 0.95-1.13 0.426 
 PTGS2 1.39 1.13-1.66 0.029 
P4HA1 1.07 0.99-1.13 0.249 
 
Table 6-5.  Real time PCR verification of microarray results at 24 h. Real-time PCR results 
were obtained from 3 independent assays. Differential expression was not observed in any 
of the genes. 
Gene Expression Standard 
Error 
P-value 
CD63 0.96 0.79 - 1.15 0.695 
MYO1F 1.00 0.92 - 1.10 0.965 
SREBF1 1.11 0.89 - 1.30 0.434 
ACOT8 0.95 0.87 - 1.08 0.532 
PRKAG1 1.00 0.90 - 1.13 0.835 
CES1 1.08 0.93 - 1.22 0.418 
LOXL3 1.14 0.97 - 1.38 0.36 
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6.3 Discussion 
6.3.1 Effects of SAA1 treatment on cytokine production in macrophages and 
neutrophils 
As variant SAA1 is associated with susceptibility to CAD, it was originally speculated that 
variant SAA1 will induce a higher level of pro-inflammatory cytokines as compared to the 
wild-type. However, results show that variant SAA1 induces lower level of pro-inflammatory 
cytokines. Although, this run contary to our expectation, the result is plausible as the 
substitution could probably alter the structure of mature SAA1 protein. In our study, the 
surface receptors, TLR2 and CLA-1, account for part of the cytokine induction property of 
SAA1 (Chapter 8.3). As such, the amino acid substitution might alter the structure of SAA1 
and affects its affinity with the surface receptors. As a reduction of the level of pro-
inflammatory cytokines is most probably athero-protective, the association of the genetic 
variant with CAD could possibly be due to a change in expression level of other genes that 
are simulataneously activated by the same surface receptors. 
Differential induction of inflammatory cytokines by p.Gly90Asp was observed in both 
macrophages and neutrophils. However, a greater difference was observed in macrophages 
for both IL-8 and MCP-1. This could probably be due to the differential regulation of 
cytokine induction in the 2 different immune cells; the macrophages could probably have 
more surface receptors and less negative regulation on its production of cytokines. In 
summary, the variant has a functional impact on cytokine production in immune cells and 
this could probably be attributed to its altered affinity to cell surface receptors. 
 
6.3.2 Effects of SAA1 treatment on cholesterol storage and metabolism 
One of the proposed anti-atherogenic potential of SAA1 is its role in preventing 
accumulation of cholesteryl ester in cells. This can take place through a dual stimulation of 
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increased cholesterol efflux from macrophages (Tam et al. 2008)  and increasing the activity 
of nCEH (Lindhorst et al. 1997). In a preliminary study, there was a small difference in 
cholesterol efflux from THP-1 derived macrophages between the wild-type and the variant, 
however, this difference was observed only at a concentration of 40µg/ml SAA1. As the 
concentration of SAA1 in the wall of the coronary artery is still unknown, it is doubtful 
whether 40µg/ml SAA1 is physiologically relevant. However, given that the serum 
concentration of SAA1 in obese subjects is 20µg/ml (Lappalainen et al. 2008), a 
concentration in excess of 40µg/ml might not be physiologically relevant, and as such 
cholesterol efflux assay was not carried out after the preliminary study. 
The nCEH assay shows that SAA1 does not have any effect on nCEH activity. In an earlier 
study, acute-phase HDL was shown to stimulate an increase in nCEH activity (Lindhorst et 
al. 1997). However, in another study, short peptides corresponding to SAA2 amino acid 
sequence but not SAA1 was shown to induce a positive effect on nCEH activity (Tam et al. 
2005). This result clarifies the two earlier published studies and shows that SAA1 does not 
have any effect on nCEH activity and that earlier observed effects could be due to SAA2.  
As technical difficulty was encountered during the process of obtaining the nCEH from 
THP-1 macrophages, porcine nCEH was used instead. However, the usage of porcine 
nCEH should have little interferance on the result, as previous study reported also involved 
the use of porcine nCEH. Thus, from the result, the association of variant of SAA1 with 
CAD is not due to its effects on nCEH activity and cholesterol efflux. 
 
6.3.3 Differential effects of wild-type and variant SAA1 on global expression level in 
macrophages 
As results from the earlier functional assays did not appear to explain the association of the 
variant with CAD, a microarray study was initiated. Two time points of 8 h and 24 h were 
     110
used for the study. Due to the inherent cost of the chips, only two samples for each 
treatment and timepoint were used. The results were compared and analysed with real-time 
PCR to ensure its validity. 
The initial results show that only a few genes were differentially expressed between wild-type 
and variant SAA1 at 8 h while there were many more genes that were differentially expressed 
at 24 h. However, real-time PCR shows that most of the genes that were deemed to be 
differentially regulated at 24 h through microarray analysis were false-positives. Various steps 
were taken to eliminate false positives. To select for genes for validation by real time PCR, 
two steps were taken; genes that were deemed to be differentially upregulated or 
downregulated by microarray were first functionally annotated. For the 8 h timepoint, only 7 
genes were identified with functional roles that might contribute to athersoclerosis. Upon 
functional annotation of genes, genes that have a high wild-type/variant SAA1 ratio and 
genes that were both differentially expressed between wild-type and variant as well as 
between wild-type and untreated were selected for validation by real-time PCR. A wild-
type/untreated ratio of > 2 together with a high value of wild-type/variant was found to be 
more reliable in determining whether the genes were differentially regulated. At 24 h, none 
of the genes that were selected for validation by real-time PCR were deemed to have 
significant differential expression. This was not surprising given that induction of global 
expression by SAA1 in macrophages ceased at 24 h and that most of the genes shown in 
Table 7-3 have wild-type SAA1/untreated ratio of less than 2.0. As the analysis of 
microarray results was carried out in a comprehensive manner, it can be concluded that only 
two genes (PTGS2 and SERPINB2) were differentially expressed at 8 h and no genes was 
differentially regulated at 24 h. 
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Of the 2 differentially expressed genes at 8 h, PTGS2 is a mediator of inflammation while 
SERPINB2 can exert atherogenic or athero-protective effects depending on where it is 
expressed. Endothelial expression of SERPINB2 is potentially atherogenic as it inhibits 
fibrinolysis through its inhibition of tissue plasminogen activator and urokinase plasminogen 
activator (uPA). Production of SERPINB2 by the macrophages in atherosclerotic lesion is 
athero-protective as it has a negative impact on THP-1 cell proliferation and differentiation 
(Yu et al. 2002a). SERPINB2 has anti-apoptotic property and its inhibiton of uPA prevents 
uPA-mediated extracellular matrix degradation which helps to reduce the invasion of 
migratory cells (Kumar and Baglioni 1991). Lastly, SERPINB2 is a negative modulator of 
pro-inflammatory Th1 responses and thus it helps to regulate the amount of inflammatory 
cytokines in atherosclerotic lesion (Schroder et al. 2010). Taken together, SERPINB2 might 
have an influence on CAD through its regulatory role in key processes of atherosclerosis 
such as matrix degradation and pro-inflammatory activity in the lesion. The decreased 
expression of SERPINB2 upon variant SAA1 treatment as compared to wild-type SAA1 
might account for the association of variant SAA1 with CAD. In our study, there was no 
quantification of the level of SERPINB2 both in the cellular lysate and the supernatant as 
THP-1 cells are not able to produce functional SERPINB2 and thus its level cannot be 
quantified with available ELISA kit (Gross and Sitrin 1990). 
NF-kappaB is a reported downstream target of A-SAA (Zhao et al. 2007). All of the genes 
that were found to be differentially regulated in our functional study are reported 
downstream targets of NF-kappaB (Schreiber et al. 2006; Wang et al. 2008a; Wang et al. 
2008b). NF-kappaB is a downstream target of several cell surface receptors of acute-phase 
SAA such as TLR2 (Baranova et al. 2005; Cheng et al. 2008) and CLA-1 (Baranova et al. 
2005). Thus, it is likely that the impaired affinity of variant SAA1 for its surface receptors 
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affects efficiency of downstream signaling resulting in lower activation of NF-kappaB 
targets. Although, NF-kappaB mediates pro-inflammatory actvity which is essentially 
atherogenic, a few studies have highlighted its athero-protective role. In one study, mice with 
diminished NF-kappaB activity developed atherosclerotic lesion that was twice the size in 
normal mice (Idel et al. 2003) . In another study, mice with induced macrophage specific 
deficiency of I-kappaB kinase beta (IKK2) have a 62% increase in lesion area (Kanters et al. 
2003). Thus, NF-kappaB has athero-protective functions through its induction of athero-
protective genes, many of which are not currently known.  Based on previous published 
studies, it is possible that SERPINB2 is one of the athero-protective genes that are induced 
by NF-kappaB. 
 
6.3.4 Intrepretation of results of the functional assays 
Previously, there has been uncertainty over the role SAA1 plays in atherosclerosis, in 
particular whether it is atherogenic or athero-protective. The identification of a non-
synonymous SNP that has a significant association with CAD allows us to clarify the role 
SAA1 plays in CAD. The first section of the functional assay involves the quantification of 
cytokine levels secreted by macrophages upon induction by either wild-type or variant SAA1. 
Although, the results are unexpected, they are clarified through the microarray analysis. 
Microarray analysis identifies a few genes that were differentially expressed and all of which 
are downstream targets of NF-kappaB. Although, IL-8, MCP-1 and TNF-• are not deemed 
to be differentially expressed in the microarray analysis, this is not unexpected as the protein 
levels of IL-8, MCP-1 and TNF-• decreased by only  57%, 50% and 39% respectively when 
they were treated with 3 µg/ml SAA1. Furthermore, microarray analysis only quantifies the 
relative amount of transcripts at that time interval. Nonetheless, the results of the study 
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indicate that a major impact of the substitution is ithe possible alteration of the efficiency of 
NF-kappaB signaling. Both atherogenic and athero-protective genes such as SERPINB2 are 
regulated by Nf-kappaB and it is possible that the balance is disrupted in variant SAA1.  
In addition, the studies also show that there are no differential expression in genes that are 
associated with lipid metabolism between wild-type and variant SAA1. Thus, the association 
of the variant with CAD is most probably not associated with altered regulation in lipid 
storage. However, the effects of wild-type and variant SAA1 has on cholesterol efflux in the 
presence of components of the extracellular matrix remain to be ascertained, however this 
area is technically harder to accomplish. 
 
6.3.5 Caveats of functional characterization of p.Gly90Asp 
Functional characterization of the variant protein was carried out at 3µg/ml and 15µg/ml 
for the quantification of cytokines secreted by macrophages. For the microarray analysis, the 
concentration used was lowered to 1µg/ml. Initial concentrations of 3 and 15µg/ml of 
SAA1 were used as this is close to the serum SAA1 concentration in healthy subjects and 
patients with metabolic syndrome respectively. There is, however, a concern that the 
concentration of SAA1 in the walls of the coronary artery might be different than that in the 
blood. As the microarray analysis includes the stimultaneous study of the differential effects 
between wild type and variant and between wild-type and untreated (Chapter 7), the 
concentration for the microarray analysis was lowered so that the global gene expression 
analysis between SAA and untreated could be conducted at a concentration that addresses 
this concern. Due to the inherent cost of the chips, only one concentration of SAA1 was 
used, nonetheless, the study was able to identify the NF-kappaB pathway as the likely 
pathway to be impacted by the amino acid substitution. There is a limitation in the number 
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of time points that were used for the microarray analysis. Originally, it was thought that a 8 
and 24 h timepoint would be sufficient to monitor the differential genetic expression in the 
macrophages. However, given the result, it would be interesting to see whether there is a 
greater degree of differential expression at 4 hr. 
THP-1 derived macrophages is one the few commercially available macrophages that 
resembles human macrophages. One major disadvantage of THP-1 derived macrophages is 
that PMA is needed to induce the differentiation of monocytes into macrophages. The 
morphology of the differentiated cells was however monitored carefully to ensure that the 
differentiated macrophages were morphologically similar for each independent experiment. 
A better alternative would be PBMCs; however, these primary cells were not available as 
human subjects need to be recruited. 
The surface receptors are most likely responsible for the functional effects induced by SAA1 
in the macrophages. However, it is not possible to directly inhibit the various receptors to 
determine whether the surface receptors are responsible for the differential production of 
cytokines. As the morphology of THP-1 derived macrophages changes when it is induced to 
differentatiate at low confluence, a large amount of antibodies are needed to inhibit a 
substantial amount of the surface receptors. Thus, the assay was not carried out, however, 
the cell surface receptors, TLR2 and CLA-1, were found to be partly responsible for the 
induction of inflammatory cytokines by SAA1 using mouse RAW264 macrophages (Chapter 
8).  
 
6.3.6 Future works 
Functional studies were carried out using an immortalized cell line which might have a 
differential cellular response as compared to a primary cell line. It is expected that SAA1 will 
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be able to induce the secretion of a significant amount of inflammatory cytokines from 
primary cells as similar effects were observed with recombinant human A-SAA in a reported 
study (Song et al. 2009). In addition, surface receptors of SAA1 such as TLR2 and CLA-1 
were found to be expressed in human primary macrophages (Erdman et al. 2009; Gallego et 
al. 2011). Nonetheless, the study should be verified in primary cell line to ascertain the 
results from THP-1 macrophages and to determine whether the global gene expression is 
different in the primary cell line.  
The binding affinity of the genetic variant to each of the surface receptors of SAA1 could be 
investigated and determined using ELISA. Recombinant fusion protein of each of the five 
surface receptors and the Fc region can be prepared using a mammalian system and the 
binding efficiency is measured by determining the fluorescence levels after SAA1 is allowed 
to bind to the recombinant cell surface receptors.  
There are currently five reported surface receptors of A-SAA and all these five receptors 
including FPRL-1 and RAGE are expressed in monocytes or macrophages (Dragomir et al. 
2011; Ernst et al. 2004). As such, the downstream signaling pathways of these receptors 
which include ERK1/2, p38, Jak-STAT and NF-kappaB might be altered between wild-type 
and variant. The pathway that accounts for the differential induction could be investigated 
through the selective inhibition of surface receptors of SAA1. 
Prior to this study, the importance of neutrophils to CAD was not exactly known and the 
pathogenesis of atherosclerosis has been mainly attributed to the interplay of macrophages, 
lymphocytes and fibroblasts. However, recent studies have indicated the importance of 
neutrophils to the pathogenesis of CAD: neutrophils were found to infiltrate arteries during 
the intial stages of atherosclerosis (Drechsler et al. 2010) and that human neutrophil peptides 
were reported to play a role in the formation of foam cells (Quinn et al. 2011). The 
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functional study of p.Gly90Asp could thus be extended to neutrophils so that the functional 
effects of the variants and its impacts on CAD can be better understood. 
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7  Gene expression profiling of THP-1 derived macrophages upon treatment 
with SAA1  
7.1 Introduction 
With the completion of the genetic variant screening, genetic association and functional 
studies of SAA1 and its variant, there are sufficient evidence to support the association of 
SAA1 with CAD. The discovery of the genetic association of p.Gly90Asp with CAD 
suggests that SAA1 is not merely a marker of chronic inflammatory disease and that it has a 
functional role in the pathogenesis of atherosclerosis.. As an evolutionary conserved protein, 
the role it plays in survival as well as its role in atherosclerosis remains to be answered. To 
solve this conundrum, the global genetic expression that is induced in THP-1 derived 
macrophages upon treatment with SAA1 was studied. The microarray analysis will help 
identify genes and pathways that are activated upon SAA1 treatment; this will be helpful in 
determining the possible roles SAA1 plays in atherosclerosis and the scope of its functional 
effects. 
Previous published studies have focused on characterizing the likely role A-SAA plays in 
atherosclerosis using a recombinant SAA with an amino acid sequence that is a hybrid of 
SAA1 and SAA2. To round up the study of SAA1, two of the reported surface receptors of 
A-SAA, TLR2 and CLA-1, were ascertained for their involvement as surface receptors of 
SAA1. Due to technical difficulties in using THP-1 derived macrophages for this particular 
study, RAW264 macrophages were used instead. This study will support the hypothesis in 
Chapter 7 where the altered affinity with the surface receptors is believed to explain for the 
lower genetic expression of cytokines and other genes. 
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7.2 Results 
7.2.1 Microarray analysis 
7.2.1.1 Quality of microarray data 
The quality of the microarray data was first verified using Genome Studio which compares 
signals from the internal controls used in the assay (Figure 7-1). The signals from the 
hybridization controls were in the correct order with the ‘high-signal’ hybridization control 
having the greatest intensity. Both the negative controls have low signal intensities. For the 
low stringency test, the signal levels were according to expectation with the perfect match 
(pm) probe having a higher signal than the mismatch (mm2) probe. Housekeeping genes 
have a total signal intensity that was much greater than the sum of the signals from all other 

























































Figure 7-1. Quality of microarray data. Data quality was verified through set a of 
internal controls (hybridisation, negative, low stringency, gene intensity). All the 
signals from the four parameters were according to expectation and indicative of 
good quality data. Signals from hybridisation controls were in the appropriate order 
with the ‘high signal’ hybridisation control having the highest signal; negative 
controls have low signal intensity; signal for perfect probe (pm) > mismatched probe 
(mm2) and signal for housekeeping genes > all genes.  
 
7.2.1.2 Effects of SAA1 on gene expression in THP-1 derived macrophages at 8 h 
In total, 94 genes were upregulated with a fold difference of > 2. The top ten most 
upregulated genes when human macrophages were treated with SAA1 are as shown in Table 
7-1. More than half of the top ten genes are involved in immune regulatory processes, these 
includes chemokine (C-C motif) ligand 4 (CCL4), tumor necrosis factor, alpha-induced 
protein 6 (TNFAIP6), (C-C motif) ligand 1 (CCL1), chemokine (C-C motif) ligand 3 
(CCL3), IL23A, and IL-8. The chemokines, CCL1, CCL3, CCL4 and IL-8 were highly 
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upregulated and made up 4 of the top 10 upregulated genes. CCL4 has the highest fold 
increase of 21.6 while IL-8 has a 6.6 increase in expression. TNFAIP6 and lysosomal-
associated membrane protein 3 (LAMP3) both have possible roles in matrix reorganization 
due to the presence of hyaluronic acid binding domain present in the protein.  
There was only one gene that was downregulated with a fold difference of < -2. Lysyl 
oxidase homolog 4 precursor (LOXL4) has a fold difference of -2.1. Differentially expressed 
genes are classified according to their functional roles which are based on information 
provided by gene annotation database, GoEAST. To minimize false positive, only genes 
with high P-value for the function indicated were included. The lists of genes classified 
according to their functions are shown in the following section. 
Table 7-1. Top 10 upregulated genes when THP-1 derived macrophages were incubated 
with SAA1 for 8 h. 
Gene symbol Gene Fold difference 
CCL4 Chemokine (C-C motif) ligand 4 21.6 
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 17.6 
CCL1 Chemokine (C-C motif) ligand 1 16.4 
CCL3 Chemokine (C-C motif) ligand 3 10.3 
SOD2 Superoxide dismutase 2, mitochondrial 8.4 
LAMP3 Lysosomal-associated membrane protein 3 8.3 
IL23A Interleukin 23, alpha subunit p19 7.8 
IL-8 Interleukin 8 6.6 
SLC2A6 Solute carrier family 2 (facilitated glucose transporter), 
member 6 
5.9 
MCOLN2 Mucolipin 2 5.3 
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7.2.1.2.1 Differentially expressed genes involved in angiogenesis 
Angiogenesis is associated with the pathogenesis of atherosclerosis as it provides oxygen and 
nutrients supply to the atherosclerotic plaque and has possible role in tissue remodeling. 
There are 7 SAA1 upregulated genes with functional role in angiogenesis: IL-8, tumour 
necrosis factor, alpha-induced protein 2 (TNFAIP2), chemokine (C-C motif) ligand 2 
(CCL2), interleukin 1, beta (IL1B), zinc finger CCCH-type containing 12A (ZC3H12A), 
IL1A and syndecan (SDC4) (Table 7-2). The fold differences are 6.6, 3.7, 2.9, 2.9, 2.6, 2.4 
and 2.1 respectively. ZC3H12A is a reported angiogenic factor and promotes angiogenesis 
partly through the upregulation of cadherin 12 and cadherin 19 (Niu et al. 2008). IL1A was 
shown to promote angiogenesis in vivo through its stimulation of VEGF synthesis and 
release (Salven et al. 2002). Mice lacking SDC4 was reported to have impaired angiogenesis 
in the granulation tissue (Echtermeyer et al. 2001). SERPINB2 and CD82, which are 
involved in anti-angiogenesis, were upregulated with a fold difference of 4.5 and 2.9 
respectively. As there are more pro-angiogenic genes upregulated, it is possible that SAA1 
stimulates angiogenesis to facilitate healing of damaged tissue and that the angiogenesis 
response is regulated by the expression of anti-angiogeneic proteins. 
Table 7-2. Changes in gene expression of genes involved in angiogenesis.  
Gene symbol Gene Fold difference 
IL-8 Interleukin 8 6.6 
TNFAIP2 Tumour necrosis factor, alpha-induced protein 2 3.7 
CCL2 Chemokine (C-C motif) ligand 2 2.9 
IL1B Interleukin 1, beta 2.9 
ZC3H12A Zinc finger CCCH-type containing 12A 2.6 
IL1A Interleukin 1, alpha 2.4 
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Gene symbol Gene Fold difference 
SDC4 Syndecan 4 2.1 
SERPINB2* Plasminogen activator inhibitor-2 4.5 
CXCL10* Chemokine (C-X-C motif) ligand 10 2.9 
CD82* CD82 molecule 2.9 
*Indicated genes have functional role in anti-angiogenesis 
 
7.2.1.2.2 Differentially expressed genes involved in apoptotic process 
Seven anti-apoptotic genes were upregulated upon SAA1 treatment. The most upregulated 
anti-apoptotic gene is SERPINB2 with a fold difference of 4.5 (Table 7-3). SERPINB2 was 
reported to inhibit TNF-induced apoptosis in HeLa cells and HT-1080 fibrosarcoma cells 
(Dickinson et al. 1995; Kumar and Baglioni 1991). Baculoviral IAP repeat-containing 3 
(BIRC3) inhibits both caspase 7 and 9 while TNF receptor-associated factor 1 (TRAF1) is 
known to be an anti-apoptotic agent. The effect of the anti-apoptotic genes is probably 
regulated with a corresponding upregulation of apoptotic genes, tumor necrosis factor 
(TNF), B-cell CLL/lymphoma 3 (BCL3) and tumor necrosis factor receptor superfamily, 
member 9 (TNFRSF9). The induction of anti-apoptotic genes could possibly be a protective 
mechanism as the phagocytosis of pathogens and the subsequent degradation of such 
pathogens can induce oxidative stress in macrophages. This hypothesis is in part supported 
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Table 7-3. Changes in gene expression of genes involved in apoptosis or anti-apoptotic 
activity  
Gene symbol Gene Fold difference 
SERPINB2 Plasminogen activator inhibitor-2 4.5 
ADORA2A Adenosine A2a receptor 3.1 
IER3 Immediate early response 3 2.7 
BIRC3 Baculoviral IAP repeat-containing 3 2.4 
TRAF1 TNF receptor-associated factor 1 2.1 
HBEGF Heparin-binding EGF-like growth factor 2.1 
PIM2 Pim-2 oncogene 2.0 
TNF* Tumor necrosis factor 2.7 
BCL3* B-cell CLL/lymphoma 3 2.1 
TNFRSF9* Tumor necrosis factor receptor superfamily, member 9 2.1 
*Indicated genes have functional role in apoptosis.  
 
7.2.1.2.3 Differentially expressed genes involved in inflammatory processes 
Genes involved in the regulation of immune processes form the bulk of the genes that were 
upregulation upon SAA1 treatment. In total, 16 pro-inflammatory genes were upregulated. 
SAA1 is a massive inducer of chemokines: CCL4, CCL1, CCL3, IL-8, Granulocyte 
chemotactic protein 2 (CXCL6), Chemokine (C-X-C motif) ligand 10 (CXCL10) and 
chemokine (C-C motif) ligand 2 (CCL2) were all upregulated (Table 7-4). 4 anti-
inflammatory genes, TNFAIP6, SERPINB2, ZC3H12A and CD83, were also upregulated. 
The large number of pro-inflammatory genes that were upregulated suggests that one of the 
major functions of SAA1 is to stimulate the migration of immune cells to site of injury. 
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Table 7-4. Changes in gene expression of genes involved in inflammatory or anti-
inflammatory activity.  
Gene symbol Gene Fold difference 
CCL4 Chemokine (C-C motif) ligand 4 21.6 
CCL1 Chemokine (C-C motif) ligand 1 16.4 
CCL3 Chemokine (C-C motif) ligand 3 10.3 
IL23A Interleukin 23, alpha subunit p19 7.8 
IL-8 Interleukin 8 6.6 
CD40 CD40 molecule 4.9 
CXCL6 Granulocyte chemotactic protein 2 3.2 
CXCL10 Chemokine (C-X-C motif) ligand 10 2.9 
IL1B Interleukin 1, beta 2.9 
CCL2 Chemokine (C-C motif) ligand 2 2.9 
IL18R1 Interleukin 18 receptor 1 2.8 
TNF Tumor necrosis factor 2.7 
PTGS2 Prostaglandin-endoperoxide synthase 2 2.7 
IL1A Interleukin 1, alpha 2.4 
CCL20 Chemokine (C-C motif) ligand 20 2.2 
CSF2 Colony stimulating factor 2 2.0 
TNFAIP6* Tumor necrosis factor, alpha-induced protein 6 17.6 
SERPINB2* Plasminogen activator inhibitor-2 4.5 
ZC3H12A* Zinc finger CCCH-type containing 12A 2.6 
CD83* CD83 molecule 2.1 
*Indicated genes have functional role in anti-inflammation. 
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7.2.1.2.4 Differentially expressed genes involved in phagocytosis 
Five genes with functional role in phagocytosis were upregulated with fold difference 
ranging from 4.6 for myristoylated alanine-rich protein kinase C substrate (MARCKS) to 2.7 
for V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (SRC) (Table 7-5). 
MARCKS, hemopoietic cell kinase (HCK) and neutrophil cytosolic factor 1 (NCF1) are 
notable genes of the Fc gamma receptor-mediated phagocytosis pathway (KEGG: ko04666).  
MARCKS and HCK are involved in the regulation of the actin cytoskeletion which is 
important for phagocytosis while NCF1 is important for the digestion of bacteria by 
initiating respiratory burst. 
Table 7-5. Changes in gene expression of genes involved in phagocytosis.  
Gene symbol Gene Fold difference 
MARCKS Myristoylated alanine-rich protein kinase C substrate 4.6 
ADORA2A Adenosine A2a receptor 3.1 
HCK Hemopoietic cell kinase 2.8 
NCF1 Neutrophil cytosolic factor 1 2.8 




7.2.1.2.5 Differentially expressed genes with possible role in tissue 
remodeling/wound healing 
In total, there are 11 genes with possible role in tissue remodeling that were upregulated 
(Table 7-6). The potential for a role in tissue remodeling is based on the ability of the gene to 
interact with the components of the extraceullar matrix. Based on gene annotation, CD44 
has functional role in collagen binding while both CD44 and TNFAIP6 are able to bind to 
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hyaluronic acid.  As tissue remodeling is an essential process of wound healing, it is possible 
that these genes also have a role in wound healing. SDC4 is upregulated  in the dermis of 
skin wounds (Gallo et al. 1996) and SDC4 knockout mice have delayed wound repair 
(Echtermeyer et al. 2001).  
Table 7-6. Changes in gene expression of genes involved in tissue remodeling/wound 
healing. 
Gene symbol Gene Fold difference 
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 17.6 
LAMP3 Lysosomal-associated membrane protein 3 8.3 
IL23A Interleukin 23, alpha subunit p19 7.8 
LEPREL1 Leprecan-like 1 3.6 
PTGS2 Prostaglandin-endoperoxide synthase 2 2.7 
BIRC3 Baculoviral IAP repeat-containing 3 2.4 
CD44 CD44 molecule 2.4 
ITGA1 Integrin, alpha 1 2.4 
SDC4 Syndecan 4 2.1 
HBEGF Heparin-binding EGF-like growth factor 2.1 
PIM2 Pim-2 oncogene 2.0 
LOXL4 Lysyl oxidase homolog 4 precursor -2.1 
  
7.2.1.3 Effects of SAA1 on gene expression in THP-1 derived macrophages at 24 h 
There are 12 SAA1 upregulated genes with fold difference of more than 2 (Table 7-7). 
Stimulation of genetic expression in THP-1 derived macrophages appears to cease at 24 h 
with fewer genes upregulated. In addition, the fold differences of upregulated genes at 24 h 
are lower as compared to 8 h. In general, the genes that were upregulated at 24 h are a subset 
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of the upregulated genes at 8 h albeit at a lower expression level. Only three genes, Bobby 
sox homolog (BBX), histone cluster 1, H4c (HIST1H4C) and PRP40 pre-mRNA processing 
factor 40 homolog A (PRPF40A), were not differentially upregulated at 8 h. However, the 
functional roles of these 3 genes are currently not established.  
Three genes were downregulated with a fold difference of less than -2. However, other than 
LOXL4, there is currently limited information on the function of both Fc fragment of IgG 
binding protein (FCGBP) and CD300A. Hence, the pattern of genetic expression in 24 h is 
not wholly different from that at 8 h in that the genes that were upregulated at 24 h were 
similarly upregulated at 8 h. Thus, the functional impact of SAA1 can be studied by just 
analyzing the genetic expression pattern at 8 h. 
Table 7-7. Genes that were differentially expressed upon treatment with SAA1 at 24 h. 
Gene symbol Gene Fold difference 
CCL1 Chemokine (C-C motif) ligand 1 7.3 
SERPINA9 Serpin peptidase inhibitor, clade A, member 9  3.5 
EBI3 Epstein-Barr virus induced 3 3.4 
SOD2 Speroxide dismutase 2, mitochondrial 3.1 
CCL4 Chemokine (C-C motif) ligand 4 2.6 
CCL3 Chemokine (C-C motif) ligand 3 2.3 
LEPREL1 Leprecan-like 1 2.3 
BBX Bobby sox homolog (Drosophila) 2.2 
IL-8 Interleukin 8 2.0 
HIST1H4C Histone cluster 1, H4c 2.0 
PRPF40A PRP40 pre-mRNA processing factor 40 homolog A (S. 
cerevisiae) 
2.0 
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Gene symbol Gene Fold difference 
LAMP3 Lysosomal-associated membrane protein 3 2.0 
   
FCGBP Fc fragment of IgG binding protein -2.5 
LOXL4 Lysyl oxidase-like 4 -2.2 
CD300A CD300a molecule -2.0 
 
7.2.1.4 Enriched pathways upon treatment with SAA1 at 8 h 
The upregulated genes at 8 h were analysed for pathway enrichment using PathwayAPI. The 
top 20 pathways are as shown in Table 7-8 and the results are agreeable with the earlier 
classification of genes according to their functions. A number of pathways involved in 
immune regulation were enriched including cytokine-cytokine receptor intereaction (P-value 
= 2.41 X 10-22), hematopoietic cell lineage (P-value = 5.19 X 10-11), toll-like receptor signaling 
(P-value = 5.31 X 10-8), inflammatory response (P-value = 1.21 X 10-6), IL10 signaling (P-
value = 4.08 X 10-5). TNF-α/NF-kB signaling (P-value = 1.11 X 10-4), IL6 signaling (P-value 
= 1.71 X 10-4) and IL-1 signaling pathway (P-value = 1.05 X 10-3). SAA1 also induces 
pathways that are important for lipid homeostasis with 2 pathways indicated: mitochondrial 
LC-Fatty acid beta oxidation (P-value = 4.62 X 10-5) and adipogenesis (P-value= 2.07 X 10-4). 
SAA1 treatment also appears to simulate the process of angiogenesis as various pro-
angiogenic pathways were enriched: epidermal growth factor receptor 1 signaling (P-value = 
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Table 7-8. Enriched pathways upon treatment with SAA1 for 8 h.  
Pathway P-value 
Cytokine-cytokine receptor interaction 2.41 X 10-22 
Hematopoietic cell lineage 5.19 X 10-11 
Toll-like receptor signaling 5.31 X 10-8 
Inflammatory response 1.21 X 10-6 
Myometrial relaxation and contraction 2.29 X 10-5 
GnRH signaling pathway 3.51 X 10-5 
IL-10 signaling 4.08 X 10-5 
Mitochondrial LC-Fatty acid beta oxidation 4.62 X 10-5 
TNF-α/NF-kB signaling pathway 1.11 X 10-4 
IL-6 signaling 1.71 X 10-4 
Gap junction 1.82 X 10-4 
Adipogenesis 2.07 X 10-4 
Apoptosis signaling 2.51 X 10-4 
p38 MAPK signaling 4.72 X10-4 
Focal adhesion 4.87 X 10-4 
IL-1 signaling pathway 1.05 X 10-3 
Cell adhesion molecules 1.29 X 10-3 
Adipocytokine signaling pathway 1.38 X 10-3 
EGFR1 signaling pathway 1.58 X 10-3 
JAK/Stat signaling 2.04 X 10-3 
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7.2.2 Validation of microarray results using real-time PCR 
Microarray results were validated using real-time PCR. Nine genes from four of the 
functional role categories (apoptosis, inflammation, phagocytosis and tissue remodeling) 
were chosen. All of the 9 genes were found to be significantly upregulated (Table 7-9). The 
fold changes were quite similar for 7 of the 9 genes; however, the fold changes for 
SERPINB2, and CCL1 were noticeably higher when compared to the microarray results 
(Table 7-10). As all the 9 genes were upregulated, the pattern of induction of genetic 
expression in THP-1 derived macrophages as determined by microarray is generally accurate. 
In addition, the correlation coefficient between the results from microarray and real-time 
PCR is 0.81 (Figure 7-2). 
Table 7-9. Validation of microarray results using real-time PCR. Fold changes between 
SAA1 treatment and untreated were determined using B2M as an internal control for all 
genes except SERPINB2 and CCL1.  FXYD5 was used as an internal control for 
SERPINB2 and CCL1. 
Gene Fold changes 95% confidence interval P–value 
BIRC3 3.2 2.9 – 3.5 <0.0001 
SERPINB2 14.7 8.9 – 20.8 0.023 
CCL1 24.7 13.9-68.9 0.022 
CCL3 9.8 8.6 – 10.8 <0.0001 
CCL4 13.4 11.5 – 16.5 <0.0001 
MARCKS 6.0 5.1 – 7.1 <0.0001 
IL23A 24.4 20.6 – 29.5 <0.0001 
ITGA1 2.3 1.8 – 3.3 <0.0001 
OLR1 2.6 2.2 – 3.1 <0.0001 
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Table 7-10. Comparision of fold changes between that determined by real-time PCR 
and microarray. 
Gene Real time PCR Microarray 
BIRC3 3.2 2.4 
CCL3 9.8 10.3 
IL23A 24.4 7.8 
ITGA1 2.3 2.4 
MARCKS 6.0 4.6 
OLR1 2.6 3.4 
CCL4 13.4 17.0 
SERPINB2 14.7 4.5 
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Figure 7-2. Correlation coefficient between microarray data and real time PCR. The genes 



























Real time PCR: log2ratio of SAA1 to untreated 
y = 0.6639x + 0.5777 
r = 0.81,  p < 0.01   
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7.2.3 Effects of SAA1 on chemokines production 
Secretion of CCL1, CCL3 and CCL4 were significantly increased upon treatment with 1 
µg/ml or 3 µg/ml SAA1 (Figure 7-3 to Figure 7-5). Upon treatment with 1 µg/ml SAA1, the 
secretion of CCL1, CCL3 and CCL4 were increased by 14, 20 and 27 fold respectively. The 
result is consistent with the high expression level obtained from real-time PCR whereby the 


































Figure 7-3.  Effects of varying concentrations of recombinant human SAA1 on the 
secretion of CCL1 from THP-1 monocytes derived macrophages. 2.5 X 106 cells were 
incubated with recombinant SAA1 for 24 hours and the supernatants were assayed for 
CCL1 using ELISA. Error bars represent standard deviations. (n = 3). *P<0.01 for 



































Figure 7-4.  Effects of varying concentrations of recombinant human SAA1 on the 
secretion of CCL3 from THP-1 monocytes derived macrophages. Error bars represent 


































Figure 7-5.  Effects of varying concentrations of recombinant human SAA1 on the 
secretion of CCL4 from THP-1 monocytes derived macrophages. Error bars represent 
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7.2.4 Surface receptors of SAA1 
Induction of secretion of TNF-α by SAA1 in THP-1 derived macrophages is partly 
dependent on the presence of both TLR2 and CLA-1 (Figure 7-6). The concentration of 
TNF-α was significantly reduced in the presence of either TLR2 antibody or CLA-1 
antibody; TNF-α decreased by 42.8% and 34.9% in the presence of TLR2 and CLA-1 
antibody respectively. 
Secretion of MCP-1 upon induction by SAA1 in THP-1 derived macrophages is partly 
dependent on TLR2 (Figure 7-7); the concentration of MCP-1 decreased by 47.1% upon 
treatment with TLR2 antibody and SAA1. However, unlike the secretion of TNF-α, CLA-1, 
appears to play a role in the negative regulation of MCP-1 production in THP1-derived 



































Figure 7-6.  Effects of blocking TLR2 and CLA-1 surface receptors on TNF-α secretion. 
Both TLR2 and CLA-1 surface receptors are required for the production of TNF-α. The 
concentration of TNF-α was significantly lower in the presence of either TLR2 or CLA-1 
antibody. Error bars represent standard deviations (n =3). *P < 0.01 for recombinant 
human SAA1 vs untreated. 
* * 
P = 0.002 P = 0.01 

































Figure 7-7.  Effects of blocking TLR2 and CLA-1 surface receptors on MCP-1 secretion. 
The concentration of MCP-1 produced was significantly reduced upon treatment with 
TLR2 antibody, however, production of MCP-1 was significantly increased in the presence 
of CLA-1 antibody. Error bars represent standard deviations (n =3). *P < 0.01 for 
recombinant human SAA1 vs untreated. 
 
7.3 Discussion 
7.3.1 Effects of SAA1 on gene expression profile in THP-1 derived macrophages 
SAA1 is a significant component of A-SAA. The exact role of SAA1 in innate immunity and 
in CAD, however, still remains unknown. As such, a microarray profiling assay was initated 
to determine the possible pathways that SAA1 induces in macrophages. The knowledge of 
the genes and pathways that are induced in the presence of SAA1 will help clarify the roles 
of SAA1 both in innate immunity and CAD.  
Microarray analysis shows that a significant number of genes involved in inflammation, 
angiogenesis, phagocytosis and tissue remodeling were upregulated. In silico pathway 
enrichment analysis also shows that pathways regulating inflammation, angiogenesis and 
tissue remodeling were enriched. The chemokines, CCL1, CCL3, CCL4 and IL-8 were 
* 
* 
P = 0.02 
P = 0.02 
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highly upregulated upon SAA1 treatment. Upregulation of the chemokines as well as genes 
that are involved in toll-like receptor response, inflammatory response, cell adhesion 
molecules and TNF-α signaling pathway indicate that SAA1 has major roles to play in acute 
inflammation.   
In addition to the mobilization of immune cells, SAA1 increases the phagocytic activity of 
macrophages through the induction of genes such as MARCKS which alters the morphology 
of macrophages to facilitate phagocytosis. SAA1 also facilitates the healing of the damaged 
tissue by inducing the expression of pro-angiogenic genes and genes with function in tissue 
remodeling. Angiogenesis helps to promote the healing of damaged tissues as newly formed 
blood capillaries are able to supply nutrients that are needed for healing. Although, the 
regulatory pathways and exact functional roles of the various genes listed with tissue 
remodeling functions are not known, emerging studies have highlighted their importance in 
tissue remodeling. CD44 is a reported cell surface receptor of hyaluronan and recruits 
MMP7 and HBEGF to the surface of various tissues (Yu et al. 2002b). Thus, as an APP, 
SAA1 plays multiple roles in acute inflammation which include stimulating the migration of 
immune cells, facilitating phagocytosis by macrophages and aiding in the healing of tissues 
that are damaged due to infection or trauma.  
To analyse whether SAA1 plays an atherogenic or atheroprotective role in CAD, it is 
important to consider the regulation and source of production of SAA1. SAA1 is secreted in 
large amount by the liver during an APR. However, the production of SAA1 during an 
acute-phase response is tightly regulated and its concentration returns to base level after a 
few days (Marhaug et al. 1986). As atherosclerosis is a gradual process, it is unlikely the A-
SAA that is produced by the liver plays an important role in the disease pathogenesis as APR 
is generally short-lived. Furthermore, as SAA1 has limited ability to move across the cell 
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membrane, it is likely that serum SAA1 concentration has little impact on atherosclerosis. 
However, the perivascular adipose tissue might be an important source of SAA1. As there is 
no physical barrier between the perivascular adipose tissue and the macrophages residing in 
the wall of the arteries, there is a likely exposure of macrophages to SAA1 produced by the 
adipose tissue. Furthermore, the adipose tissue is a major source of SAA under non acute-
phase condition (Yang et al. 2006) and the size of epicardial adipose tissue was also reported 
to correlate with risk factors for CAD (Iacobellis et al. 2003; Wang et al. 2009).  
SAA1 stimulates the production of inflammatory cytokines that is beneficial when the body 
is under stress, however, a continuous stimulation of macrophages by SAA1 might be 
potentially atherogenic. The large induction of chemokines production can lead to the 
migration and accumulation of macrophages in the walls of the coronary artery; this could 
probably account for the finding in a study in which mice with large lesions have a high 
upregulation of SAA1 in macrophages (Smith et al. 2006). In addition, chronic upregulation 
of genes involve in angiogenesis and tissue remodeling is potentially atherogenic. However, 
it is important to note that SAA1 does stimulate the expression of atheroprotective genes 
such as SERPINB2 which might help regulate the population of immune cells in the lesion. 
The balance between the atherogenic and athero-protective roles of SAA1 might however be 
altered under condition of chronic production of SAA1.  
 
7.3.2 Cell-surface receptors of SAA1 
Previous studies have indicated that TLR2 and CLA-1 are surface receptors for A-SAA. In 
this study, TLR2 and CLA-1 are shown to be cell surface receptors of SAA1. However, the 
two surface receptors have differential roles in the secretion of cytokines in macrophages. 
TLR2 contributes positively to the secretion of both TNF-α and MCP-1 while CLA-1 
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increases the secretion of TNF-α but decreases the secretion of MCP-1. Thus, the 
production of cytokines as well as the change in genetic expression induced by SAA1 in the 
macrophages is likely to be regulated by a complex interplay of signaling pathways involving 
various cell surface receptors.   
Due to technical difficultly, this assay involves the use of mouse RAW264 macrophages 
instead of human THP-1 derived macrophages. As the morphology of RAW264 
macrophages is more consistent even under low confluency, it is more suited for the assay. 
As both TLR2 and CLA-1 are generally well-conserved between mouse and human, the 
usage of mouse macrophages instead of human macrophages should have little interference 
on the result. Furthermore, both antibodies that were used for the assay are able to recognize 
both the human and mouse form of the receptors. 
For the statistical analysis, Bonferroni correction was used to correct for multiple 
comparisons. There are other methods to adjust for multiple testing; these include Sidak, 
bootstrapping and Hochberg. However, these methods are either not significantly less 
conservative than Bonferroni as in the case of Sidak or require more complex calculations as 
in the case of Hochberg. 
The expression of both TLR2 and CLA-1 receptors in RAW264 macrophages were not 
verified. RAW264 macrophages were reported to express CLA-1 (Baranova et al. 2002; 
Schafer et al. 2009) in its basal state and that RAW264 macrophages have been used in a 
number of studies involving TLR2 agonists (Curry et al. 2004; Xu et al. 2007). Thus, the 
observed results are unlikely to be a false-positive although further verification through a 
binding assay as described in the following section will confirm these results. 
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7.3.3 Future works 
The identification of the cell surface receptors for SAA1 is a preliminary study in this thesis. 
For this preliminary study, only two possible surface receptors of SAA1, TLR2 and CLA-1, 
were investigated. Three other receptors, TLR-4, FPRL1 and RAGE, were not investigated 
as suitable inhibitors or antibodies which do not have any direct interfering effect on 
cytokine secretion could be found at the time of the study. Nonetheless, these three surface 
receptors should be investigated to ascertain their role in cytokine production mediated by 
SAA1. In addition, as it is not feasible to introduce four neutralizing antibodies 
simultaneously, inhibition should be carried out by blocking a single receptor initially and 
determining which blockage has the greatest effect on cytokine production. As numerous 
receptors are likely to play a role in cytokine production, the synergistic effects of these 
receptors should be studied. This could be investigated through the simultaneous inhibition 
of two receptors. In addition, the binding of SAA1 to these five receptors should be 
determined through an in-vitro binding assay; this will confirm the role of these surface 
receptors both as a binding partner and a mediator of cytokine production. 
The effects of A-SAA on global gene expression in primary endothelial cells have been 
studied in our lab and the data can be found in GEO (GSE6241). The results also support 
an atherogenic role for A-SAA with upregulation of genes involved in inflammation, cell 
adhesion and plaque stability. It will be useful to determine the effects of SAA1 on gene 
expression in adipocytes. Adipocytes are an important secretor of adipokines such as 
cytokines and metalloproteinases which have important roles in metabolic syndrome and 
cardiovascular diseases. Both microarray and protein array study can be performed. The 
protein array study will allow for the detection of 182 adipokines that are known to be 
secreted by adipocytes. As perivascular adipocytes are located in close proximity to sites of 
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lesion development, the adipokines that are induced by SAA1 might contribute to 
atherogenesis. As there are clear differences in the global gene expression between 
endothelial cells and macrophages, it is expected that adipocytes would have a different gene 
expression profile. The results from this study will allow for a more comprehensive 
understanding of the role of SAA1 in lesion development. 
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8 CONCLUSION AND FUTURE WORKS 
Before the commencement of this study, little is known about the roles of SAA1 during an 
APR as well as in the pathogenesis of CAD. Earlier studies indicate that SAA1 might have a 
potential atherogenic role due to its ability to induce tissue factor from endothelial cells as 
well as inflammatory cytokines from macrophages. However, the role of SAA1 in 
atherogenesis is contradicted by its reported positive effects on cholesterol efflux and 
metabolism. As such, this study was initiated to clarify certain aspects of the functional role 
of SAA1. 
The variant screening of SAA1 suggests that SAA1 is a well-conserved protein. Only a few 
SNPs are present in the exons and the promoter region of SAA1. There are only two non-
synonymous SNPs present in SAA1, p.Ala70Val and p.Ala75Val, both of which were found 
to have no association with CAD. Previously, these two SNPs were associated with 
amyloidosis in patients with various diseases such as FMF and RA. However, our study 
shows that they have no association with CAD. Unlike p.Ala70Val and p.Ala75Val, 
p.Gly90Asp involves an amino acid substitution that is non-conservative in nature. This is 
the only non-synonymous SNP of SAA1 identified that involved a non-conservative amino 
acid change. The SNP, however, does not have any association with CAD. Our functional 
analysis, however, also shows that the mutant protein has functional difference in terms of 
the extent of its induction of inflammatory cytokines and SERPINB2. Two cell surface 
receptors, TLR2 and CLA-1, were found to be partly responsible for the production of 
inflammatory cytokines in macrophages in a separate study. Furthermore, as SAA1 is 
unlikely to move across the cell membrane, the amino acid substitution in the mutant 
probably affects the binding of SAA1 to cell surface receptors and alters downstream 
signaling. 
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In order to establish the role of SAA1 in CAD, a microarray analysis was performed. The 
induction of genes involved in inflammation, chemotaxis, wound healing, tissue remodeling 
and phagocytosis support the role of SAA1 in innate immunity as well as being a prominent 
component of acute phase protein. This induction of gene expression is probably tightly 
controlled as APR which produces a massive amount of SAA1 is generally short lived. 
However, a steady source of production by perivascular adipocytes could potentially be 
atherogenic as it stimulates the migration of monocytes and activates important pathways 
that are potentially atherogenic. 
Functional study shows that the variant protein induces lower levels of inflammatory 
cytokines in macrophages and neutrophils. In addition, microarray analysis shows that the 
variant induces a lower level of atheroprotective SERPINB2. A consideration of our results 
from the mutant characterization study and the microarray analysis (wild-type treatment vs 
untreated) suggests that chronic production of SAA1 is possibly atherogenic, however 
certain genes induced by SAA1 such as SERPINB2 might have atheroprotective effects and 
could be potential therapeutic targets. 
Perivascular adipocyte is an emerging area of study for both metabolic syndrome and CAD. 
The adipocytes secrete various proteins that are crucial for the pathogenesis of chronic 
diseases. The importance of perivascular adipocytes in CAD can be drawn from a study in 
which segment of coronary arteries that are adjacent to adipose tissues were found to be 
more prone to atherosclerosis (Ishikawa et al. 2009). Future works should involve in vivo 
studies conducted in SAA1 partial knockout mice. Studies should involve the quantification 
of SAA1 in region adjacent to the adipose tissue and whether this level correlates with lesion 
development. In addition, studies of the functional roles of SERPINB2 as well as its effects 
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on the gene expression in macrophages will help further our understanding on the possible 
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APPENDIX 6-1 - Differential gene expression in THP-1 macrophages upon 
treatment with either wild-type or variant SAA1 for 24 h 
Gene 
Symbol 
Gene Fold Difference 
(Wild-
type/Variant) 
CD63 CD63 molecule 0.43 
CLOCK Clock homolog (mouse) 0.43 
P704P Prostate-specific P704P 0.44 
LOC389286 Similar to FKSG62  0.47 
TERF2IP Telomeric repeat binding factor 2, interacting protein 0.47 
LST1 Leukocyte specific transcript 1 0.49 
NUPR1 Nuclear protein 1 0.49 
MED24 Mediator complex subunit 24 0.49 
RASSF4 Ras association (RalGDS/AF-6) domain family 
member 4 
0.49 
NPTXR Neuronal pentraxin receptor 0.49 
IFT122 Intraflagellar transport 122 homolog 
(Chlamydomonas) 
0.49 
OSGEP O-sialoglycoprotein endopeptidase 0.49 
LOC402221 Similar to actin alpha 1 skeletal muscle protein 0.49 
EIF4EBP1 Eukaryotic translation initiation factor 4E binding 
protein 1 
0.50 
MRPL28 Mitochondrial ribosomal protein L28 0.51 
PPIL1 Peptidylprolyl isomerase (cyclophilin)-like 1 0.51 
BAT3 HLA-B associated transcript 3 0.51 
CINP Cyclin-dependent kinase 2-interacting protein 0.51 
HS.523127 hd35c03.x1 Soares_NFL_T_GBC_S1 Homo sapiens 
cDNA clone 
0.51 
IFI30 Interferon, gamma-inducible protein 30 0.52 
LOC644029 Similar to 60S ribosomal protein L7a 0.52 
LOC644934 Similar to 40S ribosomal protein S26 0.52 
OXA1L Oxidase (cytochrome c) assembly 1-like 0.53 
MYO1F Myosin IF 0.53 
SPTY2D1 Suppressor of Ty, domain containing 1 (S. cerevisiae) 0.53 
CPNE2 Copine II 0.53 
MEMO1 Mediator of cell motility 1 0.53 
C9ORF98 Chromosome 9 open reading frame 98 0.53 
LOC651894 Similar to ribosomal protein S12 0.53 
RIOK2 RIO kinase 2 0.53 
INHBE Inhibin, beta E 0.53 
AP2B1 Adaptor-related protein complex 2, beta 1 subunit 0.53 
RPL14 Ribosomal protein L14 0.54 
C20ORF149 Chromosome 20 open reading frame 149 0.54 
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Gene 
Symbol 
Gene Fold Difference 
TUBB6 Tubulin, beta 6 0.54 
MRAS Muscle RAS oncogene homolog 0.54 
MTHFS 5,10-methenyltetrahydrofolate synthetase (5-
formyltetrahydrofolate cyclo-ligase) 
0.54 
LOC651816 Similar to Ubiquitin-conjugating enzyme E2S  0.54 
CKS1B CDC28 protein kinase regulatory subunit 1B 0.54 
WDR55 WD repeat domain 55 0.54 
CLTA Clathrin, light chain (Lca) 0.54 
FTO Fat mass and obesity associated 0.54 
SRFBP1 Serum response factor binding protein 1 0.54 
TMEM97 Transmembrane protein 97 0.54 
ATXN3 Ataxin 3 0.55 
CD37 CD37 molecule 0.55 
SREBF1 Sterol regulatory element binding transcription factor 1 0.55 
NUDT16L1 Nudix (nucleoside diphosphate linked moiety X)-type 
motif 16-like 1 
0.55 
C11ORF48 Chromosome 11 open reading frame 48 0.55 
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APPENDIX 6-2 - Raw data for real-time PCR 
  Crossing point value for THP-1 
(untreated) 
Gene symbol Efficiency 1 2 3 
B2M 0.684 20.53 20.71 20.58 
BIRC3* 0.841 28.75 28.945 28.72 
CCL1** 0.689 29.825 30.38 30.22 
CCL3* 0.849 25.655 25.77 25.645 
CCL4* 0.647 30.255 30.71 30.28 
FXYD5 0.849 22.285 22.455 22.505 
IL23A* 0.693 32.945 33.40 32.90 
ITGA1* 0.735 27.65 28.21 27.89 
MARCKS* 0.878 31.75 31.75 31.595 
OLR1* 0.767 25.305 25.785 25.29 
 
 
 Crossing point value for THP-1 (with wild-type SAA1 treatment) 
Gene symbol 1 2 3 
ACOT8*** 28.04 27.87 28.38 
B2M1 20.9 20.725 20.38 
B2M2 23.07 23.52 23.95 
BIRC3* 27.045 26.94 26.835 
BMPR2** 28.13 28.27 27.94 
CCL1** 22.685 24.8 25.285 
CCL3* 22.095 22.035 21.98 
CCL4* 25.235 25.54 25.045 
CD63*** 24.58 24.18 25.03 
CES1*** 28.30 28.01 28.56 
CXCL6* 28.27 28.29 28.08 
FXYD53 22.815 22.345 22.675 
FXYD54 22.96 23.05 22.53 
IL23A* 27.13 27.315 26.785 
ITGA1* 26.21 26.585 26.505 
ITGB1BP1*** 23.74 23.55 24.16 
LASP1 22.18 22.11 22.20 
LOXL3*** 31.73 31.05 31.33 
MARCKS* 29.09 28.78 28.85 
MYO1F*** 23.93 23.93 24.25 
OLR1* 23.98 23.925 23.715 
P4HA1** 26.00 26.04 25.72 
PRKAG1*** 27.57 27.54 27.95 
PTGS2* 28.04 28.46 28.25 
SERPINB2** 28.13 28.66 28.19 
SREBF1*** 27.92 27.54 28.41 
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 Crossing point value for THP-1 (with variant SAA1 treatment) 
Gene symbol 1 2 3 
ACOT8*** 27.51 27.77 27.61 
B2M2 23.51 23.44 23.22 
BMPR2** 27.91 28.38 28.09 
CD63*** 24.23 24.29 23.90 
CES1*** 28.13 28.09 28.06 
CXCL6* 28.13 28.62 28.87 
FXYD54 22.68 22.92 22.80 
ITGB1BP1*** 23.27 23.23 23.37 
LASP1 21.92 21.89 21.71 
LOXL3*** 31.61 30.82 31.18 
MYO1F 23.72 23.80 23.64 
P4HA1** 25.92 26.09 25.95 
PRKAG1*** 27.57 27.26 27.17 
PTGS2* 28.56 28.69 28.8 
SERPINB2 28.74 29.56 29.36 
SREBF1 27.75 27.78 27.74 
 
* B2M was used as internal control. 
** FXYD5 was used as internal control. 
*** LASP3 was used as internal control. 
1  Used as internal control for BIRC3, CCL1, CCL3, CCL4, IL23A, ITGA1, MARCKS, 
OLR1. 
2   Used as internal control for CXCL6 and PTGS2. 
3   Used as internal control for CCL1. 
4   Used as internal control for BMPR2, P4HA1 and SERPINB2. 
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APPENDIX 6-3 - ELISA raw data for the quantification of cytokines secreted by 
macrophages upon induction by either wild-type SAA1 or variant SAA1 
Wild-type vs variant SAA1 treatment (3 µg) on THP1 derived macrophages 
 Medium Wild-type SAA1 Variant SAA1 
IL-8  
(µg/ml) 
   2.7 2.92 2.35 1.25 0.987 1.23 
MCP-1 
(ng/ml) 
16.1 18.3 15.5 29.25 28.5 27 15.75 13.875 12.825 
TNF-α 
(ng/ml) 
0.25 0.28 0.2 21.35 18.5 19.45 9.38 13.6 11.9 
 
Wild-type vs variant SAA1 treatment (15 µg) on THP1 derived macrophages 
 Medium Wild-type SAA1 Variant SAA1 
IL-8  
(µg/ml) 
   3.33 3.64 3.06 1.47 1.74 1.22 
MCP-1 11.85 12.3 9.675 26.1 18 24.4 10.35 10.05 11.33 
TNF-α 
(ng/ml) 
0.244 0.27 0.268 28.25 30 31.5 19.88 21.98 17.93 
 
Wild-type vs variant SAA1 treatment (3 µg) on HL-60 derived neutrophils 
 Medium Wild-type SAA1 Variant SAA1 
IL-8 
(ng/ml) 
15.3 7.9 11.4 101 92 107.5 87 90 93 
MCP-1 
(ng/ml) 
0.13 0.206 0.210 3 3.55 3.625 2.325 2.675 2.75 
 
Wild-type vs variant SAA1 treatment (15 µg) on HL-60 derived neutrophils 
 Medium Wild-type SAA1 Variant SAA1 
IL-8 
(ng/ml) 
14.4 11.5 11.2 266 236 221 219 171 181 
MCP-1 
(ng/ml) 
0.2515 0.24 0.24 10.1 9.56 8.85 5.275 6.325 5.55 
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APPENDIX 6-4 - Raw data for microarray 
Wild-type vs untreated at 8 h 
Gene symbol Wild-type SAA1 Untreated 
BIRC3 174.9 144 77.4 55.2 
CCL1 2079 2595.1 130.8 154.8 
CCL3 16584.7 19155.6 1746.1 1707.2 
CCL4 4107.2 3642.4 179.1 179.2 
IL23A 437.5 339.5 51.2 48.3 
ITGA1 154.2 145.2 66.8 58.6 
MARCKS 1292 1121.5 266.5 252.9 
OLR1 3496.8 2820.4 910.2 926.2 
SERPINB2 196.4 234.4 47.5 49.3 
 
Wild type vs variant at 8 h 
Gene symbol Wild-type SAA1 Variant 
BMPR2 277.2 263.5 188.2 162.5 
CXCL6 175.7 181.3 117.5 105.7 
P4HA1 522.2 404.4 354.1 262.7 
PTGS2 328.6 194.8 214.2 126.8 
SERPINB2 234.4 196.4 152.5 118.3 
 
Wild type vs variant at 24 h 
Gene symbol Wild-type SAA1 Untreated 
ACOT8 64.6 54.8 111 102.8 
CD63 341.3 665 1072 1287.4 
CES1 116.4 95.3 193.3 172.7 
ITGB1BP1 310.1 214.9 398.6 459 
LOXL3 175.6 151.5 301.6 261.4 
MYO1F 386.1 296.8 691.7 603 
PRKAG1 238.3 215.2 415.9 384 
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APPENDIX 7-1 - Upregulated genes upon wild-type SAA1 treatment at 8 h 
Gene 
Symbol 
Gene Fold Difference 
CCL4 Chemokine (C-C motif) ligand 4 21.6 
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 17.6 
CCL1 Chemokine (C-C motif) ligand 1 16.4 
CCL3 Chemokine (C-C motif) ligand 3 10.3 
SOD2 Superoxide dismutase 2, mitochondrial 8.4 
LAMP3 Lysosomal-associated membrane protein 3 8.3 
IL23A Interleukin 23, alpha subunit p19 7.8 
IL-8 Interleukin 8 6.6 
SLC2A6 Solute carrier family 2 (facilitated glucose transporter), 
member 6 
5.9 
MCOLN2 Mucolipin 2  5.3 
EBI3 Epstein-Barr virus induced 3 5.1 
CD40 TNF receptor superfamily member 5 4.9 
MARCKS Myristoylated alanine-rich protein kinase C substrate 4.6 





DKFZP564O0823 protein 4.4 
TNFAIP2 Tumor necrosis factor, alpha-induced protein 2 3.7 
GBP2 Guanylate binding protein 2, interferon-inducible 3.7 
LEPREL1 Leprecan-like 1 3.6 
OLR1 Oxidized low density lipoprotein (lectin-like) receptor 
1 
3.4 
HS.551128 MSTP131 3.4 
STAT4 Signal transducer and activator of transcription 4 3.3 
CXCL6 Granulocyte chemotactic protein 2 3.2 
ADORA2A Adenosine A2a receptor 3.1 
KYNU Kynureninase 3.1 
FOSB FBJ murine osteosarcoma viral oncogene homolog B 3.0 
IL1B Interleukin 1, beta 2.9 
CD82 CD82 molecule 2.9 
CCL2 Chemokine (C-C motif) ligand 2 2.9 
CXCL10 Chemokine (C-X-C motif) ligand 10 2.9 
HCK Hemopoietic cell kinase 2.8 
NCF1 Neutrophil cytosolic factor 1 2.8 
IL18R1 Interleukin 18 receptor 1 2.8 
NCF1C Neutrophil cytosolic factor 1C pseudogene 2.7 
PTGS2 Prostaglandin-endoperoxide synthase 2 2.7 
SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene 
homolog (avian) 
2.7 
IER3 Immediate early response 3 2.7 
EPB41L3 Erythrocyte membrane protein band 4.1-like 3 2.7 
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Gene 
Symbol 
Gene Fold Difference 
TNF Tumor necrosis factor (TNF superfamily, member 2) 2.7 
LOC647650 Hypothetical protein LOC647650 2.6 
ITGA1 Integrin, alpha 1 2.4 
HS.575038 FLJ21027 fis, clone CAE07110 2.4 
SVIL Supervillin  2.4 
IL4I1 interleukin 4 induced 1  2.4 
CD44 CD44 molecule 2.4 
IGFBP3 Insulin-like growth factor binding protein 3 2.4 
PTPRK Protein tyrosine phosphatase, receptor type, K 2.3 
LRFN5 Leucine rich repeat and fibronectin type III domain 
containing 5 
2.3 
ZC3H12A Zinc finger CCCH-type containing 12A 2.3 
CCL20 Chemokine (C-C motif) ligand 20 2.2 
EHD1 EH-domain containing 1 2.1 
TNFRSF9 Tumor necrosis factor receptor superfamily, member 9 2.1 
BCL3 B-cell CLL/lymphoma 3 2.1 
FKBP5 FK506 binding protein 5 2.1 
HS.374023 cDNA DKFZp686N1644 2.1 
SDC4 Syndecan 4 2.1 
CT45-4 Cancer/testis antigen CT45-4 2.1 
TRAF1 TNF receptor-associated factor 1 2.1 
ZNF394 Zinc finger protein 394 2.1 
CD83 CD83 molecule 2.1 
NKX3-1 NK3 homeobox 1 2.1 
CD97 CD97 molecule 2.1 
SLC7A2 Solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 2 
2.1 
HS.10862 cDNA: FLJ23313 fis, clone HEP11919 2.1 
HS.523127 hd35c03.x1 Soares_NFL_T_GBC_S1 Homo sapiens 
cDNA clone 
2.1 
HBEGF Heparin-binding EGF-like growth factor 2.1 
SLCO3A1 Solute carrier organic anion transporter family, member 
3A1 
2.1 
CYP26A1 Cytochrome P450, family 26, subfamily A, polypeptide 
1 
2.0 
CXCR7 Chemokine (C-X-C motif) receptor 7 2.0 
CSF2 Colony stimulating factor 2 2.0 
PIM2 Pim-2 oncogene 2.0 
CYP26B1 Cytochrome P450, family 26, subfamily B, polypeptide 
1 
2.0 
MS4A14 membrane-spanning 4-domains, subfamily A, member 
14 
2.0 
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APPENDIX 7-2 - ELISA raw data for the quantification of chemokines upon 
treatment with SAA1 
 Medium 1 µg/ml SAA1 3 µg/ml SAA1 
CCL1 
(ng/ml) 





0.112 1.87 2.08 2.07 2.5 2.463 2.462 
CCL4 
(ng/ml) 
12.6 14 14 358 356 403 442 442 461 
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APPENDIX 7-3 - ELISA raw data for the quantification of cytokines upon antibody 
and SAA1 treatment 
Inhibition of TLR2 cell surface receptor  




343 272 371 666 600 778 371 290 420 
TNF-α 
(pg/ml) 
350 355 396 1398 1601 1527 812 779 998 
 
Inhibition of CLA-1 cell surface receptor  




343 272 371 650 770 633 1200 1310 1520 
TNF-α 
(pg/ml) 
350 355 396 1428 1485 1294 913 870 956 
 
